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Abstract... 
Transglutaminases catalyse the formation of isopeptide bonds which 
covalently link proteins together and these enzymes have been previously 
implicated in cardiovascular repair processes. This thesis explores the 
transglutaminases, Factor (F)XIII-A and Transglutaminase (TG)2, and their 
roles within the vasculature. To do this, we bred and characterised single and 
double knockout mice deficient for FXIII-A and/or TG2. 
Previously, a protective role has been postulated for FXIII-A, as humans and 
mice lacking FXIII-A fail to maintain pregnancy potentially due to a failure of 
remodelling within the placental artery. This finding was also repeated in this 
study and further to this a significant decrease in the number of FXIII-A-/- pups 
born to FXIII-A+/- mothers was seen. FXIII-A-/- mice develop cardiac fibrosis 
and suffer significant mortality following injury and this phenotype is 
exacerbated with additional loss of TG2, highlighting the importance of FXIII-A 
and TG2 as protective enzymes. 
Interestingly, despite being present in the blood at μg/mL concentrations, the 
cellular source that maintains the plasma pool of FXIII-A has not been 
identified. FXIII-A is known to be produced by megakaryocytes, chondrocytes, 
osteoclasts, monocytes and macrophages and the prevailing view is that 
platelets are the most likely cellular source. 
To delineate the cellular source of plasma FXIII-A, we commissioned a de 
novo FXIII-A floxed mouse which was bred with tissue specific cre 
recombinase mice. These novel models were used to determine plasma and 
platelet FXIII-A activity, together with FXIII-A gene expression in the aorta and 
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heart. The results presented here discount the platelet as the cellular source 
of plasma FXIII-A. Mouse bone marrow transplants and gene expression in 
whole and fractionated organs instead implicate a resident tissue cell, possibly 
a macrophage, in the wall of the aorta (and perhaps the heart) as the cellular 
source of FXIII-A. 
Beyond its repair role, TG2 has been suggested to potentiate apoptosis in 
response to stress signalling. However, previous studies have utilised 
monodansylcadaverine and hence have not inhibited TG2 directly. Here, 
transglutaminase activity assays and characterisation of MAPK signalling in 
wildtype and TG2-/--derived vascular smooth muscle cells are used to 
demonstrate that TG2 is the main transglutaminase involved in calphostin C-
induced apoptosis. 
The findings shown here explore the common and distinct functions of these 
enzymes and details potential avenues for translation into therapy. 
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Chapter 1 – General Introduction 
1.1 Transglutaminases 
Mammals express 8 catalytically active transglutaminases, most of which 
have restricted functions and tissue expression patterns. These are 
transglutaminase (TG) 1 through 7 and FXIII-A, all of which contain the 5 
consensus transglutaminase active site residues Gly-Gln-Cys-Trp-Val 
(Korsgren et al., 1990). Mammals also express a 9th protein known as 
erythrocyte band 4.2 which appears to function as a structural membrane 
protein in red blood cells, and although it possesses the consensus 
transglutaminase active site sequence, it has an alanine mutation of the active 
site cysteine and is therefore catalytically inactive (Korsgren et al., 1990). 
Transglutaminase activity involves calcium-dependent covalent crosslinking 
of two proteins through a glutamine-lysine isopeptide bond (Folk and 
Finlayson, 1977).  First, a glutamine residue on a protein is targeted by the 
transglutaminase, the active site cysteine displaces the -NH2 group of the side 
chain thereby deamidating the glutamine to a glutamic acid and eliminating an 
ammonia group. This intermediate complex with the transglutaminase 
covalently attached is then displaced by a primary acyl acceptor, a lysine 
residue on an adjacent protein, thereby releasing the transglutaminase from 
the complex and forming the isopeptide, ε-(γ-glutamyl) lysine, bond (depicted 
in Figure 1-1). Other reactions are described later. 
The transglutaminase family members are reported to have roles in blood 
coagulation (FXIII-A), keratinocyte differentiation and skin-barrier formation 
(TG1 and 3), extracellular-matrix assembly (FXIII-A and TG2), semen 
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coagulation in rodents (TG4) and brain plaque stabilisation (TG2). Deficiency 
of the transglutaminases is rare but causes spontaneous haemorrhage 
(FXIII-A), lamellar ichthyosis (TG1) and hereditary spherocytosis (Band 4.2) 
(Lorand and Graham, 2003; Greenberg et al., 1991).
- 3 - 
Figure 1-1 – Depiction of a typical transglutaminase catalysed reaction 
The formation of a glutamyl-lysyl bond involves the free cysteine in the catalytic site of a transglutaminase forming an intermediate 
with a glutamine side chain, which is located within a transglutaminase recognition motif. The formed intermediate is available for 
attack by the primary amine group of an adjacent lysine residue which displaces the active site cysteine from the intermediate and 
results in the formation of the stable amide isopeptide bond. 
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1.1.1 Factor XIII-A 
Plasma FXIII (also known as Laki-Lorand factor or fibrin stabilising factor) is a 
320 kDa heterotetrameric (A2B2) complex consisting of 2 catalytic A subunits 
and 2 carrier B subunits. The A subunit is 83 kDa in size and contains 2 
β-barrel domains, a catalytic core domain including the triad of Cysteine-314, 
Histidine-373 and Aspartate-396 (human co-ordinates), a β-sandwich and an 
NH2-terminal activation peptide (Schwartz et al., 1973; Ichinose et al., 1990). 
The B subunit is a 76.5 kDa glycoprotein consisting of 10 sushi domains, each 
stabilised by a pair of disulphide bridges (Schwartz et al., 1973; Komáromi et 
al., 2011). 
Figure 1-2 – Crystal structure of FXIII-A 
FXIII-A exists as a homodimer of two A subunits (one coloured) which 
when inactive show a ‘closed’ conformer. Activation of FXIII-A requires 
binding of calcium dications which causes the two β-barrel domains 
(green and yellow) to undergo a large steric movement (denoted by the 
red arrow) revealing the activation peptide (orange) and the active site. 
Adapted from (Stieler et al., 2013). 
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FXIII-A is expressed as a pro-transglutaminase, which when activated by the 
enzymatic cleavage of thrombin and in the presence of calcium ions, plays an 
important role in the final part of the clotting cascade by crosslinking exposed 
glutamine and lysine residues (generating ε(γ-glutamyl)lysyl bonds) 
(Aeschlimann and Paulsson, 1994; Lorand and Conrad, 1984; Folk and 
Finlayson, 1977) between opposing fibrin α- and γ- chains (Muszbek et al., 
1999). FXIII-A is known to also catalyse the covalent linkage of the serpin 
α2-antiplasmin to the insoluble fibrin mesh. This crosslinking of the fibrin 
chains enables the clot to resist mechanical lysis (i.e. shear-stress) and 
incorporation of serpins imparts resistance against enzymatic fibrinolysis (e.g. 
by plasmin) (Muszbek et al., 2011). Lorand has proposed that inhibition of 
FXIII-A may be considered as a safe therapeutic candidate for the treatment 
of atherosclerosis, coronary heart disease and thrombosis (Lorand, 2000).  
FXIII-A is present in moderate abundance in the plasma (7-14 μg/mL in 
humans) (Yorifuji et al., 1988) and has a short half-life of 5 to 10 days (Ponce 
et al., 2005; Inbal et al., 2004; Hsieh and Nugent, 2008). While the secretory 
source is unknown, the abundance and short half-life suggest that plasma 
FXIII-A is unlikely be maintained by a rare cell type. 
Expression of the FXIII-A homodimer occurs in the bone marrow and 
specifically in megakaryocytes, monocyte/macrophages (Henriksson et al., 
1985; Töröcsik et al., 2005; Muszbek et al., 1985) and dendritic cells (Caux et 
al., 1996; Nestle et al., 1993) and is secreted, through an uncharacterised, 
non-classical pathway, into the blood circulation (Kaetsu et al., 1996). 
Expression of the FXIII-B homodimer takes place in hepatocytes and is 
subsequently secreted into the plasma in excess of FXIII-A. This excess 
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promotes rapid formation of the A2B2 quaternary structure of circulating FXIII. 
FXIII-A2B2 formation is important for haemostasis with the key responsibility of 
FXIII-B2 being to protect FXIII-A2 from oxidation of its cysteine residues in the 
circulation (Robinson et al., 2000). 
There is an emerging view in the literature that FXIII-A is not just involved in 
maintenance of haemostasis. Recently, (Nikolajsen et al., 2014) identified 147 
substrates of plasma FXIII-A, of which 48 were cross linked into the insoluble 
fibrin clot. The other non-clot incorporated substrates which include members 
of the complement cascade, monocyte differentiation antigen and 
immunoglobulin chains led the authors to suggest that FXIII-A has roles in 
complement activation, inflammation and immune response. However, 
immune defects would be expected but are not seen in FXIII-A deficient 
patients and mice and hence this substrate crosslinking activity is either non-
essential or is compensated for by another enzyme. 
A whole range of potential functions have been postulated for FXIII-A in both 
the intracellular and extracellular spaces. 
Intracellularly, FXIII-A2 is present in the cytoplasm and the nucleus of certain 
cell types where it been suggested that it has functions in cytoskeletal 
organisation (e.g. crosslinking actin, myosin, filamin and vinculin in platelets 
and Fcγ-mediated phagocytosis in monocyte-macrophages (Sárváry et al., 
2004; Richardson et al., 2013)) and remodelling (Muszbek et al., 2011). 
FXIII-A has also been identified in the nucleus of monocyte-macrophages, by 
electron microscopy, co-localised with the electron-dense nuclear material 
and shown to be catalytically active in this location by fluorescent 
monodansylcadaverine incorporation assay (Adány et al., 2001). 
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In the extracellular space FXIII-A is suggested to be involved in crosslinking 
proteins to the extracellular matrix (ECM) such as von Willebrand factor (Hada 
et al., 1986) which regulates cell-matrix and cell-cell interactions, and also 
catalysing collagen/fibronectin interactions (Adány and Bárdos, 2003). 
1.1.2 Deficiency of FXIII-A 
Homozygous loss of FXIII-A has a frequency of 1 in 5,000,000 people (Board 
et al., 1993) and affects people of all races. Sixty-nine mutations have so far 
been mapped in FXIII-A and 7 in FXIII-B. Deficiency of the A subunit produces 
a phenotype consisting of severe bleeding, spontaneous intracranial 
haemorrhage, poor wound healing and miscarriage (Hsieh and Nugent, 2008). 
However, treatment with recombinant FXIII-A has shown remarkable success 
in deficient patients and is used routinely in clinical practice. 
Rotational thromboelastometry (ROTEM) is used clinically for detecting 
coagulopathies in people. The system detects clot “stiffness” and as FXIII-A 
activity is responsible for 60-70% of the overall clot strength, it is sensitive to 
FXIII-A deficient states (Nielsen et al., 2004). Patients with FXIII-A deficiency 
show, by ROTEM, delayed clot formation time and reduced overall clot 
stiffness (Nielsen et al., 2007).  
Mouse models deficient for FXIII-A have shown: spontaneous uterine bleeding 
and miscarriage (Koseki-Kuno et al., 2003), development of fatal cardiac 
fibrosis in male, but not female, mice within 12 months as determined by the 
presence of histochemical haemosiderin and collagen positive staining in the 
myocardium (Souri et al., 2008) and left ventricular cardiac rupture following 
coronary artery ligation which could be mitigated with FXIII-A2B2 replacement 
therapy (Nahrendorf et al., 2006). 
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1.1.3 Transglutaminase 2 
TG2 is a 78 kDa monomeric protein which, unlike the other transglutaminases, 
is ubiquitously expressed. As with FXIII-A, TG2 is secreted by a non-classical 
pathway into the extracellular space (van den Akker et al., 2012). Activation 
of TG2 requires the binding of Ca2+ and guanosine diphosphate (GDP) which 
induces the “open” active conformation. Conversely, in states where Ca2+ is 
low and in the presence of bound guanosine triphosphate (GTP), TG2 adopts 
the “closed” inactive conformer. 
While the presence of TG2 in the extracellular space is undisputed, its 
extracellular activity under normal conditions is less well defined. Beyond the 
Ca2+/GTP reciprocal control described earlier, a further level of 
post-translational control is evident extracellularly. In this mechanism, a 
disulphide bridge between two vicinal cysteine residues in the open 
conformation is reduced to enable transamidation to occur (Pinkas et al., 
2007; Stamnaes et al., 2010). Reduction of this bond has been proposed to 
occur in states of tissue damage in which the enzyme thioredoxin is released 
from cells (Jin et al., 2011) (Figure 1-3). Within the ECM, two roles are 
proposed to exist for TG2; the first is a repair function whereby TG2 becomes 
activated following cellular damage and functions to assist in rebuilding the 
ECM. A second function for TG2 is in the establishment of the basal structure 
of the ECM whereby TG2 is suggested to constitutively crosslink a number of 
matrix proteins (e.g. fibronectin, osteonectin and osteopontin) (Kim et al., 
2002) as well as proteinase inhibitors (e.g. elafin) which protect the ECM from 
proteolytic degradation (Nara et al., 1994). However, this constitutive function 
appears to be at odds with the strict activation mechanisms of extracellular 
TG2 (i.e. the requirement for Ca2+, GDP and the reduction of cysteine 
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residues) and it is unclear how this activation would occur in the developing 
ECM.
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Figure 1-3 – Structure and post-translational control of TG2 
TG2 is known to adopt two steric conformations; ‘closed’ and ‘open’. Binding of GTP locks TG2 in the closed conformer, while 
Ca2+ and GDP allows the large conformational change to the catalytically open conformer. Extracellularly, a disulphide bridge 
is formed between two vicinal cysteines due to the oxidative environment. This bridge inactivates TG2 until a reducing agent, 
thought to be thioredoxin, is released from cells following tissue damage. Adapted from (Eckert et al., 2014). 
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Intracellularly, TG2 has been implicated in modulating cell signalling and can 
supposedly function as a G-protein and also as a protein kinase (Mishra and 
Murphy, 2006; Stephens et al., 2004). However, these functions are the 
subject of debate within the field. 
A common pro-apoptotic stimulus is the rapid influx of calcium into the cell 
which should result in the activation of intracellular TG2. This activation may 
under certain circumstances cause large-scale crosslinking of intracellular 
proteins, which potentially keeps the contents of the dying cell intact and 
prevents the leakage of intracellular proteins into the ECM (Park et al., 2010; 
Fesus et al., 1996). Besides protecting against the consequences of 
apoptosis, TG2 may also itself induce apoptosis. The earliest pro-apoptotic 
report of TG2 was described by (Fesus et al., 1987), when TG2 activity and 
antigen were shown to be significantly increased in hepatocytes undergoing 
apoptosis following lead nitrate induced hyperplasia. 
TG2 has also been implicated in neurodegenerative conditions (e.g. 
Alzheimer’s and Parkinson’s disease) whereby accumulation and hyper-
phosphorylation of tau and amyloid β proteins in neurons and glial cells results 
in cell death followed by a steady decline in cognitive function. TG2 is known 
to crosslink and stabilise these protein aggregates and symptoms of 
Huntington’s disease were ameliorated in TG2-/- mice (Mastroberardino et al., 
2002). TG2 also plays an important role in the development of coeliac disease 
whereby glutamine residues (Figure 1-4) in wheat proteins are selectively 
deamidated to glutamic acid due to a lack of proximal amines in the protein 
structure to displace TG2 and form the isopeptide bond. In this instance, water 
is able to act as the acyl acceptor allowing the release of TG2. In certain 
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individuals, these peptides can be recognised as neo-antigens thus triggering 
an immune reaction (Klöck et al., 2012). 
There are two TG2 knockout mouse lines available, one produced by 
Professor Gerry Melino (De Laurenzi and Melino, 2001) which has been 
reported to show a number of pathological phenotypes such as defective 
clearance of apoptotic cells by macrophages and impaired glucose-stimulated 
insulin secretion (Szondy et al., 2003; Bernassola et al., 2002) and a second 
created by Professor Robert Graham (Nanda et al., 2001) which does not 
show either of these phenotypes (Nanda et al., 2001). Whilst both lines are 
deficient in TG2, it remains to be determined whether the Melino mouse 
carries further underlying mutations which produce the deleterious 
phenotypes seen. However, what does seem clear is that the lack of a 
phenotype seen in the Graham mouse is not due to a compensatory rescue 
mutation, since the TG2 knockout mouse has been backcrossed from the 
founder onto distinct mouse lines without producing any pathology.
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Figure 1-4 – Reaction mechanism of TG2-catalysed deamidation 
While TG2 is known for its transamidation activity, it can also catalyse a second reaction when the pH is acidified and a lack of 
appropriately positioned primary amines are available to act as acyl acceptors. In this instance, a water molecule is able to act as the 
acceptor and results in the glutamine residue being deamidated to a glutamic acid. In certain individuals this reaction causes wheat 
proteins, namely gliadin, to be seen as neoantigens resulting in the body mounting an immune reaction leading to coeliac disease. 
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1.1.4 Redundancy between FXIII-A and TG2 
There is a commonly held belief that there is significant crossover in activity 
between FXIII-A and TG2 due to the findings that they both perform the same 
catalytic transamidation activity and are present both intra- and extracellularly. 
An example of this suggested overlap of function is in skeletal tissue formation 
whereby the enzymes are externalised into the extracellular space prior to 
mineralisation and they also function in chondrocyte differentiation 
(Aeschlimann et al., 1993; Nurminskaya et al., 1998; Nurminskaya and 
Kaartinen, 2006). It was suggested by (Tarantino et al., 2009) that in states of 
TG2 deficiency no skeletal defects are observed in mice due to FXIII-A and 
TGF-β being upregulated in response. However, this seems improbable due 
to the different activation mechanisms of the two enzymes which have been 
previously discussed. Further to this, work carried out in a collaboration 
between our group and Dr Christopher Jackson (Bristol) showed no skeletal 
defects (Figure 1-5) in FXIII-A-/-.TG2-/- double knockout mice by DEXA 
scanning (Cordell et al., 2015).  
However, while both FXIII-A and TG2 crosslink proteins at glutamine residues, 
it has been shown that each has differing substrate specificities using phage 
display peptide libraries. It was shown that FXIII-A prefers glutamines residing 
in motifs containing QxxΦxWP (Φ = hydrophobic) residues whereas TG2 
favours QxPΦ, QxPΦD(P) and QxxΦDP motifs (Sugimura et al., 2006). 
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On the other hand, (Bakker et al., 2006) provided substantial evidence for 
compensation between the two enzymes in a model of inward arterial vessel 
remodelling. They showed that in TG2-/- mice, remodelling was delayed but 
still occurred, with transglutaminase mediated crosslinks present in the vessel 
wall and an increase in local FXIII-A content. This compensation was 
suggested to be the result of increased numbers of FXIII-A positive 
macrophages in the vessel wall. When these cells were depleted with the 
cytotoxic drug clodronate, FXIII-A levels decreased and inward remodelling 
was further reduced. 
A further complication which clouds the understanding of redundancy between 
the two enzymes is the mechanism of secretion into the extracellular space. 
As neither FXIII-A nor TG2 have a secretory signal sequence they cannot be 
released from the cell by the classical Golgi-ER pathway. However, the 
non-classical mechanism by which TG2 is secreted from the cell is 
understood. TG2 has been shown in smooth muscle cells to be secreted as a 
result of TG2 crosslinking itself to secretory microparticles (van den Akker et 
Figure 1-5 – DEXA scans of FXIII-A+/+.TG2+/+ and FXIII-A-/-.TG2-/- mice 
Representative images from dual-energy X-ray absorptiometry which 
showed no difference in skeletal morphology or mineral density between 
wildtype and double knockout mice. Adapted from (Cordell et al., 2015). 
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al., 2012). In contrast, FXIII-A externalisation has yet to be convincingly 
demonstrated; suggesting that it must occur by a distinct pathway. 
1.2 The Platelet Hypothesis of Plasma FXIII-A 
There is a long standing view in the literature that the cellular source of FXIII-A 
is the platelet due, primarily, to the fact that platelets contain approximately 
50% of the total FXIII-A in the blood (Adány and Bárdos, 2003). It has been 
argued that simple turnover of these platelets, whereby the intracellular FXIII-
A is released into the blood, is sufficient to explain the high plasma FXIII-A 
concentration. However, no explanation to date has been suggested as to the 
mechanism of release from platelets, and simple “bursting” seems improbable 
as other platelet proteins are not seen in the plasma at comparable 
concentrations. 
The first report of platelets as the cellular source of FXIII-A was by (Wölpl et 
al., 1987), in a case series of three patients who had undergone bone marrow 
transplantation with donor cells carrying a different electrophoretic variant of 
FXIII-A. They found that as early as 6 days post-transplant the recipient 
plasma and platelet FXIII-A phenotype had changed to match the donor and 
this persisted to at least 361 days with no reports of the phenotype reverting 
back to the original recipient variant. 
(Poon et al., 1989) also described patients who had received allogenic stem 
cell transplantation (following myeloablation) again with donor bone marrow 
which carried a different electrophoretic variant of FXIII-A. They showed that 
even though the recipient’s bone marrow had been completely replaced by 
the donor’s, there was a delay of between 115–458 days until the plasma 
FXIII-A phenotype changed to match that of the donor. This is far longer than 
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the plasma half-life of FXIII-A of 5-10 days (Ponce et al., 2005; Inbal et al., 
2004; Hsieh and Nugent, 2008)). The authors concluded that there was 
insufficient evidence to discount either circulating platelets or monocytes 
derived from the bone marrow as the plasma source, and they hypothesised 
that there may be an extrahaematological source of FXIII-A such as the liver.  
(Pihusch et al., 2002) provided the first evidence to suggest a cellular source 
of FXIII-A originating from outside of the bone marrow. They described that 
plasma FXIII-A levels declined slightly following autologous bone marrow 
transplantation (which may suggest a haematological origin), however, the 
levels remained within the normal range. The authors concluded that this was 
as a result of secretion from “long-living” macrophages residing in the liver, 
spleen and lungs. Evidence to discount the liver and spleen as the tissue 
source of plasma FXIII-A is provided later in this thesis. 
However, upon reappraisal of the original literature, it does appear that some 
groups have jumped to the conclusion that platelets are the cellular source 
even though their results point to a distinct origin. 
Despite the work of Pihusch et al, more recent literature, (Inbal et al., 2004) 
has again suggested that platelets are the source of plasma FXIII-A. Inbal et 
al followed 20 patients with various forms of lymphoma and myeloma, who 
received autologous blood stem cell transplantation. They concluded that the 
observed drop in platelet, but not blood monocyte, numbers following 
high-dose chemotherapy to ablate the bone marrow resulted in a 
commensurate drop in FXIII-A concentration which they attributed to impaired 
megakaryocyte activity during the myeloablative treatment. However, the 
conclusions they provided do not match the results they reported. They 
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showed that a >90% drop in platelet count resulted in only a modest 15% 
maximal drop in FXIII-A plasma activity, which does not appear to be 
consistent with a platelet derived source of FXIII-A.  
The above findings also suggest that the circulating monocyte cannot maintain 
the plasma pool as like the platelet, the monocyte has a short half-life of just 
1 to 3 days (Yona et al., 2013; Yang et al., 2014).  
Work from our group has provided the first substantial evidence that platelets 
do not maintain the plasma levels of FXIII-A (Cordell et al., 2010). In this study 
we observed unchanged plasma FXIII-A levels in two different lines of 
thrombocytopenic mice (Bcl-xplt20/plt20 and Mpl-/-). The Bcl-xplt20/plt20 mice, 
possess a homozygous missense mutation in the anti-apoptotic gene Bcl-xL 
which causes the mice to produce platelets which are rapidly cleared with a 
life span of 1 day (Mason et al., 2007). These Bcl-x mice also argue against 
the slow, continual, release of FXIII-A from the platelet over its lifetime rather 
than release from megakaryocytes or at death, as the platelets are born and 
die at the same rate yet the plasma FXIII-A levels remain unchanged. The 
Mpl-/- mice have a targeted deletion of the thrombopoietin receptor which 
vastly reduces megakaryocyte precursor cell numbers and therefore platelet 
production (Alexander et al., 1996; Ng et al., 2014). Due to the low levels of 
platelet biogenesis and clearance in these mice, early or late release of FXIII-
A from the platelet is also excluded as it would be expected that the altered 
equilibrium of platelet synthesis would affect the amount of FXIII-A in the 
plasma. These findings implicated nucleated cells as the secretory source of 
plasma FXIII-A. Our lab also showed - using 35S-methionine labelling 
experiments in THP-1 human monocyte cells - that under conditions where 
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the paradigm non-classically secreted protein, IL-1β, is released from the cell, 
no FXIII-A is secreted. 
These findings support the notion that a cell maintained outside of the 
megakaryocyte lineage is responsible for maintaining the plasma pool of 
FXIII-A and the identity of this cell is addressed in this thesis. 
1.3 Haematopoiesis 
Based on previous literature in the area and the range of cells known to 
express FXIII-A, plasma FXIII-A is expected to be secreted from a 
haematopoietic cell type. 
Haematopoiesis is the process by which all blood cells are generated. These 
cells arise from a common stem cell, the haematopoietic stem cell (HSC). 
Cytokines control the proliferation and differentiation patterns of these stem 
cells by regulating distinct sets of transcription factors. External factors, such 
as blood oxygen saturation, can also stimulate production of mature cells; for 
example, red blood cell (RBC) production is upregulated in states of hypoxia. 
There are three stages of haematopoiesis, divided into early embryogenesis 
(primitive), postnatal and adult (definitive). Of these, the primitive and 
definitive stages are clearly defined and differ markedly from each other whilst 
the post-natal stage is intermediate between the other two and could be 
described as a “handover” stage in haematopoiesis. 
1.3.1 Foetal Haematopoiesis 
During embryogenesis, macrophages are present in the yolk sac and within 
the developing embryo. These cells are found prior to the start of definitive 
haematopoiesis and before monocytes are seen in the foetal circulation 
(Perdiguero and Geissmann, 2016; Samokhvalov, 2014; Garcia and Larina, 
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2014). Early works detected these cells (Naito et al., 1990; Takahashi et al., 
1983; Takahashi et al., 1989) in the blood islands of the yolk sac and also later 
in development, in the foetal liver. These macrophages lacked phagocytic 
activity and showed weak expression of the widely used macrophage marker 
F4/80 (Naito et al., 1990; Takahashi et al., 1989) and it was shown by 
peroxidase staining of foetal rat liver that the resident macrophages were 
capable of self-replication (Deimann and Fahimi, 1978). 
Primitive haematopoiesis involves rapid differentiation of stem cells into 
mature cells and appears to skip a number of intermediary differentiation 
stages (Ginhoux and Jung, 2014; Takahashi et al., 1989). 
As the embryo develops (E8.5-10.5), the first early HSCs emerge in the aorta-
gonad-mesonephros (AGM) and begin production of all lineages of blood 
cells. 
After this (E10.5 to the perinatal period), the foetal liver functions as the major 
site of haematopoiesis following the migration of the HSCs in the AGM 
migrating to the liver. However, it is only perinatally that the transition to 
traditional (adult) haematopoiesis in the bone marrow occurs (Orkin and Zon, 
2008). 
1.3.2 Adult Haematopoiesis 
Occurring in the bone marrow, adult haematopoiesis produces all of the blood 
cells required from birth onwards. The pivotal cell involved in this process is 
the HSC which is able to undergo mitosis to maintain its number and is able 
to differentiate into the multi-potential progenitor (MPP) cell.  
There are known to be two differentiated states of HSCs; the long term (LT-) 
and short term (ST-) HSC. LT-HSCs are responsible for maintaining the cell 
- 21 - 
number of the HSC pool. These cells are able to differentiate into the ST-HSC 
through a Flt3-dependent mechanism. These ST-HSCs have a limited self-
renewal capacity and further differentiate into the MPP. The MPP cells have 
a reduced potential for self-renewal but have the ability to differentiate into all 
the lineages of blood cells (Kondo et al., 2003).  
Both HSCs and MPPs require the transcription factor c-myb for the processes 
of self-renewal and differentiation, and targeted disruption of the c-myb gene 
produces mice with a depleted HSC pool and reduced numbers of all mature 
blood cells (Lieu and Reddy, 2009). 
The MPPs are able to differentiate into two precursor cells, the common 
myeloid precursor (CMP) and common lymphoid precursor (CLP). These cells 
are lineage committed; with the CMP producing the 
megakaryocyte/erythroid/granulocyte/macrophage cells and the CLP 
producing the T- and B-lymphocyte cells. Adult haematopoiesis is 
summarised in Figure 1-6.
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Figure 1-6 – Overview of adult haematopoiesis  
  Adult haematopoiesis occurs in the bone marrow and follows a tightly regulated scheme. All haematopoietic cells originate 
from the long term-haemopoietic stem cell (LT-HSC), which maintains the HSC pool. The LT-HSC is able to differentiate into 
the short term-haemopoietic stem cell (ST-HSC) through a Flt3-dependent pathway and again through a myb-dependent 
pathway to the multipotent progenitor (MPP). The MPP is able to give rise to the common myeloid progenitor (CMP) and the 
common lymphoid progenitor (CLP) which are able to produce all the adult blood cells. As the cells becomes more 
differentiated they lose the ability to self-replicate (adapted from (Ramsay and Gonda, 2008)). 
- 23 - 
1.3.2.1 Platelet Production 
Megakaryocytes in the adult bone marrow shed platelets into the blood stream 
through fenestrations in the capillaries that run adjacent to the bone marrow. 
Work by (Ng et al., 2014) and colleagues recently clarified the expression 
patterns of PF4-cre and endogenous Mpl within the megakaryocyte lineage. 
PF4 is a protein released from platelet alpha-granules on platelet activation, 
which binds heparin with high affinity to modulate coagulation. Mpl is also 
known as the thrombopoietin receptor, a known regulator of megakaryocyte 
differentiation. These authors concluded that PF4-cre is only expressed in the 
precursor cell directly before the megakaryocyte (and in the megakaryocyte 
and platelet) but not in the granulocyte/monocyte precursor (Figure 1-7). The 
group also revised the mechanism by which the body senses platelet number. 
They showed that the Mpl receptor is expressed on all megakaryocyte 
precursors (and not the granulocyte/monocyte precursor). However, the 
purpose of this receptor on the megakaryocyte and platelet is to “mop up” and 
degrade free thrombopoietin. Therefore, increased numbers of these cells 
result in less circulating thrombopoietin to stimulate the precursors. This 
enables megakaryocytes (and therefore platelets) to self-regulate their 
number whilst still being able to rapidly respond to thrombocytopenic events 
when more free thrombopoietin is available to stimulate stem cell expansion. 
While the previous study by Ng et al showed quite specific and limited 
expression of PF4 (and therefore PF4-cre), earlier lineage tracing experiments 
had not (Calaminus et al., 2012). Calaminus et al described the use of a 
PF4-cre crossed stop-floxed RFP mouse which showed RFP expression, and 
therefore recombination, in platelets as expected, but wider cell analysis 
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showed RFP expression in a number of other cells types. Their results 
suggested that PF4-cre had shown recombination in approximately 50% of 
stem and primitive progenitor cells meaning that various haematopoietic cell 
types could show the effects of recombination. This theme will be returned to 
in the experimental work presented in this thesis.
Figure 1-7 – PF4 and Mpl expression in bone marrow cells 
The thrombopoietin receptor (Mpl) is expressed on all cells of the 
megakaryocyte lineage (including stem cells) and the receptor is activated 
by the cytokine, thrombopoietin (TPO) which stimulates proliferation of the 
megakaryocyte precursors. The function of the Mpl receptors on 
megakaryocytes and platelets is to mop up and degrade free TPO which 
therefore limits proliferation of the precursors and reduces the rate of 
platelet production. In thrombocytopenic states, the TPO is not degraded 
as quickly and therefore more is available to activate the Mpl receptors on 
the stem cell precursors which results in their expansion and therefore 
increases platelet production to counter the thrombocytopaenia (Ng et al., 
2014). 
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1.4 Cre-Lox Recombination 
In light of the significant uncertainty regarding the cellular source of FXIII-A, 
this thesis aims to employ the use of cre-lox technology to generate mice with 
reduced FXIII-A gene expression. 
Mutations in any mouse gene can now be induced by either conventional gene 
knockout (i.e. homologous recombination to irreversibly inactivate the gene) 
or, through conditional gene targeting with cre-lox technology which allows for 
temporal and/or spatial control of gene recombination depending on the type 
of cre recombinase construct used. 
The cre-lox system (Sauer and Henderson, 1988) works by flanking the gene 
of interest with small palindromic sequences known as LoxP sites which act 
as recognition motifs for the Cre DNA recombinase enzyme. 
Cre recombinase cleaves and reattaches the flanked DNA sequences and 
depending upon the orientation of the LoxP sites, can result in deletions (same 
orientation), inversions (opposing orientation), insertions and translocations to 
the sequence. These processes are summarised in Figure 1-8. 
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Figure 1-8 – An overview of cre-lox recombination events 
Cre-lox mediated recombination requires the action of; (1) a DNA 
recombinase (cre), and (2) recombination signalling DNA markers (LoxP 
sites). Depending on the orientation and position of these markers, cre 
recombinase can perform 4 separate actions on DNA; deletion of bases 
between the LoxP sites, insertion of DNA between the sites, inversion of 
the DNA between the sites or translocation of a region of DNA. Adapted 
from (Bockamp et al., 2002). 
 
The expression pattern of the cre recombinase can be determined by 
replacing the promoter sequence of the cre gene with either a promoter to 
enable whole body expression (e.g. the immediate early promoter of human 
cytomegalovirus, CMV) or a promoter that has a defined cell expression 
pattern (e.g. PF4-cre which was presumed to be expressed in cells of the 
megakaryocyte lineage (Tiedt et al., 2007; Ng et al., 2014)). A further level of 
(temporal) control, can be added to this system by creating a fusion protein 
whereby the cre recombinase is attached to a ligand binding domain of a 
mutant form of the oestrogen receptor. This then requires injection of 
tamoxifen into the mouse which causes the release of the tethered cre 
enzyme from the cytoplasm and therefore initiation of recombination. This 
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control avoids issues with embryonic lethality and developmental problems 
which can occur with classical gene knockout models. 
With cre-lox recombination, especially for conditional cre constructs, it is 
important to know that the cre gene is only expressed in the tissues of interest. 
One method for testing the expression pattern is through the use of a 
stop-floxed mouse. A stop-flox mouse contains a transgene in which 
expression of a marker gene (e.g. LacZ (Soriano, 1999) or fluorescent protein 
marker (Muzumdar et al., 2007) are interrupted by a floxed region of DNA 
(usually an in-frame stop codon). This floxed region disrupts expression of the 
reporter gene until excision by cre recombinase. 
When a floxed mouse is crossed with a mouse expressing a cre construct, the 
resulting pups contain both the floxed and cre genes. These pups, depending 
on the expression pattern of the cre gene, will either undergo recombination 
immediately and in most cells (i.e. CMV-cre, which has a 90% recombination 
efficiency) and generate a stable germline mutation (after the F2 generation), 
or later and in limited cells (i.e. PF4-cre) and be a non-germline de novo 
mutation in every litter. Figure 1-9 shows an overview of potential cre-lox 
recombination strategies for gene knockout. 
It has been noted in the literature that insertion of short DNA sequences (i.e. 
LoxP sites) can alter expression patterns of the target and also off target 
genes at distances of >100 Kb away (Meier et al., 2010). Therefore, it is 
important to first determine any effects which are due to the insertion of the 
ectopic sequence before any interpretations are made about the effects of 
ablation of the target gene. 
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Figure 1-9 – An overview of cre-lox recombination strategies 
Cre-lox is amenable for use in a number of different ways. Global knockout mice can be easily produced by generating gene fusions 
with the viral cytomegalovirus promoter (CMV) which is transcriptionally active in cells of all lineages and therefore produces germline 
recombination. Gene fusions can also be made with tissue specific promoters (such as the supposedly megakaryocyte-specific gene, 
PF4) which restricts recombination to these cells. A further layer of control is possible in both of the above situations by fusing the cre-
promoter gene to a modified version of the oestrogen receptor. This allows temporal control of recombination by administration of a 
synthetic activator of the receptor (e.g. tamoxifen). 
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1.5 The Blood Vessel 
The work in this thesis also focusses on cells within the arterial wall and their 
functions. The arterial wall consists of three main layers; tunica intima, tunica 
media and the tunica adventitia which are bound together by two internal 
elastin-rich layers. These layers are the internal elastic lamina (between the 
intima and media) and external elastic lamina (between the media and the 
adventitia). 
The intimal layer consists of a single layer of squamous endothelial cells which 
control vascular barrier function and allow the passage of blood solutes 
ranging from small molecules (e.g. metabolites) up to whole cells (e.g. 
immune cells following inflammation) from the circulation into the surrounding 
tissue space and vice versa. The endothelial cells also play a key role in 
detecting changes in shear-stress through cell-surface mechanoreceptors 
and signalling to the smooth muscle layer to contract to resist this change. 
They also mediate blood vessel dilation in response to neuronal signals by 
releasing nitric oxide (Bauer and Sotníková, 2010; Alberts B, Johnson A, 
2002). 
The medial layer is made up of elastin fibres (arranged as fenestrated elastic 
lamellae) along with a high density of vascular smooth muscle cells. This layer 
is responsible for maintaining the contractile tone of the vessel and the width 
of the layer is variable depending on the size of the vessel. 
The adventitial layer is comprised of collagenous fibres, elastic fibres, 
fibroblasts, macrophages and the perivascular nerves. This layer is thought to 
contain resident progenitor cell niches which are primed to respond to 
vascular injury and is also a major site of immune surveillance and 
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inflammatory cell trafficking in response to foreign antigens. The adventitia is 
also in physical contact with the tissue surrounding the vessel and is thought 
to mediate the exchange of signals between the tissue and the vessel 
(Majesky et al., 2011).  
1.5.1 The Vascular Smooth Muscle Cell 
Vascular smooth muscle cells (VSMCs) are the most abundant cell type found 
within the vascular wall. Located within the medial layer of the artery, these 
stromal cells are responsible for maintaining local blood pressure (in 
resistance vessels) as well as providing the vessel with the means to 
withstand the high pressure blood flow through it. 
During development, these cells are responsible for synthesising the ECM of 
the medial layer and throughout adult life are capable of remodelling and 
repairing the ECM in response to injury (Lacolley et al., 2012). 
VSMCs are known to be a heterogeneous cell type. Two phenotypes known 
as contractile and synthetic sit at two ends of a spectrum with cells showing 
phenotypes between the two. The contractile cells, which comprise the 
majority of VSMCs, perform the classical functions of the smooth muscle cell, 
i.e. maintaining vascular tone, whereas the synthetic cells are thought to be a 
dedifferentiated form of the VSMC which perform the remodelling of the ECM 
(Owens et al., 2004). In states of chronic inflammation, stress (both oxidative 
and mechanical) and chemokine activation tip the balance in favour of the 
synthetic cells and results in overactive remodelling of the ECM and, if 
prolonged, the destruction of the ECM and weakening of the vessel (e.g. in 
aortic aneurysm disease) (Rensen et al., 2007). 
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VSMCs are also known to be key mediators of atherosclerosis and restenosis 
after angioplasty. Both conditions show the characteristic migration of VSMCs 
from the media into the intimal layer of the vessel where they accumulate, 
proliferate and promote formation of atheromatous plaques (Hao et al., 2003). 
These cells are then known to undergo apoptosis and it has been 
hypothesised that this cell death causes the destabilisation of the shoulder 
regions of the plaque leading to rupture (Davies et al., 1993; Geng and Libby, 
1995; Bauriedel et al., 1999; Bennett and Boyle, 1998). 
It has been shown previously, albeit in rats, that aortic vascular smooth muscle 
cells express both transglutaminase 1 and 4 (Johnson et al., 2012) as well as 
the ubiquitously expressed transglutaminase 2. 
1.6 Vascular Disease Models in Mice 
This thesis explores the roles of the two transglutaminases FXIII-A and TG2 
in the vasculature and their roles in repair. Parallel work within the group 
employs two disease models to study them in this context; aortic aneurysm 
and cardiac fibrosis. Other models have subsequently been investigated and 
are presented later in this thesis. 
1.6.1 Abdominal Aortic Aneurysm 
Abdominal aortic aneurysms (AAA) are localised dilatations of the abdominal 
aorta occurring primarily between the renal arteries which, in human patients, 
may rupture with fatal consequences. The pathophysiology of AAA includes 
four specific events; infiltration of the aortic wall by inflammatory 
macrophages, destruction of the elastic media and adventitia by matrix 
metalloproteinases leading to a reduced elastin:collagen ratio, rapid 
proliferation and invasion of VSMCs into the lumen from the tunica media 
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followed by apoptosis causing thinning of this layer of the vessel, and 
neovascularisation (Ailawadi et al., 2003). 
Several AAA mouse models are described in the literature, these are 
adventitial application of calcium chloride (Gertz et al., 1988), infusion of 
angiotensin II into hypercholesterolaemic mice (Daugherty et al., 2000) and 
peri-aortic application of elastase (Pyo et al., 2000). Of these, our group chose 
to use the calcium chloride model due to the presence of the following features 
which mimic the human condition: calcification, inflammatory cell invasion, 
MMP activation, elastin loss and fibre fragmentation and VSMC apoptosis. 
The model requires neither genetically altered mice (i.e. ApoE deficient male 
mice are required for the angiotensin model) nor weakening of the vessel to 
start the process (i.e. the elastase model). 
1.6.2 Cardiac Fibrosis 
Progressive organ fibrosis is a hallmark of aging which affects the heart, 
kidney, liver and lung and is characterised by deposition of collagen and loss 
of organ function (Biernacka and Frangogiannis, 2011). In the heart, this is 
seen as a loss of ventricular compliance and impaired diastolic function 
(Lakatta, 2003). 
In mice, increased microvascular permeability can result in the development 
of spontaneous cardiac fibrosis. This permeability causes microvascular 
haemorrhage and stimulates the invasion of inflammatory cells into the 
cardiac tissue which in turn carry out remodelling of the ECM and lead to the 
increased deposition of ECM components (Wynn, 2008). Previous reports in 
the literature have postulated roles for numerous clotting factors in the 
protection of the myocardium from fibrosis, with deficiency of Factor VII (Xu et 
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al., 2009), plasminogen activator inhibitor-1 (Xu et al., 2010), tissue factor 
(Pawlinski et al., 2002) and FXIII-A and FXIII-B in male mice (Souri et al., 
2008) all causing spontaneous cardiac fibrosis. In our hands, cardiac fibrosis 
developed spontaneously in FXIII-A-/-.TG2-/- mice irrespective of high fat 
feeding and this is explained in detail later in 3.5.1. 
1.7 SAPK/JNK Signalling Pathway 
It has been hypothesised by (Robitaille et al., 2004; Robitaille et al., 2008) that 
a transglutaminase is able to crosslink and activate the upstream protein 
kinase in the MAPK signalling pathway and thus promote pro-apoptotic 
signalling within the cell. 
The MAPK signalling pathway provides the cell with the machinery to relay, 
magnify and incorporate signals from a vast range of exterior stimuli. In 
mammals, these responses involve; proliferation, differentiation, inflammation 
and initiation of programmed cell death (Weston and Davis, 2007). 
Activation of the MAPK pathway by “stress” factors (e.g. IL-1β, IL-6, TNF-α 
and nitric oxide) allows the cell to respond to extracellular stimuli and chronic 
activation of this pathway typically results in apoptosis of the cell (Cafueri et 
al., 2012; Verma and Datta, 2010). 
The components of signal transduction in the MAPK pathway involve a 3 tier 
array of kinases with each tier being able to modulate the function of the next 
through phosphorylation of key residues on specific substrates. The three tiers 
are referred to as; MAP kinase kinase kinase (MAP3K or MAPKKK), MAP 
kinase kinase (MAP2K or MAPKK) and MAP kinase (MAPK). 
Activation of the pro-apoptotic MAPK pathway results in recruitment of dual 
lineage kinase (also referred to as DLK or MAP3K12) to the cell surface where 
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it is activated by phosphorylation and oligomerisation followed by covalent 
crosslinking, which is catalysed by a transglutaminase (Robitaille et al., 2004; 
Robitaille et al., 2008). Once activated, DLK is able to phosphorylate both 
SEK1 (MKK4) and SEK2 (MKK7) which in turn are able to phosphorylate 
JNK1 (MAPK8) and JNK2 (MAPK9) (Cui et al., 2007). Activated JNK 
(phosphorylated at threonine-183 and tyrosine-185 residues (Fleming et al., 
2000)) has been shown to be able to phosphorylate a range of substrates 
such as the nuclear transcription factors c-Jun, ATF and c-Fos (Gupta et al., 
1995) allowing the cell to switch on and off expression of many stress 
response genes. 
JNK comprises a family of three genes; JNK 1 and 2 are widely expressed 
whereas JNK 3 is exclusively expressed in neurones. All three genes have 
been individually “knocked out” by homologous recombination in mice and 
these JNK-deficient mice are viable but show defects in apoptotic and immune 
signalling (Coffey, 2014). Whilst JNK is predominantly known as a pro-
apoptotic mediator, growth factors (e.g. IGF-1, EGF and NGF) are also able 
to activate JNK through a separate pathway resulting in a proliferative cellular 
phenotype (O’Blenes et al., 2000). Compound knockout mice (JNK1-/-.JNK2-/-) 
show early embryonic lethality (Kuan et al., 1999); embryonic fibroblasts 
isolated from these mutants show a resistance to stress-induced apoptosis 
but also have decreased rates of proliferation (Tournier et al., 2000) 
suggesting that JNK activation is necessary for these functions in addition to 
mediating cell death. 
The apoptotic and proliferative arms of MAPK signalling are summarised in 
Figure 1-10.
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Figure 1-10 – MAPK apoptotic and proliferation signalling pathway 
The mitogen activated protein kinase pathway comprises two pathways, apoptotic and proliferative, which both require 
JNK to effect changes within the cell. The two pathways are activated by different stimuli and switch on different 
transcription factors. Global inhibition of JNK to stop cell death, therefore, appears unwise as it would result in the loss of 
the proliferative capability. 
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1.7.1 Global JNK inhibition in previous studies 
c-Jun N-terminal kinase (JNK) has been implicated as the major factor in AAA 
pathogenesis. (Yoshimura et al., 2006) reported that JNK activation was 
markedly increased in the walls of human AAA resulting in the induction of the 
ECM degrading enzyme matrix metalloproteinase-9 (MMP-9) and 
suppression of ECM synthesis through the down-regulation of lysyl oxidase 
(LOX).  
Inhibition of JNK by the small molecule SP600125 (an ATP competitor) 
followed by AAA induction with 0.5 M CaCl2 in mice did not lead to a significant 
increase in aortic diameter or damage to the vessel when compared to 
controls. However, whilst Yoshimura et al describe SP600125 as a specific 
inhibitor of JNK (Yoshimura et al., 2006), it appears to also inhibit closely 
related kinases such as protein kinase B and C, as shown in Table 1-1 
(Bennett et al., 2001). It may be that it is the inadvertent inhibition of one of 
these other kinases that prevents the vessel dilatation and aneurysm 
formation, either in concert with JNK inhibition, or independently. Additionally, 
due to the requirement of JNK activation for non-apoptotic signalling (namely 
proliferation), wholesale JNK inhibition may not prove to be a viable long-term 
therapeutic strategy. This notion is also reflected in the findings of the 
compound JNK1 and 2 deficient mice (Tournier et al., 2000). 
SP600125 has also been shown to protect mice from small intestinal injury 
caused by diclofenac (Ramirez-Alcantara et al., 2009), hepatic fibrosis 
resulting from either bile duct ligation or carbon tetrachloride injury (Kluwe et 
al., 2010). JNK has been implicated in both acute liver injury resulting from 
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paracetamol overdose (Win et al., 2011) and appears necessary for 
macrophage differentiation into foam cells (Rahaman et al., 2006). 
Beyond this, significant interest is being focussed on MAPK inhibitors for use 
in the treatment of traumatic brain injury and stroke as well as in 
neurodegenerative conditions such as Alzheimer’s disease and Huntington’s 
disease (Kim and Choi, 2010; Coffey, 2014).  
1.7.2 Transglutaminases in Cell Apoptosis and Survival 
Many authors have reported that intracellular TG2 activity is pro-apoptotic in 
the in vitro situation (Robitaille et al., 2004; Robitaille et al., 2008; Hébert et 
al., 2000). For example, Robitaille et al (2004) undertook work in a monkey 
kidney fibroblast like-cell line transformed with a T7-tagged DLK vector and 
used an inhibitor (monodansylcadaverine, MDC) to block the action of TG2. 
Enzyme IC50 (µM)
JNK1 0.04
JNK2 0.04
JNK3 0.09
MKK4 0.4
MKK6 1.0
PKB (AKT) 1.0
MKK3 1.5
PKCa 1.5
p56Lck 4.3
MKK7 5.1
ERK2 >10
p38-2 >10
Chk1 >10
EGF-TK >10
IKK-1 >10
IKK-2 >10
MEKK1 >10
PKA >10
Table 1-1 – Inhibitory profile of SP600125 
The most promising and widely cited JNK inhibitor is known as SP600125. 
While it is known to inhibit the kinase activity of all 3 JNK genes it also is 
known to inhibit numerous other kinases with a similar affinity (Bennett et 
al., 2001). 
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They induced apoptosis in culture using the fungi metabolite calphostin C 
which is able to specifically inhibit protein kinase C (PKC) by a light-dependent 
mechanism. Inhibition of PKC causes rapid mobilisation of intracellular 
calcium ion stores, resulting in induction of apoptosis and this increase in 
[Ca2+] should activate intracellular TG2 as described previously (Zhang et al., 
1998). Robitaille et al found that initiation of apoptosis resulted in the formation 
of higher-order oligomers of DLK which corresponded with a direct increase 
in phosphorylated JNK, caspase cleavage and cellular apoptosis. These 
effects could be significantly reduced by pre-treating the cells with an inhibitor 
of transglutaminase activity, MDC. 
However, the use of an immortalised cell line in this work is problematic, as 
defects in apoptotic signaling may result from the immortalisation process thus 
rendering these cells unsuitable to study the apoptotic role of TG2. 
Furthermore, the use of MDC as an inhibitor means that all transglutaminase 
activity is inhibited (not simply TG2 activity) as MDC acts as a primary amine 
acceptor i.e. as a competitive substrate in the transamidation reaction. MDC 
is also known to block TNF-α receptor internalisation which is a MAPK 
activating signal (Schütze et al., 1999) and can also act as a lysosomotropic 
agent which causes the breakdown of intracellular ion gradients and therefore 
causes an increase in cellular acidity (Niemann et al., 2000) both of which 
could disrupt the normal apoptotic signaling pathway. 
Paradoxically, TG2 has also been seen to play a role in cell survival. This dual 
function appears to be dependent on whether or not the stressor results in an 
increase in transamidation activity (Tucholski and Johnson, 2002; Milakovic et 
al., 2004), with activation promoting apoptosis (as described above) and no 
- 39 - 
activation repressing apoptosis. This anti-apoptotic response could be, in part, 
due to TG2’s ability to bind calreticulin in a GTP-dependent manner at a site 
distinct from the transamidation catalytic site (Feng et al., 1999) as 
overexpression of calreticulin is known to sensitise the cell to apoptotic signals 
(Nakamura et al., 2000). 
1.8 General Aims 
a) To determine if FXIII-A and TG2 individually or co-operatively influence 
the outcome of cardiac fibrosis and abdominal aortic aneurysm in mice. 
b) To find the cell responsible for secreting and maintaining the levels of 
plasma FXIII-A using a novel FXIII-A floxed mouse and several tissue 
specific cre mice. 
c) To describe the role TG2 plays in apoptosis using a cell based model 
and TG2-knockout mice. 
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Chapter 2 – General Methods 
2.1 Mouse Husbandry 
All animal husbandry, housing and procedures were carried out in line with 
the regulations and guidelines of the University of Leeds Central Biologicial 
Services facility and under the authority of a United Kingdom Home Office 
approved Project licence (Dr Stephen Wheatcroft – 70/8115) and my own 
Personal licence (Mr Kingsley Simpson – 70/25614). All mice were maintained 
on a 12 h light/dark cycle and had access to water and standard laboratory 
chow diet at all times. 
2.2 Origins of the Mice  
2.2.1 Thrombocytopenic (Mpl Knockout) 
The Mpl (thrombopoietin receptor) knockout mice were obtained from 
Professor Warren Alexander (Walter and Eliza Hall Institute, Australia) on a 
defined C57BL/6 background. Despite a severe bleeding phenotype following 
injury, female homozygote knockouts breed normally. The Mpl-/- males were 
crossed with Mpl-/- females, in trios, to produce Mpl-/- pups. 
2.2.2 TG2 Knockout 
TG2+/- knockout mice, on a C57BL/6 background, were a kind gift from 
Professor Robert Graham (Victor Chang Institute, Australia). These mice have 
a targeted deletion of exons 6-8 of the TG2 gene which was carried out using 
cre-lox recombination of a TG2 floxed mouse (Nanda et al., 2001). TG2+/- x 
TG2+/- breeding was established to produce TG2-/- offspring at an expected 
ratio of 1 in 4. Following this, TG2-/- pups from distinct litters were crossed in 
trios to produce pure litters of TG2-/- pups which were used for study. 
- 41 - 
2.2.3 FXIII-A Floxed Mouse 
Figure 2-1 shows the process by which C57BL/6:129/Sv chimeric offspring 
habouring the FXIII-A targeted locus were backcrossed onto a C57BL/6 
mouse expressing Flp recombinase to remove the neomycin resistance 
cassette from the homologous recombination targeting vector. The offspring 
produced contain one wildtype allele and one floxed allele (FXIII-A+/flox). This 
mouse was then backcrossed onto either a wildtype C57BL/6 mouse (to 
generate backcrossed heterozygous floxed mice, FXIII-A+/flox) or a C57BL/6 
mouse expressing CMV-cre (to produce FXIII-A heterozygous knockouts, 
FXIII-A+/-). At this stage the mice were 75% C57BL/6 and were further 
backcrossed to >93.75% C57BL/6 to remove stain differences. 
Figure 2-1 – Schematic of the FXIII-A breeding strategy used by 
GenOway 
Chimeric floxed C57BL/6:129Sv mice were backcrossed onto a C57BL/6 
background and the neomycin resistance cassette excised by Flp 
recombinase. FXIII-A floxed and global knockout mice were produced by 
crossing either with wildtype C57BL/6 or CMV-cre expressing C57BL/6 
mice respectively. The background was then further enriched by 
backcrossing with C57BL/6 mice. 
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2.3 Flox Sequencing 
Genomic DNA was isolated from livers as per 2.10 below. The entire FXIII-A 
floxed locus was amplified by PCR with primers that hybridised both upstream 
and downstream of the two LoxP sites, using a proofreading Pfu/Taq 
polymerase mix (Bio-Rad). The primer sequences used are detailed in Table 
8-1. 
Taq polymerase adds a single adenosine nucleotide overhang to the 3’ end 
of each amplicon and the PCR product was ligated into a pCR4-TOPO vector 
(ThermoFisher Scientific) which possesses 5’ thymidine overhangs. The 
system utilises topoisomerase to recircularise the vector once the Taq 
amplified product has hybridised. E. coli DH5-α cells were transformed by heat 
shocking the cells at 42oC in the presence of the plasmid, spread onto an agar 
plate containing ampicillin (100 μg/mL) and allowed to replicate overnight at 
37 oC. Single colonies were selected and grown overnight at 37 oC with 
shaking (225 rpm) in lysogeny broth containing ampicillin (100 μg/mL). The 
plasmid was recovered using Qiagen miniprep kits as per the manufacturer’s 
recommended instructions and diluted to 20 ng/µL in ultrapure water. The 
DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, 
College of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) 
using Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied 
Biosystems model 3730 automated capillary DNA sequencer.  
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2.4 Generation of de novo FXIII-A Knockout Mice 
2.4.1 FXIII-A Knockout 
All FXIII-A global and conditional knockout mice in this study were generated 
using cre-lox technology. A floxed FXIII-A mouse was commissioned by 
GenOway which had LoxP sites inserted, flanking exon 8 (coding exon 7) 
within intron 7 and intron 8 of the FXIII-A gene (Figure 2-2). Recombination of 
these sites in cells expressing cre recombinase produces a truncated mRNA, 
which lacks the catalytic domain.  
Homozygous global FXIII-A knockout mice were produced by crossing 
non-sibling pups from separate FXIII-A+/- litters. 
Due to FXIII-A deficient females being unable to survive pregnancy, the 
breeding strategy consisted of trios of a FXIII-A-/- male and two FXIII-A+/- 
females. This was expected to give a frequency of 1 in 2 for FXIII-/- pups 
however, as described later in 3.4.2, the frequency of homozygous knockout 
pups obtained was markedly below expectation. 
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Figure 2-2 – Depiction of the wildtype and genetically modified FXIII-A locus 
The FXIII-A gene was targeted by homologous recombination by GenOway. Flanking coding exon 7, a pair of LoxP sites 
were added along with a neomycin resistance cassette (which was enclosed between two FRT sites, and subsequently 
removed by recombination with Flp recombinase). Cre-mediated recombination removes coding exon 7 and the remaining 
recombined FRT site. Primer locations for genotyping are shown as labelled arrows. 
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2.4.2 Conditional FXIII-A Knockouts 
To induce cell lineage specific deletion of FXIII-A, floxed mice were crossed 
with mice harbouring cre recombinase constructs fused to the promoter of one 
of four genes: Platelet Factor 4 (PF4) (Tiedt et al., 2007), Integrin Alpha M 
(CD11b) (Ferron and Vacher, 2005), Lysozyme 2 (LysM) (Faust et al., 2000) 
and Fms-related Tyrosine Kinase 3 (Flt3) (Benz et al., 2008). The PF4-cre 
transgene is present on an unidentified autosome(s) whereas the CD11b-cre 
and Flt3-cre transgenes reside on the Y chromosome and as such are only 
present in male mice. LysM-cre is a knock-in into the endogenous Lys2 gene. 
PF4-cre utilises a 100Kb bacterial artifical chromosome to target expression 
of a codon-optimised cre recombinase to the megakaryocyte lineage (Tiedt et 
al., 2007). The construct comprises of PF4 (which has the first exon fused to 
the cre sequence) and 4 other chemokine genes. However, while PF4-cre has 
been used in a large number of studies, the endongeous PF4 gene has been 
reported to be expressed in other cell types (e.g. monocytes (Schaffner and 
Rhyn, 2005)). More recent evidence from (Pertuy et al., 2015) has 
demonstrated clear expression of the PF4-cre transgene outside of the 
megakaryocytic lineage in F4/80+ macrophage cells in the majority of mouse 
tissues (which are presumably tissue resident macrophages). 
The PF4-cre+.FXIII-Aflox/flox mice were produced by crossing 
PF4-cre+.FXIII-Awt/wt and FXIII-Aflox/flox mice. This produces 
PF4-cre+.FXIII-Awt/flox mice, which were then crossed against FXIII-Aflox/flox 
mice to generate PF4-cre+.FXIII-Aflox/flox mice at a mendelian frequency of 1 in 
2. Once generated, PF4-cre+.FXIII-Aflox/flox mice were crossed against 
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FXIII-Aflox/flox mice to ensure a constant production of PF4-cre+.FXIII-Aflox/flox 
mice (Figure 2-3). 
 
In some studies a second PF4-cre allele was bred into these mice (Figure 
2-4). These mice were bred through hemizygous crosses of 
PF4-cre+.FXIII-Aflox/flox and PF4-cre+.FXIII-Aflox/flox. Real time PCR of genomic 
DNA was used to discrimate pups with one or two copies of the cre transgene 
(i.e. PF4-cre+ or PF4-cre++). 
LysM-cre+.FXIII-Aflox/flox mice were bred in a similar fashion to the single copy 
PF4-cre mice with LysM-cre+.FXIII-Aflox/flox crossed with FXIII-Aflox/flox mice to 
Figure 2-3 – Generation of 1 copy PF4-cre.FXIII-A floxed mice 
Single copy PF4-cre.FXIII-Aflox/flox mice were produced by crossing 
PF4-cre mice with the de novo FXIII-Aflox/flox mouse as per the diagram. 
Figure 2-4 – Generation of 2 copy PF4-cre.FXIII-A floxed mice 
Two copy PF4-cre.FXIII-Aflox/flox mice were produced by crossing 
hemizygotic PF4-cre.FXIII-Aflox/flox mice as per the schematic above. 
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produce LysM-cre+.FXIII-Aflox/flox offspring. Pups were genotyped based on the 
presence or absence of the transgene using a 3 primer strategy with a 
common oligo hybridising just upstream of the insertion site. 
CD11b-cre+.FXIII-Aflox/flox and Flt3-cre+.FXIII-Aflox/flox mice were bred using the 
same strategy as the single copy PF4-cre mice but as male mice only habour 
a single Y chromosome, only one cre allele can ever be present. 
CD11b-cre+.PF4-cre+.FXIII-Aflox/flox mice were bred by crossing 
CD11b-cre+.FXIII-Aflox/flox males with PF4-cre++.FXIII-Aflox/flox females which 
produce male mice that are hemizygous for both the CD11b-cre and PF4-cre 
alleles and homozygous for the floxed FXIII-A locus. 
2.4.3 FXIII-A.TG2 (Double) Knockout 
Double knockout, FXIII-A-/-.TG2-/-, (DKO) mice, were bred by crossing 
FXIII-A-/- males with TG2-/- females to produce FXIII-A+/-.TG2+/- offspring. 
These offspring were backcrossed twice against TG2-/- mice to increase the 
Figure 2-5 – Breeding of double knockout mice 
Global FXIII-A and TG2 double deficient mice were produced by 
breeding mice deficient for the two genes through the scheme above.  
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C57BL/6 background of the mice resulting in FXIII-A+/-.TG2-/- mice on a 97% 
C57BL/6 background. These mice were bred in sibling-sibling crosses to 
produce FXIII-A-/-.TG2-/- offspring. Beyond this, mice were bred in trios 
consisting of a single FXIII-A-/-.TG2-/- male and two FXIII-A+/-.TG2-/- females 
and the DKO offspring used for study. This breeding strategy is summarised 
in Figure 2-5. 
2.5 Routine Genotyping 
Pups were ear notched at weaning (~3 weeks of age) and gDNA extracted by 
subjecting each individual sample to high temperature (95 oC) in 100 µL of an 
alkaline solution (final concentration of 25 mM NaOH and 0.2 mM EDTA) for 
20 min followed by the addition of 100 µL of a pH neutralising solution 
containing Tris-HCl (final concentration of 20 mM, pH 5.5). These samples 
were frozen at -20 oC, if not immediately used for PCR.  
PCR reactions were carried out in 25 µL total volumes containing 2 µL of the 
undiluted gDNA isolate along with 12.5 µL of MyTaq Red master mix (Bioline). 
For all genotypes, common PCR reaction conditions were used; 
1. 94 ºC for 2 min 
2. 94 ºC for 15s 
3. Tm (shown in 8.1) for 20s 
4. 72 ºC for 45s 
5. Repeat steps 2-4 another 29 times 
6. 72 ºC for 5 min 
7. Cool at 4 ºC 
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PCR primers, sequences and melting temperatures for each genotype are 
defined in 8.1. 
Figure 2-6 shows the expected electrophoretic product sizes for each 
genotype.
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Figure 2-6 – Representative samples of PCR genotyping of mouse lines 
Regions of gDNA were amplified by PCR to produce electrophoretic bands that show the presence of the floxed locus 
of FXIII-A (e.g. FXIII-A Flox), the wildtype or recombined alleles (e.g. FXIII-A+/- and TG2+/-) or the presence or absence 
of the cre gene (e.g. -cre lines). 
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2.5.1 Agarose Gel Electrophoresis 
To determine the genotype of the different mouse lines, PCR products 
(generated as outlined in 2.5 above) were separated using agarose gel 
electrophoresis, whereby smaller DNA molecules migrate through the gel 
faster than larger ones. 
Gels were cast in 8 cm x 15 cm gel tanks with two 16 well combs embedded 
within. For all genotyping assays 2% (3 g/150 mL) agarose gels were used in 
a total volume of 150 mL of 1x TAE buffer (40 mM Tris-HCl, 20 mM acetic 
acid, 1 mM EDTA, pH 7.6). The agarose and TAE buffer were mixed in a 500 
mL conical flask and brought to melting in an 800 W microwave. Once heated 
and the agarose totally dissolved, 1 µL of ethidium bromide solution (10 
mg/mL, Sigma-Aldrich) was added to the gel mix. The tank was filled with 1x 
TAE buffer until the gel was submerged and 1 µL ethidium bromide solution 
added to the cathode end of the gel tank. Then, 5 µL (50 ng/µL) of 100bp 
GeneRuler Ladder (ThermoFisher Scientific) was added to the first lane and 
the total 25 µL PCR reaction added to subsequent wells. It was then 
connected to a PowerPac Basic power supply (Bio-Rad) and electrophoresis 
carried out at 125 V for 60 min.  
After electrophoresis, gels were imaged on a G:Box (Syngene) using UV 
illumination and the genotyping gel images saved as JPG files. The genotypes 
of all mice were determined manually and corroborated by two independent 
parties and then recorded on the local mouse database if agreement was 
reached. 
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2.6 Mouse Blood Isolation 
Eight week old mice were anaesthetised using inhaled Isoflurane gas and a 
laparotomy performed. The inferior vena cava was exposed and blood was 
taken using a 25G needle into 0.3 mL of CTAD (citrate, theophylline, 
adenosine and dipyridamole) anticoagulant. Syringes were weighed before 
and after blood sampling to determine the dilution factor of blood into CTAD. 
2.7 Plasma FXIII-A Activity Assay 
Whole blood isolated as described in 2.6 above was centrifuged at 200 xg for 
10 min; the platelet-rich plasma was removed, centrifuged at 500 xg for 10 
min and the platelet depleted supernatant removed for assay. 
Plasma FXIII-A activity was measured by means of a microtiter plate assay 
using immobilised fibrinogen and 5-(biotinamido)pentylamine as substrates. 
This method was based on that described by (Song and Sheng, 1994). Nunc 
Immuno Maxisorp 96-well plates (Nunc A/S) were coated with 4 µg of 
fibrinogen (40 µg/mL in TBS, pH 8.3) (Calbiochem) per well overnight at 4 oC. 
The plate was emptied and washed 3 times with 300 µL of TBS (pH 8.3) 
followed by blocking of the plate by addition of 300 µL of 1% BSA and 
incubation at 37 oC for 90 min. The plate was washed 4 times with 300 µL of 
TBS and 1:100, 1:200, 1:400 CTAD-inhibited mouse plasma samples added 
in duplicate to wells. The crosslinking reaction was started by addition of 150 
µL of the reaction mix (DTT (2.2 µM), biotinpentylamine (6.6 µM), CaCl2 (220 
µM) and thrombin (21.75U)). 
The plate was incubated at 25 oC and the reaction stopped by addition of 200 
µL of 200 mM EDTA at 7.5 min. The wells were washed 4 times with 300 µL 
TBS/Tween-20 (0.1%) followed by incubation with 100 µL of 10 µg/mL alkaline 
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phosphatase conjugated streptavidin at 37 oC for 1 h in 1% BSA, TBS and 
0.1% Tween-20. 
The wells were washed 4 times with 300 µL TBS/Tween-20 (0.1%) and colour 
was developed by addition of 100 µL of 1 mg/mL 4-nitrophenyl phosphate 
(Sigma-Aldrich) in 1 M diethanolamine and 0.5 mM MgCl2 (pH 9.8) for 1 h at 
30 oC. Absorbance readings, measured at 405 nm on a Labtek plate reader 
(ThermoScientific), were taken every 1 min for 1 h and rates derived from the 
linear portion of the reaction curve. Final activities were corrected for CTAD 
dilution of the whole blood in the initial sample. 
2.8 Platelet Isolation and Characterisation 
To determine the FXIII-A levels in mouse platelets, whole blood samples, 
described in 2.6 above, were centrifuged at 200 xg and the platelet rich plasma 
layer was retained. This platelet-rich plasma was re-centrifuged at 1000 xg to 
sediment the platelet cells and the plasma layer removed and stored for 
plasma FXIII-A assays. For FACS experiments the platelet activation 
inhibitors apyrase (0.02 U/mL, Sigma-Aldrich) and prostacyclin I2 (0.5 uM, 
Cayman Chemical) were added prior to antibody labelling to prevent 
aggregation. For FXIII-A activity determination platelet pellets were washed 
twice with Tyrode’s buffer (10 mM HEPES (pH 7.4), 134 mM NaCl, 12 mM 
NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2) to remove residual 
plasma proteins and the platelets stored at -80 oC until use. 
2.8.1 Fluorescence Activated Cell Sorting of Mouse Platelets 
To determine counts and morphology, the centrifuged and washed platelets 
were labelled with a monoclonal FITC-conjugated anti-CD42b antibody 
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(Emfret) in PBS supplemented with 1% BSA and FACS analysis was 
performed on a FACSAria II (Becton Dickinson).  
2.8.2 FXIII-A Activity Assay 
To normalise the FXIII-A activity measurement in the platelets of the various 
mouse lines, lactate dehydrogenase levels were determined (as described in 
2.25.1.1 below) in the pelleted platelets. The LDH normalised platelet pellets 
were resuspended in a total volume of 100 µL which was added to 96-well 
Nunc Immuno Maxisorp 96-well plates (Nunc A/S) coated with 4 µg of 
fibrinogen (40 µg/mL in TBS, pH 8.3) (Calbiochem). The activity assay was 
then performed as per 2.7 above. The resulting activity was corrected for cell 
number and all genotypes normalised to the wildtype. 
2.9 Mouse Organ Isolation 
Following blood sampling as described in 2.6, mice were perfused via the left 
ventricle with 10 mL of saline to remove circulating blood. The animals were 
exsanguinated via the IVC and organs were harvested in the following order; 
liver, spleen, aorta and heart, into labelled 1.7 mL eppendorf tubes, snap-
frozen in liquid nitrogen and then stored at -80 oC until use. 
2.10 Genomic DNA Isolation 
For assays relating to PF4-cre copy number determination (2.11) and genomic 
recombination (2.19), high purity gDNA (A260/230 and A260/280 >1.8) was 
required. gDNA was isolated from organs by incubating in 0.5-1 mL lysis buffer 
(2% SDS, 400 ng RNase A, 400 ng proteinase K) at 55 oC overnight. These 
samples were centrifuged at 14000 xg for 20 min to pellet insoluble material 
and the supernatant mixed 1:1 with 25:24:1 Phenol:Chloroform:Isoamyl 
Alcohol, shaken, and then left for 10 min at room temperature to equilibrate. 
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These samples were centrifuged at 14000 xg for 10 min and the upper layer 
containing DNA was removed to a new tube. This step was repeated twice in 
total. Residual phenol was removed from the sample by mixing 1:1 with 
bromochloropropane (BCP), the mixture was centrifuged and the upper layer 
removed to a new tube. This step was carried out twice in total. DNA was 
precipitated by addition of 0.1 volumes of 3 M sodium acetate (pH 5.2) and 
2.2 volumes of 100% ethanol. These samples were left at -80 oC for 1 h 
followed by centrifugation at 14000 xg for 20 min at 4 oC. The pellet was 
washed 4 times with 70% ethanol and resuspended in 100-1000 µL of TE 
buffer depending on concentration (as determined by a NanoDrop 1000 
Spectrophotometer). 
2.11 PF4 Copy Number Determination 
The location of the PF4-cre transgene within the genome is unknown but the 
initial report (Tiedt et al., 2007) describing the transgenic mouse suggests it 
may be present in more than one location depending on which transgenic 
founder was used. 
To determine the copy number of the PF4-cre mice, 3 primers were designed 
to be compatible with real time PCR (optimal melting temperature of 60 oC 
and ~100 bp products). The forward primer hybridises with a common region 
in both the PF4-cre transgene and the endogenous PF4 gene and the two 
reverse primers each recognises a unique region in either the codon-
optimised cre recombinase or the endogenous PF4 gene. The real time PCR 
reactions were set up in quadruplicate using 60 ng (all samples normalised to 
15 ng/µL with ultrapure water) of gDNA (extracted using the method in 2.10), 
10 µL of the Roche LightCycler 480 SYBR green I Master Mix and 500 nM of 
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each primer. The reactions were separated to generate a single product in 
each well and had a total volume of 20 µL. 
The reaction conditions used were; 95 oC for 10 min, 45 cycles of 95 oC for 20 
s, 64 oC for 20 s and 72 oC for 45 s, followed by a melting curve from 65 oC to 
95 oC to ensure only a single product was made. The raw crossing points (Ct) 
were collected for each reaction and averaged per sample (if technical 
replicates were within 0.3 Ct). The average transgenic product Ct was 
subtracted from the endogenous product Ct giving a ΔCt which was converted 
into an amount of gene product by the Livak (2-ΔCt) method. When plotted as 
a bar chart, the mice fell into groups identifiable as having 0, 1 or 2 copies of 
the PF4-cre gene. 
2.12 Heart Fractionation 
Heart fractionation was performed by Dr Sumia Bageghni and colleagues 
(University of Leeds) using the Neonatal Cardiac Fibroblast Isolation Kit 
(Miltenyi Biotech) after size exclusion of cardiomyocytes and RNA isolation 
samples from each purified fraction were kindly donated. The RNA samples 
were reverse transcribed as per 2.17 and real time PCR carried out as per 
2.18 below. 
2.13 Cell Isolation and Culture 
2.13.1 Vascular Smooth Muscle Cell Culture 
2.13.1.1 Poly-L-lysine Coating of Culture Plastic and Glassware 
Five mg of poly-L-lysine hydrobromide with a molecular weight between 30-
70 kDa (Sigma-Aldrich) was dissolved in 50 mL tissue culture grade sterile 
water. In a laminar flow hood, 150 µL or 300 µL of poly-L-lysine solution was 
added to 24- or 12-well plates. If cells grown in these wells were intended for 
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microscopy, then a single 6 mm glass coverslip was placed in each well and 
coated at the same time. The plates were incubated for 5 min at room 
temperature, the solution removed and the plates allowed to dry for 2 h at 
room temperature under laminar flow. 
2.13.1.2 Vascular Smooth Muscle Cells 
Aortas (descending aortic arch to iliac bifurcation) were harvested into 500 µL 
antimycotic solution (10 µL antimycotic in DMEM) (ThermoFisher Scientific) 
as described in 2.9 above. Following harvest, the adventitia was removed with 
straight forceps using a stripping motion originating in the centre of the tissue. 
Each individual aorta was placed in a 100 mm culture dish containing a small 
volume of culture medium (DMEM (ThermoFisher Scientific), 10% FCS, 1% 
antibiotic-antimycotic solution and 1% L-glutamine) and cut into several 2 mm 
pieces. The pieces were placed into a 1.7 mL eppendorf tube containing 100 
µL of enzyme solution (7.5 mg collagenase type II (Merck Millipore) dissolved 
in 5.5 mL culture medium). The tubes were capped and taped awry to allow 
gas exchange and placed in a 37 oC/5% CO2 incubator for 5 h to allow tissue 
digestion. Following digestion, dispersed cells were resuspended by gently 
flicking the tube. The cell suspension was moved to a 15 mL falcon tube, 3 
mL of culture medium added to the suspension and the cells were pelleted by 
centrifugation (300 xg, 5 mins, 18 oC). The medium was removed by vacuum 
aspiration and the pellet washed in 5 mL of culture medium followed by 
centrifugation (300 xg, 5 mins, 18 oC). The pelleted cells were resuspended 
in 700 µL of culture medium, and the whole volume transferred to a single well 
of a poly-L-lysine coated 24-well plate where it was left undisturbed for 3 days 
in a 37 oC/5% CO2 incubator. After 3 days, the media was refreshed and on 
day 5 the cells split (Ray et al., 2001; Bochaton-Piallat et al., 1992; Furmaniak-
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Kazmierczak et al., 2007). For the immunocytochemistry, gene and protein 
expression experiments, the cells were split 1 in 4 into 2 wells of a coated 
12-well plate (or into 4 wells of a 24-well plate with coverslips if required).  
2.13.2 Macrophage Isolation and Culture 
Fore and hind limbs were harvested (with epiphyses intact) from 8-week old 
wildtype mice into chilled in PBS on ice. The bones were cleaned of muscle 
and soft tissue and washed with PBS. The epiphyses were removed with 
strong surgical scissors and placed into a 0.7 mL eppendorf with the bottom 1 
mm removed of the tube. The 0.7 mL tube was then placed inside a 1.7 mL 
eppendorf. The bones were centrifuged at 1200 xg to remove the bone 
marrow cells then the bones turned over and centrifuged again. 
The isolated cells were plated in 100 mm tissue culture dishes (Nunc) using 
10 mL media (RPMI-1640 supplemented with 10 ng/mL M-CSF) and cultured 
for 7 days until a point where other researchers have defined them as 
differentiated (Bellora et al., 2012). The cells were either harvested for RNA 
isolation or were trypsinised and seeded at a density of 5x106 cells in 100 mm 
dishes (10 mL culture media) the night before being used for mRNA or 
clodronate assays. 
2.14 RNA Isolation from Whole Organs 
Messenger RNA isolated from mouse organs using a TissueLyser II (Qiagen) 
to homogenise the sample and TRIzol (ThermoFisher Scientific) to lyse the 
cells releasing the cellular contents (Chomczynski and Sacchi, 1987). TRIzol 
contains a mixture of guanidinium thiocyanate (a chaotrophic agent to aid in 
the denaturation of proteins) and phenol. The addition of BCP causes phase 
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separation in which the RNA moves to the aqueous layer, protein to the 
organic layer and DNA to the interphase. 
The ribonucleic acid was precipitated from the aqueous layer using 100% 
ethanol and DNA removed using the “DNA-free” kit (ThermoFisher Scientific). 
This kit contains a highly active variant of deoxyribonuclease I which cleaves 
any residual single stranded or double stranded DNA molecules, the kit also 
removes any divalent metal ions (Ca2+, Mg2+, etc) which are required for 
ribonuclease activity. 
2.15 RNA Isolation from the Liver 
Livers were homogenised in 1 mL of Trizol (ThermoFisher Scientific). The 
RNA extraction protocol was the same as described in 2.14 above with the 
exception of taking 50 µL of the chloroform fraction for ethanol precipitation 
rather than the whole fraction (~600 µL) to avoid precipitating too large a 
quantity of RNA which would result in contaminated final samples. 
2.16 RNA Isolation from Cells 
2.16.1 Macrophages 
Cultured macrophages (prepared as in 2.13.2 above) were washed twice with 
ice cold PBS and lysed in 1 mL of Trizol. The RNA was then isolated following 
the method in 2.14 above. 
2.16.2 VSMCs 
Total RNA was isolated from VSMCs (as in 2.13.1.2 above) cultured in 12-well 
plates. Due to the small cell numbers cultured (~3.5 x105 cells per well) the 
RNeasy Micro Kit (Qiagen) was preferred over the TRIzol based method 
(described in 2.13 above) as silica based extraction methods more readily 
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isolate small amounts of nuclei acids (Kim et al., 2012). The method described 
by the manufacturer was followed without alteration. 
Quantitative qPCR was performed (as described in 2.18 below) on each 
sample in duplicate using 20 ng of cDNA per reaction for the following 
transcripts; Collagen I, Collagen III, Elastin, FXIII-A, TG2, MMP-2, MMP-9, 
MMP-12, αSMA, JNK1, c-Jun, Src, Sek1, ATF2, Lysyl Oxidase, β-actin, 
RPL32 (all primer sequences are described in 8.2). 
2.17 Reverse Transcription 
The resulting mRNA was reverse transcribed to cDNA using the High Capacity 
Reverse Transcription Kit (ThermoFisher Scientific). This uses a recombinant 
form of the Moloney mouse leukaemia virus reverse transcriptase to generate 
single stranded complementary DNA (cDNA) from single stranded RNA 
molecules. The cDNA produced was stored at -80 oC until required for real 
time PCR (qPCR). 
2.18 Quantitative PCR 
Real time quantitative polymerase chain reaction (qPCR) was used both for 
specialised genotyping (i.e. PF4-cre copy number) and for measurement of 
mRNA levels in tissue. 
qPCR works on the principle that PCR is an exponential process, i.e. each 
cycle results in a doubling of the DNA product concentration (under optimal 
conditions). Therefore, a greater amount of input DNA produces more reaction 
product (and therefore more detected fluorescence). With Sybr Green 
detection, the point at which the fluorescence breaks through the background 
and begins exponential amplification, the Ct or crossing point, is reported. 
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The primers used in qPCR are designed to have an optimal annealing 
temperature of approximately 60oC, this allowed multiple primer pairs to be 
run on the same reaction plate thereby improving throughput.  
To detect whether or not the catalytic exon was present in the mature FXIII-A 
mRNA and determine the abundance of other gene transcripts, quantitative 
PCR was carried out with samples run in duplicate. The cycling conditions 
used were; 95 oC for 10 min, 45 cycles of 95 oC for 10 s, 60 oC for 1 min, 
followed by a melting curve to ensure a single product was amplified. 
The first stage of processing the results from a qPCR assay involves 
normalising the determined Ct value for a target gene to the Ct of a 
housekeeper gene (i.e. a gene that does not vary its expression dependent 
on the experimental conditions). Typically, qPCR studies have relied upon the 
use of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the 
housekeeper however, reports in the literature have suggested that this gene 
may show substantial variation within mouse tissues (Szabo et al., 2004; 
Barber et al., 2005). To combat this, other researchers have advocated for the 
use of multiple housekeeper genes, and the geometric mean of these genes 
used as the normaliser value (Thellin et al., 1999; Vandesompele et al., 2002). 
Testing of mouse aortic tissue samples from our experimental genotypes by 
qPCR showed that the housekeeper genes β-actin (a cytoskeletal protein) and 
ribosomal protein L32 (RPL32) (a protein component of the 60S subunit of the 
ribosome) showed little variation between the genotype groups. For β-actin 
the average Ct was 26.69 +/- 0.31 and for RPL32 the average Ct was 24.61 
+/- 0.07 (Figure 2-7). All qPCR assays of mRNA expression described in this 
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thesis used the geometric mean of β-actin and RPL32 to normalise all target 
genes. 
 
The results (Ct values) generated were manipulated using the Livak method. 
This method calculates the exponential amount of DNA product produced 
from the Ct value by first subtracting the mean of the reference genes from 
the target gene Ct (giving the delta Ct, ΔCt), then transforming the normalised 
ΔCt by calculating 2-ΔCt which converts the logarithmic ΔCt value into linear 
space. All results are shown as normalised to the geometric mean of the 
housekeeper genes β-actin and RPL32 and are depicted as the group mean 
+/- 95% confidence interval. To calculate the significance of the results, 
groups were compared to the wildtype by 2-way ANOVA and if significant by 
ANOVA then compared by Sidak’s multiple comparisons method. 
Figure 2-7 – Testing of qPCR housekeeper genes 
The average Ct value (mean +/- SEM) of the housekeepers’ β-actin and 
RPL32 across wildtype and global transglutaminase knockout groups. 
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2.19 Quantification of Fractional Genomic 
Recombination 
To enable measurement of the proportion of recombined floxed to 
unrecombined floxed FXIII-A alleles, an assay was established based on real 
time PCR. Utilising the FXIII-A multiplex genotyping primers in separate 
reactions, 300 ng of genomic DNA extracted organs (as described in 2.10) 
was mixed with 500 nM of each primer and 10 µL of the Roche LightCycler 
480 SYBR Green I Master Mix in a total volume of 20 µL. The reaction 
conditions used were; 95 oC for 10 min, 45 cycles of 95 oC for 20 s, 63 oC for 
20 s and 72 oC for 45 s, followed by a melting curve from 65 oC to 95 oC. The 
reactions were carried out in quadruplicate and normalised to an artificial 50% 
deletion reference which was run at the same time. This reference was made 
by mixing genomic DNA from a FXIII-Aflox/flox mouse 1:1 with genomic DNA 
from a FXIII-A-/- mouse. Each sample Ct was subtracted from the respective 
50% reference and the amount of product calculated using the Livak 2-Ct 
method. The percentage of recombination in the sample was calculated by 
the following equation: 
  
2.20 Bicinchoninic Acid Assay 
The bicinchoninic acid (BCA) assay was performed as per the manufacturer’s 
recommended method (Sigma-Aldrich). The BCA assay relies on two 
reactions; the first is protein peptide bonds reducing Cu2+ ions in copper(II) 
sulphate to Cu+ and this is followed by chelation of these Cu+ ions by the 
bicinchoninic acid at a 1:2 molar ratio. The amount of Cu+ ions reduced is 
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proportional to the amount of protein present in solution and is detected by the 
bicinchoninic acid:Cu+ complex which absorbs light at 562 nm. 
An appropriate volume of sample (up to a maximum of 25 µL) was added to a 
single well of a 96-well plate (Greiner) in duplicate. A standard curve was run 
on each plate made in duplicate, consisting of the following concentrations 
diluted from a 2 mg/mL stock of BSA (0, 25, 125, 250, 500, 750, 1000, 1500, 
2000 µg/mL). To each well 200 µL of 50:1 mixed bicinchoninic acid:copper (II) 
sulphate solution was added and mixed for 30 s on a plate shaker. The plate 
was incubated at 37 oC for 30 min and the absorbance of each well read at 
490 nm on an ELx808 (BioTek) plate reader. The values were then imported 
into Microsoft Excel and sorted by sample ID, duplicates were averaged and 
the blank subtracted for each average. A standard curve was plotted using the 
concentration in µg/mL as the x-axis and absorbance at 490 nm as the y-axis. 
The equation of the line (𝑦 = 𝑚𝑥 + 𝑐) was rearranged and used to calculate 
the concentration (x) of the unknown samples, 𝑥 =
(𝑦−𝑐)
𝑚
. 
2.21 SDS-PAGE 
The protein concentration was determined in each sample to be run by adding 
25 µL of cleared lysate in duplicate to a microwell plate and a BCA assay 
carried out as per 2.20 above. 
The required amount of protein per sample was chemically reduced and 
denatured by addition to a final concentration of 50 mM DTT and 1x SDS 
loading buffer (ThermoFisher Scientific) in a total volume of 20 µL. The 
samples were then heated to 70 oC for 10 min and 20 µL loaded per well into 
a 12-well 4-12% acrylamide gradient Novex bis-tris gels (ThermoFisher 
Scientific) along with 5 µL of Precision Plus Protein WesternC pre-stained 
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molecular weight marker (Bio-Rad). The gel was loaded into a Novex Mini Cell 
electrophoresis system (ThermoFisher Scientific) and the tank filled with 800 
mL of 1x MOPS running buffer (ThermoFisher Scientific) and connected to a 
Powerpac Basic power supply (Bio-Rad) for 1 h at 160 V. 
The electrophoresed gels were either further processed by western blotting or 
post-stained with Coomassie blue (45% methanol, 10% glacial acetic acid, 
45% ultrapure water and 3 g/L Coomassie Brilliant Blue R250) for 1 h at room 
temperature with shaking. This was followed by 2 h of destaining (20% 
methanol, 10% glacial acetic acid, 70% ultrapure water) at room temperature 
with shaking. The gels were imaged post-stain on a G:Box imager (Syngene) 
using a white UV blocking screen. 
2.22 MAPK Signalling in VSMCs 
The VSMCs from individual mouse aortas were isolated and grown as 
described in 2.13.1.2 and on day 5 of culture split at a ratio of 1 in 4 into 2 
wells of a 12-well plate. Standard culture conditions were maintained for a 
further 5 days until ~80% confluency. The media was removed and the cells 
washed twice with ice cold PBS before harvesting for gene expression or 
protein expression analysis. 
2.22.1 Immunocytochemistry 
The VSMCs seeded on 6 mm glass coverslips were first washed with sterile 
PBS, fixed by incubation in 3.7% paraformaldehyde for 10 min at room 
temperature and washed three times in PBS to remove the remaining PFA. 
Cell permeabilisation was carried out by immersing coverslips in PBS 
containing 0.2% Triton X-100 for 2 min at room temperature followed by two 
washes in PBS to remove the detergent. To reduce off-target staining 
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coverslips were incubated in 5% BSA for 30 min at room temperature. The 
primary antibody was diluted to its working concentration (as per 8.3 below) 
in 3% BSA and 125 µL of this solution added to each coverslip and incubated 
at room temperature (in the dark if fluorescent) for 2 h. Coverslips were 
washed 3 times in PBS for 10 min per wash; 5 µL of rhodamine labelled 
Phalloidin (ThermoFisher Scientific) in 200 µL of PBS was added to one of the 
washes if F-actin was to be visualised. To a frosted microscopy slide, a single 
drop of Vectashield soft-set mountant containing DAPI (Vectorlabs) was 
added and the coverslip, cell side down, placed on top. The slide was sealed 
with clear nail polish and left at room temperature for a minimum of 2 h to set 
before imaging. 
The imaging of the slides was performed on a Zeiss LSM880 inverted confocal 
microscope using a 40x/1.4 oil Plan-Neofluar objective. Image analysis and 
processing was carried out using ImageJ v1.47 (NIH, USA). 
2.22.2 SDS-PAGE of Cell Lysates 
The cultured cells (from 2.13.1.2 above) were lysed in 150 µL of radio-
immunoprecipitation assay (RIPA) buffer supplemented with a non-covalent 
protease and phosphatase inhibitor cocktail (Sigma-Aldrich) for 30 min at 4 oC 
on a shaking platform. The lysate was aspirated into separate 1.7 mL 
eppendorf tubes and centrifuged at 14000 xg for 30 min at 4 oC to pellet any 
insoluble material. 
The protein concentration was determined in each sample by adding 25 µL of 
cleared lysate in duplicate to a microwell plate and a BCA assay carried out 
as per 2.20 above. 
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Fifteen micrograms of protein per sample was reduced and denatured by 
addition of 1x SDS reducing buffer and 1x (final concentration) SDS loading 
buffer (ThermoFisher Scientific) in a total volume of 60 µL. The samples were 
then heated to 70 oC for 10 min and 30 µL loaded per well into two single wells 
across two 12 well 4-12% Novex bis-tris gel (ThermoFisher Scientific) along 
with 5 µL of Precision Plus Protein WesternC pre-stained molecular weight 
marker (Bio-Rad). The two gels were loaded into a Novex Mini Cell 
electrophoresis system (ThermoFisher Scientific) and the tank filled with 800 
mL of 1x MOPS running buffer (ThermoFisher Scientific) and connected to a 
Powerpac Basic power supply (Bio-Rad) for 1 h at 160 V. 
2.22.3 Western Blotting of MAPK Pathway Antigens 
After electrophoresis, the gel was transferred to a blotting cassette containing 
a 7 x 8.4 cm piece of methanol activated PVDF membrane placed between 
two pieces of blotting filter paper and two sponges which were soaked in 
Towbin transfer buffer (25 mM Tris base, 192 mM glycine, 20% v/v methanol, 
0.1% SDS). A blotting tank containing the assembled cassettes was filled with 
800 mL of transfer buffer and electrophoresis carried out at 100 V for 60 min. 
The transfer was confirmed by presence of the prestained marker on the 
membrane. Each membrane was placed into a 50 mL falcon tube with the 
protein side facing into the tube and 5 mL of 5% BSA in TBS-T (19 mM Tris 
base (pH 7.4), 137 mM NaCl, 2.7 mM KCl, 0.1% Tween-20) added for 1 h with 
continuous rolling to block the membrane. The blocking solution was poured 
off and replaced with 3 mL of 5% BSA in TBS-T containing the primary 
antibody as per 8.3 and incubated overnight (16 h) at 4 oC with continuous 
rolling.  
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The membranes were washed 3 times with 5 mL TBS-T for 15 min per wash 
and the horseradish peroxidase conjugated secondary antibodies (as per 8.3 
below) diluted in 5 mL of milk solution (1.25 g milk powder in 25 mL TBS-T) 
per membrane. The secondary incubation was carried out at room 
temperature for 1 h with constant rolling. The membrane was again washed 
three times in 5 mL of TBS-T for 15 min per wash. 
The blots were visualised using the Clarity Western ECL blotting substrate 
(Bio-Rad) whereby 500 µL of the substrate was mixed with 500 µL of the 
enhancer solution and applied to the membrane which was placed between 
two acetate sheets. The membrane was incubated for 5 min before imaging 
on a G:Box (Syngene) at 428 nm. 
After imaging, the membranes were stripped by incubation in 5 mL stripping 
buffer (200 mM glycine (pH 2.2), 0.1% SDS, 1% Tween-20) for 20 min with 
replacement of the buffer at 10 min, followed by two 10 min washes in PBS 
and two 5 min washes in TBS-T. The membranes were then blocked as before 
and probed for β-actin to use as a normaliser for densitometry. 
Files were saved in the TIFF and proprietary SGD formats. Band densities 
were calculated by the inbuilt software using the ladder to define the size of 
the bands and the densities of the bands of interest were normalised to the 
β-actin density for each lane.  
2.22.4 Calphostin C 
For experiments using calphostin C, the drug was dissolved into 100% DMSO 
to make a 1000x stock and added to the cell media at 1x concentration (0.1% 
DMSO final concentration). Calphostin C mediated apoptosis was initiated by 
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illumination of the culture plates with an LED lamp. The control cells received 
the drug but no light treatment. 
2.22.5 JNK Activity Assay 
VSMCs cultured in 12-well plates using the same conditions described in 
2.13.1.2 above were harvested by first washing the cells in ice cold PBS 
followed by 100 µL of cell lysis buffer containing 1% Triton X-100 (Cell 
Signalling Technology) on ice for 30 min. Lysates were centrifuged at 14000 
xg for 10 min at 4 oC and the supernatant transferred to a new tube. 10 µL of 
cleared lysate was assayed for protein concentration using the BCA method 
described in 2.20 above. JNK activity was measured using the SAPK/JNK 
nonradioactive kinase activity assay kit (Cell Signalling Technology) following 
the manufacturer’s recommended protocol.  
Twenty micrograms of protein in 200 µL of lysis buffer was 
immunoprecipitated by incubation with 10 µL of immobilised 
phospho-SAPK/JNK (Thr183/Tyr185) rabbit mAb bead slurry overnight at 4 oC 
with gentle agitation. The cell lysate/slurry mix was centrifuged at 14000 xg 
for 30 s at 4 oC and the supernatant removed carefully without disturbing the 
pellet. The pellet was washed twice with 500 µL of cell lysis buffer and twice 
with 500 µL of kinase buffer with centrifugation between steps. 
The kinase assay uses the precipitated phospho-JNK to catalyse the 
phosphorylation of a recombinant truncated form of c-Jun (residues 1-89) in 
an ATP-dependent reaction. 
The pellet was resuspended in 50 µL of kinase buffer supplemented with 200 
µM ATP and 1 µL of c-Jun fusion protein (Cell Signalling Technology). The 
reaction was allowed to proceed for 30 min at 30 oC and was terminated by 
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the addition of 4x SDS loading buffer containing DTT (final concentration: 1x 
loading buffer, 50 mM DTT). 
Activity was measured by electrophoretic SDS-PAGE separation followed by 
blotting the reaction mixture on a PVDF membrane as described in 2.22.3 
above and probing the membrane with a rabbit anti-phospho-c-Jun (Ser63) 
antibody. The image files were saved in the TIFF format and imported into 
ImageJ for densitometry analysis. The density of the resulting band was 
directly proportional to the activity of JNK in the sample. 
2.22.6 In situ Transglutaminase Activity Determination 
In order to assay cellular transglutaminase activity, cultured vascular smooth 
muscle cells were treated with 2 mM 5-(biotinamido)pentylamine (BPA) for 1 
h before addition of the apoptosis-inducing agent calphostin C at 100 nM 
(0.1% DMSO) final concentration. Following treatment, the cells were 
harvested in RIPA buffer containing proteinase inhibitors for 2 h following 
calphostin C addition and a BCA assay performed as per 2.20 above to 
calculate the total protein concentration.  
Once activated, TG2 will begin crosslinking substrates to each other as normal 
but also crosslinking the competitive reporter BPA to these substrates as well. 
It was hoped that these BPA crosslinked intracellular substrates could be 
affinity purified using streptavidin conjugated beads and identified using mass 
spectrometry techniques. 
2.22.6.1 Kinetic Activity Assay 
A continuously recording activity assay for transglutaminase activity was 
designed based upon the FXIII-A activity assay described in 2.7 above. One 
microgram of total protein, harvested in 2.22.6 above, was diluted in 50 µL of 
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coating buffer (TBS, pH 7.4) and applied to a 96-well Nunc Maxisorp plate in 
duplicate, overnight at 4 oC. Two hundred microlitres of blocking buffer (1% 
BSA in TBS) was added to each well and incubated for 2 h at 37 oC. The 
contents of each well were removed by shaking the plate upside down then 
washed with wash buffer (1% BSA, 0.1% Tween-20 in TBS) once. To detect 
the biotinylated proteins coated to the well, 100 µL of 10 µg/mL alkaline 
phosphatase conjugated streptavidin was added and incubated at 37 oC for 1 
h. The plate was then washed 4 times with 300 µL of wash buffer. It was then 
dried by inversion on a paper towel and colour development initiated by the 
addition of 100 µL of 1 mg/mL 4-nitrophenyl phosphate and the reaction 
followed by reading absorbance at 405 nm every 1 min for 1 h on an ELx808 
spectrophotometer (Biotek). The samples were blanked to the average of the 
wells coated with TBS (no protein) and the mean velocity over 1 h calculated 
by the software. Technical replicates were averaged and standard error of the 
mean calculated for each genotype. 
2.22.6.2 Ligand Blot of Transglutaminase Crosslinked Proteins 
Five micrograms of total protein were reduced, denatured and electrophoresis 
performed as per 2.22.2 above. The blots were incubated with horseradish 
peroxidase conjugated streptavidin (see 8.3 below for antibody dilutions) for 1 
h at room temperature and imaged using the Clarity Western ECL blotting 
substrate (Bio-Rad) on a G:Box (Syngene). The blots showed proteins that 
were modified by transglutaminase activity and the total density of the 
resulting lanes provided qualitative evidence as to overall transglutaminase 
activity. 
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2.22.7 Protein Sequence Alignment 
The protein sequences of DLK (MAP3K12) from 28 sequenced species, were 
aligned using Clustal-Omega (Söding, 2005) and consensus protein domains 
highlighted. Potential TG2 crosslinking sites (QxPΦ) were identified in each 
animal homolog using the ExPASy ScanProsite tool (Sigrist et al., 2002). 
2.23 Identification of TG2 Substrates in Apoptosis 
2.23.1 Enrichment of Biotinylated Proteins 
Samples tested for in situ transglutaminase activity in 2.22.6 above were kept 
and later the biotinylated proteins (i.e. proteins to which TG2 had covalently 
attached biotinpentylamine) were enriched by streptavidin affinity using 
magnetic beads. 
Fifty micrograms of cell lysate were diluted to 300 µL in binding buffer (50 mM 
Tris-HCl, 150 mM NaCl, pH 7.5) and added to 100 µL of washed magnetic 
streptavidin beads (GE Healthcare). The biotinylated proteins were left to bind 
to the beads for 30 min at room temperature with end-over-end mixing. The 
beads were pulled to the side of the tube using a magnet and the liquid 
removed. The beads were washed three times in total with 500 µL of washing 
buffer (50 mM Tris-HCl, 150 mM NaCl, 2 M urea, pH 7.5), removing the liquid 
each time. Dry samples were then frozen at -20 oC until trypsinisation and 
mass spectrometry analysis. 
2.23.2 Protein Identification by LC-MS 
The protein identification of the precipitated samples was performed by Dr 
James Ault in the Mass Spectrometry Facility, Faculty of Biological Sciences, 
University of Leeds. 
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2.24 Identification of TG2 Crosslinking Partners 
2.24.1 Heart Protein Fractionation 
Hearts were harvested from TG2+/+ and TG2-/- mice as described in 2.9 above 
and shaken at 1000 rpm in 5 mL of wash buffer (PBS, 25 mM EDTA and 50 
µL of 100x MS-SAFE proteinase and phosphatase inhibitors (Sigma-Aldrich) 
for 1 h (fraction 1; extracellular, non-covalent, non-electrostatically bound 
proteins). The hearts were not frozen to avoid cell rupture, and therefore 
contamination of extracellular fractions with intracellular proteins. Each of the 
hearts were sliced into 4 equal sized pieces using a scalpel and washed 3 
times for 5 min each in PBS. 
The heart segments were incubated for 2 h at room temperature with shaking 
in 5 mL salt buffer (500 mM NaCl, 10 mM Tris-base (pH 7.5), 25 mM EDTA, 
50 µL 100x MS-SAFE inhibitors) and the supernatant was collected by 
centrifugation (14000 xg, 10 min, 4 oC) and stored at -80oC (fraction 2; 
extracellular, non-covalent, electrostatically bound proteins). The tissue was 
washed 3 times in 5 mL salt buffer followed by 3 times in 5 mL distilled water. 
The heart pellet was decellularised at room temperature with shaking in 5 mL 
of SDS buffer (0.5% w/v sodium dodecyl sulphate, 0.5% w/v sodium 
deoxycholate, 10 mM Tris-base (pH 7.5), 25 mM EDTA, 50 µL 100x MS-SAFE 
inhibitors) for 72 h and the buffer replaced at 36 h. The supernatant was 
collected by centrifugation (14000 xg, 10 min, 4 oC) and stored at -80oC 
(fraction 3; intracellular protein). The remaining tissue (insoluble ECM) was 
washed 3 times with 5 mL of distilled water to remove any residual detergent. 
Insoluble elastin was acid extracted by boiling (95 oC in a water bath) the ECM 
in 5 mL of 0.25 M oxalic acid for 2 h. Oxalic acid breaks desmosine-
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isodesmosine isopeptide bonds with comparable kinetics and specificity to the 
enzyme pancreatic elastase (Partridge et al., 1955) generating the soluble 
product alpha-elastin. After boiling, the supernatant was collected by 
centrifugation (14000 xg, 10 min, 4 oC) and stored at -80oC (fraction 4; elastin 
and elastin-bound proteins). 
2.25 Biochemical Assays 
Biochemical measurements were made in the uninjured aortas from the 
various mouse genotypes. 
2.25.1 Vessel Biochemistry 
Snap frozen aortas, harvested as described in 2.9 above, were first 
dehydrated under vacuum for 1 h and weighed to ascertain the dry weight of 
the tissue. Before the assays, the samples were lysed for 48 h at 4oC in 750 
µL of lysis buffer (50 mM sodium phosphate, 50 mM NaCl, 1% Triton X-100, 
0.1% SDS, pH 7.4) followed by clarification by centrifugation (14000 xg for 10 
min at 4 oC). 
The resulting supernatant was used for measuring intracellular protein 
concentration (by BCA assay), lactate dehydrogenase activity (by commercial 
assay) and DNA concentration (using a fluorescent intercalating dye). The 
remaining tissue pellet was further processed and used to measure the elastin 
and collagen concentration. While the intracellular assays could be carried out 
on every sample, the elastin and collagen assays were incompatible with each 
other and therefore both measures could not be made on the same tissue. 
The values produced from the elastin and collagen assays were normalised 
to an intracellular measure to allow comparison between samples and groups. 
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2.25.1.1 Lactate Dehydrogenase Assay 
Following lysis, the lactate dehydrogenase (LDH) activity was measured by a 
commercial colourimetric coupled assay (Promega CytoTox 96 LDH assay). 
Fifty microliters of sample and an aliquot of the supplied positive control 
enzyme were added to wells of a 96-well plate in triplicate. These samples 
were incubated for 30 min at room temperature with an equal volume of LDH 
substrate solution. LDH converts lactate into pyruvic acid which involves 
reduction of the cofactor NAD+ to NADH. The production of NADH drives a 
diaphorase catalysed reaction whereby iodonitro-tetrazolium violet (a 
tetrazolium salt) was converted to the red formazan product. After 30 min this 
reaction was stopped by addition of 100 µL of stop solution (1 M acetic acid) 
and the resulting red colour was measured by visible absorbance at 490 nm 
on an ELx808 plate reader (BioTek). The resulting value was therefore 
proportional to the starting amount of LDH in the sample. 
2.25.1.2 DNA Assay 
After lysis, double stranded genomic DNA content was determined by binding 
of the fluorescent intercalating dye, Sybr Green I. Ten microlitres of sample 
was added to a 96-well plate in triplicate along with 200 µL of assay buffer (50 
mM sodium phosphate, 2 M NaCl, pH 7.4) supplemented with a 1:20000 
dilution of Sybr Green I gel stain (10000x concentrate, ThermoFisher 
Scientific). The samples were incubated for 2 h at room temperature in the 
dark. Fluorescence intensity was measured on a Varioskan fluorescence plate 
reader (ThermoFisher Scientific) with the following monochromator settings; 
493 nm excitation, 530 nm emission, 12 nm bandwidth. The DNA 
concentrations were calculated by comparison with a gDNA standard curve 
(derived from mouse spleen) from 0 ng to 1000 ng. 
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2.25.1.3 Elastin Assay 
Mice were perfused with PBS and aortas excised as in 2.9 above. In order to 
quantify the concentration of elastin present in the extracellular space, the 
aortas were boiled in 750 µL of 0.25 M oxalic acid for 3 h. The oxalic acid was 
replaced every 1 h and the supernatant (2.25 mL total) kept for analysis. The 
oxalic acid converts insoluble elastin fibres into soluble α-elastin by chemically 
cleaving the desmosine-isodesmosine crosslinks that hold the elastin polymer 
together. The amount of α-elastin present in each sample was quantified using 
the Fastin elastin assay kit (Biocolor) following the manufacturer’s 
recommendations. Two hundred and fifty microlitres of oxalic acid treated 
aorta sample was run in duplicate alongside an 8 point (0, 15, 30, 45, 60, 75, 
90 and 100 µg) α-elastin standard curve. All assays and replicates were 
carried out individually in 1.7 mL eppendorf tubes and the final coloured 
sample transferred to a 96-well plate and the absorbance of each well read at 
490 nm using an ELx808 plate reader (BioTek). The concentration of α-elastin 
present in the sample was calculated by finding the equation of the straight 
line generated by the standard curve (𝑦 = 𝑚𝑥 + 𝑐).  
This is rearranged to 𝑥 =
(𝑦−𝑐)
𝑚
 and the absorbance of the unknown sample (y) 
used to calculate the concentration (x). 
2.25.1.4 Collagen Assay 
The collagen content of harvested aortas was assayed following collagen fibre 
solubilisation by enzymatic treatment with 750 µL of 0.1 mg/mL Pepsin in 
0.5 M acetic acid overnight at 4 oC. The enzymatic digestion of pepsin assists 
in cleaving the non-helical ends of the collagen molecules (known as 
telopeptides) which act as intermolecular crosslinks (Kiew and Don, 2013). 
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The concentration of solubilised collagen was measured using the Sircol 
collagen assay kit (Biocolor) according to the manufacturer’s method. One 
hundred microlitres of pepsin solubilised aorta was assayed in duplicate along 
with an 8-point standard curve covering 0 to 50 µg of collagen. Each replicate 
was performed in separate 1.7 mL eppendorf tubes and the processed sample 
transferred to a 96-well plate before reading the absorbance of each well at 
490 nm on an ELx808 plate reader (Biotek). The amount of collagen present 
was calculated using the equation of the straight line produced by the standard 
curve on each plate. This equation is rearranged to 𝑥 =
(𝑦−𝑐)
𝑚
 and the 
absorbance of the unknown sample (y) used to calculate the concentration 
(x). 
2.26 Clodronate Liposome (Clodrosomes) 
2.26.1 Preparation of Clodrosomes 
Clodrosomes were prepared following the method detailed by (Rooijen and 
Hendrikx, 2010) whereby the small hydrophobic cytotoxic molecule clodronate 
is encapsulated in a phospholipid liposome made of phosphatidylcholine and 
cholesterol. 
One millilitre stock solutions of 100 mg/mL phosphatidylcholine (Sigma-
Aldrich), 10 mg/mL cholesterol (Sigma-Aldrich) using 100% ethanol as the 
solvent and 250 mg/mL clodronate in distilled water were prepared in separate 
1.7 mL eppendorf tubes. Into each a new 1.7 mL eppendorf tube, 215 µL of 
phosphatidylcholine and 200 µL cholesterol were mixed and the ethanol 
removed by rotary evaporation under low vacuum at 40 oC (150 rpm). The 
sample was then dried until a thin phospholipid film was present at the bottom 
of the tube. 
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This film was dispersed in either 1 mL of the clodronate solution (to make 
active clodrosomes) or 1 mL of PBS (to make inactive control liposomes) with 
continuous gentle rotation at room temperature. Once resolubilised, the 
solution was held at room temperature for 2 h followed by sonication at 55 kHz 
for 3 min. The suspension was kept at 4 oC overnight to allow the liposomes 
to form. To limit the maximum size of the liposomes the solution was filtered 
through a 3 mm filter (Millipore) so as to avoid any risk of embolism once 
intravenously injected. 
The filtrate was then ultracentrifuged at 24000 xg (average force, in a 
Beckman MLS-50 rotor) for 60 min at 10 oC to pellet the clodrosomes, the 
supernatant (unincorporated clodronate) was recovered and stored at 4 oC 
and then reused in future preparations. 
The pelleted clodrosomes were then washed twice with 1 mL of PBS and re-
pelleted, and if required, labelled with the fluorescent, lipophilic, label DiI 
following the manufacturer’s method. 
2.26.2 Testing of Clodrosomes 
2.26.2.1 In vitro 
Bone marrow derived macrophages were labelled with 1 µg/mL Hoechst 
33258 (Sigma-Aldrich) to stain the nuclei and follow apoptosis (Hoechst 
increases in fluorescence as the nucleus condenses) and treated with 200 
µL/10 mL of culture media of the DiI-labelled clodrosome preparation. The 
uptake and subsequent apoptosis of the cells was followed by imaging the 
brightfield, DAPI and Cy3 channels every 30 s for 1 h at 20x magnification 
with a water objective on a fluorescence microscope (Olympus). 
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2.26.2.2 In vivo 
Eight-week old Mpl-/- mice were injected intravenously via the tail vein with 
100 µL of the clodrosome preparation containing 3-5 mg/mL of encapsulated 
clodronate. The injections were repeated 3 times per week for 2 weeks, 
followed by a terminal blood sample and organ harvesting as per 2.6 and 2.9 
above for plasma FXIII-A activity and FXIII-A mRNA determination. 
2.27 Bone Marrow Transplantation 
FXIII-A+/- mice were rederived behind a specific pathogen free (SPF) barrier 
at St James’ University Hospital, Leeds. These FXIII-A+/- mice were crossed 
to produce both FXIII-A+/+ and FXIII-A-/- mice for use. 
Seven week old female FXIII-A+/+ or FXIII-A-/- recipient mice were given 
access only to water containing enrofloxacin (50 µg/mL) (Bayer) for seven 
days prior to irradiation. Following this, the mice were subjected to total body 
lethal irradiation (8.45 Gy). This clears the fast replicating cells of the bone 
marrow, opening the niches for repopulation by the donor bone marrow cells. 
Bone marrow from male donor mice was isolated by harvesting the femur 
bones under terminal anaesthesia. The bone marrow was extracted from the 
bones as per the method described in 2.26 above under sterile conditions. 
The cells were counted using a haemocytometer and 1x106 cells/mL were 
injected via the tail vein into the irradiated recipients 24 h after ablation. The 
recipient mice were left to recover and to allow the engraftment to take place 
for 10 weeks. 
Following this, blood and organs were harvested as per 2.6 and 2.9 above for 
plasma and platelet FXIII-A activity, FXIII-A mRNA level and FXIII-A genotype 
determination. 
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2.28 Rotational Thromboelastometry 
Whole blood samples were taken from mice of the following genotypes; 
FXIII+/+, CD11b-cre+.flox/flox, FXIII+/-, PF4-cre+.flox/flox, CD11b-cre+.PF4-
cre+.flox/flox, FXIII-/- and Mpl-/-. Blood was drawn through the inferior vena 
cava as described in 2.6 above and clotting was inhibited by the addition of 
10% v/v 0.1 M sodium citrate and the samples were kept on ice until use. 
Rotational thromboelastometry (ROTEM) was performed on a ROTEM delta 
analyser (ROTEM.de). This technique gives a quantitative value to clot 
formation (and clot lysis if a thrombolytic agent is added). The system uses a 
cup and pin which is connected to an optical detector system. The rotational 
torque is transferred through the pin into the clot. As the fibrin clot forms, the 
impedance of rotation is detected using a laser and plotted as a value of 
amplitude in millimetres (mm). The greater the amplitude value, the more ‘stiff’ 
the clot (Luddington, 2005). 
For all assays the INTEM protocol - which activates clotting through the 
intrinsic (contact activation) pathway - was utilised. 
One hundred and five microlitres of well mixed whole blood was pipetted into 
a mini-cup. The sample was recalcified by addition of 7 µL of 0.2 M CaCl2 and 
then clotting was initiated by addition of 7 µL of rabbit brain thromboplastin 
and mixed twice by gentle pipetting. The clot was formed at 37 oC and the 
reaction followed for 2 h. 
2.29 Carotid Injury 
Eight week old mice weighing 20-30 g were anaesthetised through inhalation 
of Isoflurane gas and anaethesia maintained through the use of a ventiliation 
mask. Mouse body temperature was regulated on a warmed operating table 
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set to 37 oC. With the mouse laying on its back facing away from the operator 
the neck was shaved and an incision, approximately 0.5 cm in length made to 
the right of the midline in the neck. Using a dissection microscope magnifying 
at 6x the thymus and salivary glands were separated using blunt dissection 
and the right common carotid artery exposed. The artery was isolated from 
the surrounding tissue using blunt curved forceps. 10% (0.617 M) iron (III) 
chloride heptahydrate (Sigma-Aldrich) was applied to the artery, below the 
birfucation, using a piece of Whatman grade 2 filter paper (1mm x 2mm) and 
left for 3 min. Utmost care was taken to avoid application of FeCl3 to other 
structures. After 3 min, the filter paper was removed and the area thoroughly 
washed with 10 mL of saline. The wound was closed using 6/0 vicryl 
continuous sutures and animals allowed to recover in a warmed clean cage. 
At selected timepoints following clot induction, mice were reanaesthetised as 
previously and prepared for a laparotomy. The mice were sacrificed by 
exsanguination through the inferior vena cava followed by opening of the 
chest cavity and perfusion of 5 mL of saline and 5 mL of 10% buffered formalin 
via cardiac puncture. The right common carotid artery was excised using 
vanus spring scissors from below the carotid bifurcation to its origin at the 
branch from the aortic arch and was then wax embedded for future sectioning 
(as per 8.5 below). 
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2.30 Statistical Analysis 
All of the data described in this thesis is presented as mean +/- standard error 
of the mean, apart from real time PCR data which is shown as mean +/- 95% 
confidence intervals. Statistical significance was determined by several 
methods and accepted when the probability of the outcome occurring by 
chance was less than 5% (p=0.05). 
First, data sets were imported into Graphpad Prism 7 (GraphPad Software, 
San Diego, CA, USA), technical replicates were averaged and normality was 
determined by the Shapiro-Wilks test. For two group comparisons the means 
were compared by a Student’s unpaired t-test, for multiple group comparisons 
of one measure one-way ANOVA was used (with Dunnett’s multiple 
comparison correction applied) and for multiple group comparisons of more 
than one measure two-way ANOVA (with Dunnett’s correction) was used. For 
ANOVA testing, multiple comparisons were only tested if the F-test indicated 
significant variation in the dataset. For non-continuous data (i.e. knockout 
breeding numbers) the chi-squared test was applied and Fisher’s exact test 
of proportions was used for the aneurysm development data. 
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Chapter 3 – Characterisation of transglutaminase 
knockout mice in the context of cardiac fibrosis 
and vascular injury 
3.1 Introduction 
Previous publications had highlighted a protective role for FXIII-A in the 
development of cardiac fibrosis in male mice (Souri et al., 2008). Further to 
this, evidence also suggested that transglutaminase 2 can compensate for 
(i.e. is upregulated) in states of FXIII-A deficiency (Bakker et al., 2006). 
We sought to determine if this compensatory action does indeed exist and to 
also characterise the roles of the two transglutaminases in states of 
cardiovascular disease. 
To do this, mice were bred which harboured either a single deletion of the 
FXIII-A or the TG2 gene or a double deletion of both the FXIII-A and TG2 
genes. These mice were then allowed to age for the cardiac fibrosis study 
after which the heart was excised under terminal anaesthesia and stained for 
markers of fibrosis. For experiments relating to abdominal aorta aneurysm 
development, mice underwent laparotomy and peri-aortic application of 0.5 M 
CaCl2 in order to induce the AAA. These mice were then left for 6 weeks or 6 
months then the aorta was harvested and used for study. 
This chapter also examines a potential role for maternal and embryonic 
FXIII-A, but not TG2, in pregnancy. 
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3.2 Aims 
To determine the effect of FXIII-A and TG2 deficiency on the development of 
cardiac fibrosis and abdominal aortic aneurysm in mice by: 
1. Breeding FXIII-A and TG2 single and double knockout mice. 
2. Allowing these mice to age and harvesting the heart at 8 and 21 weeks 
to determine the extent of fibrosis by collagen deposition and 
haemosiderin staining. 
3. Initiating aortic aneurysm by peri-aortic application of 0.5 M CaCl2 
followed by harvest of the aorta at 6 weeks and 6 months post-
induction. 
3.3 Hypothesis 
FXIII-A and TG2 individually or co-operatively influence the outcome of 
cardiac fibrosis and abdominal aortic aneurysm in mice.  
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3.4 Results 
3.4.1 Flox Sequencing 
To identify the LoxP sites within the FXIII-A floxed mouse and to confirm that 
the gene was otherwise intact, sequencing of the locus was performed on 
products obtained from PCR of genomic DNA isolated from spleen.  
The automated sequencing results were aligned using MultAlin (Corpet, 1988) 
to the deduced sequence for the floxed FXIII-A gene and showed perfect 
agreement with the expected sequence flanking coding exon 7 as judged by 
the sequence of the targeting construct (Figure 3-1). Confirmation of these 
sequences allowed us to define the floxed allele and from this information 
design 3 primer strategies to genotype future offspring. 
The floxed mouse was further crossed with a CMV-cre mouse to produce a 
de novo global knockout as outlined in the methods.
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Figure 3-1 – Multiple sequence alignment of the FXIII-A floxed sequence with initial floxed breeders 
The floxed FXIII-A locus was amplified by PCR from gDNA isolated from the initial FXIII-Aflox/flox breeders, sequenced by automated 
Sanger sequencing and aligned to the deduced FXIII-A floxed sequence (LoxP) using MultAlin. (A) shows the upstream LoxP site and 
(B) shows the downstream site. The LoxP sites are highlighted by the blue boxes. 
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3.4.2 Mouse Breeding 
Female global FXIII-A knockout C57BL/6 mice were fertile, however, it was 
previously reported that FXIII-A-/- mice are unable to survive pregnancy and 
die from uterine haemorrhage later on in pregnancy. This suggests that 
FXIII-A is critical for supporting the extensive vascular and structural 
remodelling that pregnancy requires. Despite this, a previous cohort of 
FXIII-A-/- mice derived from the “Dickneite” line which was obtained from 
Harland laboratories was able to complete pregnancy. To determine if this 
effect was seen in the newly derived knockout mouse, breeding was 
attempted in 4 FXIII-A-/- females derived from the new floxed mouse after 
discussion with CBS staff and the project licence holder. Unfortunately, this 
resulted in the deaths of all 4 of the females from extensive haemorrhage. To 
this end, FXIII-A heterozygous females were bred with FXIII-A-/- males in trios 
thus lowering the expected ratio of knockout progeny to 1 in 2.  
The Mendelian frequency expected for generating FXIII-A-/- pups from this 
breeding strategy was signficantly less than expected (FXIII-A-/- observed 226, 
expected 296, p=<0.0001) which is closer to 1 in 3 than 1 in 2. Single 
deficiency of TG2 produced no difference in observed:expected pups (TG2-/- 
observed 80, expected 78, p=>0.99) and mice lacking both FXIII-A and TG2 
showed the same reduced frequency of knockout pups produced as the 
FXIII-A-/-  (DKO observed 265, expected 350, p=<0.0001). (Figure 3-3). 
It is known that female C57BL/6 mice release on average 10.5 eggs per 
ovulation but only produce 6.2 (+/- 0.2) pups per litter (Nagasawa et al., 1973). 
Analysis of the litter sizes of each genotype showed a significant decrease in 
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litter sizes between the wildtype and FXIII-A-/- (6.8 vs 5.4, p=<0.01) and 
wildtype and DKO groups (6.8 vs 5.6, p=<0.01). 
Transglutaminase deficient mice showed no gross or phenotypic 
abnormalities and grew at the same rate as the controls (Figure 3-2). Further 
to this, FXIII-A deficient mice showed no spontaneous deaths over the period 
of characterisation although as described in 3.5.1 some myocardial fibrosis 
was seen in these mice. 
Figure 3-2 – Mouse growth curves 
The global FXIII-A, TG2 and DKO mice were weighed weekly from 
weaning (week 3) through to week 16 (n=>4 per time point). No 
significant differences were seen between the weights of each genotype 
at any age. Data is expressed as weight in grams. 
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Figure 3-3 – Expected vs observed breeding and litter sizes 
(A and B) Bar charts showing birth rates of mice. Significant 
differences were noted in the numbers of both FXIII-A-/- (p=0.00005) 
and DKO (p=0.000006) pups produced, however no differences were 
seen in FXIII-Aflox/flox or TG2-/- pups. (C) Litter sizes were also 
significantly smaller in the FXIII-A-/- and DKO groups when compared 
to the wildtype (WT vs FXIII-A-/- p=<0.01) and (WT vs FXIII-/-.TG2-/- 
p=<0.01). Data is expressed as mean +/- SEM, Chi-squared testing 
used for A and B and 1-way ANOVA for C to determine significance. 
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3.4.3 Biochemical Assays 
3.4.3.1 Aortic Collagen and Elastin Content 
Before any conclusions can be drawn about the effects of FXIII-A and TG2 on 
the vasculature following injury, the basal morphology must first be tested. To 
do this, measures of elastin and collagen content were seen as crucial, as 
were measures of cellularity which were determined by intracellular LDH and 
gDNA content normalised to detergent solubilised protein.  
Previous reports in the literature have identified a role for FXIII-A and TG2 in 
the development of cardiac fibrosis (Sane et al., 2007; Souri et al., 2008) and 
it may be expected that if the lack of FXIII-A and/or TG2-/- also resulted in 
fibrotic changes within the vasculature that there would be a loss of cellularity 
and/or a relative increase in collagen deposition detected in the aortic tissue 
samples. 
Figure 3-4A shows the results of the cellularity assays in which the 
LDH:protein ratio in the DKO mice was significantly reduced compared to the 
wildtype (mean +/- SEM) (WT 0.013 +/- 0.0009 OD/µg, DKO 0.009 +/- 0.0007 
OD/µg, p=0.0124). Figure 3-4B depicts the results of the DNA:protein ratios 
and shows that both the FXIII A-/- and DKO groups have significantly reduced 
ratios (WT 0.003 +/- 0.0002 ng/µg, FXIII-A-/- 0.002 +/- 0.00017 ng/µg, DKO 
0.002 +/- 0.0001, p=0.0002). These results indicate that mice lacking FXIII-A 
have a decreased cell mass within the aorta. 
The concentrations of elastin and collagen were assayed; however, as the 
extraction methods used were incompatible with each other, each harvested 
aorta was assayed for either elastin or collagen, not both. This made 
calculating an elastin:collagen ratio difficult as it required a normalised value 
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for each sample (i.e. elastin:protein vs collagen:protein) to enable 
comparisons between genotype groups. A further issue was related to 
defining an error for the overall elastin:collagen ratio; methods do exist for 
calculating errors from non-matched data (e.g. bootstrapping) but these 
require sample sizes far larger than those presented here. Nevertheless, the 
results from these assays (Figure 3-5A&B) suggest that there are no 
differences in normalised aortic elastin content across the experimental 
genotypes but that there is a trend towards an increased normalised collagen 
content in the DKO group compared to the WT (WT 0.014 +/- 0.0017 µg/µg, 
DKO 0.017 +/- 0.0026 µg/µg) but this did not reach statistical significance. 
When taken together, the elastin:collagen ratios of all the experimental 
genotypes suggest that the DKO mice have a greater proportion of collagen 
in the aortic wall and that they may exhibit vascular fibrosis from an early age 
(Figure 3-6). 
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Figure 3-4 – Solubilised protein normalised LDH and DNA results 
(A) Shows the aortic LDH:protein ratios (mean +/- SEM) of the 
experimental genotype groups. The DKO group shows a significantly 
decreased ratio (WT vs DKO p=0.0124). (B) is the aortic DNA:protein 
ratio and suggests that both the FXIII-A-/- and DKO groups have a 
significantly reduced ratio (WT vs FXIII-A-/- and WT vs DKO p=0.0002). 
1-way ANOVA was used to determine significance. 
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Figure 3-5 – Solubilised protein normalised aortic elastin and collagen 
measures 
Soluble protein normalised elastin (A) and collagen (B) concentrations 
(mean +/- SEM) in mouse aorta. No significant difference (by 1-way 
ANOVA) in either elastin or collagen content was seen but there is a 
trend (p=0.34) towards an increased amount of collagen in the aortas of 
the DKO mice compared to the wildtypes. 
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3.4.3.2 mRNA Measurements 
3.4.3.2.1 Transglutaminase Family 
As mammals code for 8 transglutaminase enzymes with closely related 
activities but distinct tissue expression patterns, it may be possible that if one 
of the family is defunct that upregulation of one or more of the others could 
compensate for the deficit. Real time PCR assays of transcripts of the 
transglutaminase family in both the aorta and heart showed that none of the 
transglutaminases were upregulated to compensate for the deficiency of 
FXIII-A (Figure 3-7 and Figure 3-8); in fact, in the aorta of the FXIII-A 
knockouts the TG2 mRNA was significantly decreased (2.1 vs 0.5, p=0.0001). 
Therefore, any phenotypes observed in these mice are not underestimated as 
a result of compensating transglutaminase action. 
Figure 3-6 – Aortic elastin to collagen ratios 
Aortic elastin:collagen ratios were calculated by dividing the 
collagen:protein by the elastin:protein values. This ratio illustrates the 
increase in collagen content in the vessel of the DKO mice and suggests 
that the vessels of these mice are potentially fibrotic. Data is shown as 
mean ratios without associated error as the methodology used did not 
allow sampling of both elastin and collagen content in the same mice and 
therefore represents non-matched data. 
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Figure 3-8 – Transglutaminase family mRNA in heart 
The mRNA transcripts in the hearts of the FXIII-A-/- mice showed no 
compensatory changes in transglutaminase expression as a result 
of FXIII-A deficiency. Data shown as mean +/- 95% confidence 
intervals and 2-way ANOVA used for significance testing. 
Figure 3-7 – Transglutaminase family mRNA in aorta 
None of the other transglutaminases were upregulated in response to 
the loss of FXIII-A. The TG2 transcript shows a significant decrease in 
transcription in the FXIII-A knockout (WT vs TG2-/- p=0.0001). Data 
expressed as the mean +/- 95% confidence intervals and significance 
determined by 2-way ANOVA testing. 
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3.4.3.2.2 Basal Aortic Gene Expression 
As part of determining the basal characteristics of the aorta, gene transcripts 
relating to ECM structural proteins, ECM degrading matrix metalloproteinases 
and a smooth muscle cell marker were assayed by real time PCR. 
A significant decrease (>2-fold) in the alpha-smooth muscle actin transcript 
was seen in the TG2-/- mice when compared with the wildtype group (WT 68.6, 
TG2-/- 16.7, p=0.0005) but this was not replicated in the FXIII-A-/- or DKO 
groups (Figure 3-9). No difference was seen in any of the MMP genes for any 
of the genotype groups and of these genes, only MMP-2 was seen to be 
expressed in any large quantity (Ct <30) (Figure 3-10). 
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Figure 3-9 – Basal aortic structural protein expression 
mRNA expression of four ECM proteins (elastin, collagen I, collagen III 
and vimentin) and a vascular smooth muscle cell marker was determined 
in basal mouse aorta. Significantly decreased mRNA amounts were 
found in the alpha-smooth muscle actin transcript in the TG2-/- group (WT 
vs TG2-/- p=0.0005). Data is shown as mean +/- 95% confidence interval 
and significance calculated by 2-way ANOVA. 
Figure 3-10 – Basal aortic expression of matrix metalloproteinases 
mRNA expression of the three main matrix metalloproteinases (-2, -9 and 
-12) associated with a range of vascular pathologies was determined in 
basal mouse aortas. MMP-2 is the only gene that appears to be 
transcribed (Ct <30) the others are not (Ct >30). No significant difference 
was found in expression of any of the MMPs between the various 
genotype groups. Data is shown as mean +/- 95% confidence interval. 
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3.5 Parallel Work 
Work was carried out in collaboration with other members of the group to 
further characterise the WT, FXIII-A-/-, TG2-/- and DKO mice and the role that 
these genes play in the pathogenesis of vascular disorders. 
3.5.1 Cardiac Fibrosis 
Following the finding that the DKO mice develop spontaneous vascular 
fibrosis, work was carried out in collaboration with Dr Cora Beckers in our 
group to determine if this fibrosis was also present in the heart, a finding which 
has been previously seen in the literature in FXIII-A-/- mice (Souri et al., 2008). 
To quantify the levels of cardiac fibrosis in the transglutaminase knockout 
mice produced above in 2.2, the amount of collagen and haemosiderin 
(haemoglobin degradation product) deposition was determined 
histochemically in sectioned tissue. This tissue was derived from mice aged 8 
and 21 weeks of age which had been fed on a chow diet. 
Collagen deposition was highlighted by Sirius Red staining and haemosiderin 
deposition by Prussian Blue staining. The proportion of stained area relative 
to the total tissue area was measured using ImageJ. 
It was found that neither the wildtype nor the TG2-/- mice developed cardiac 
fibrosis at either time point. However, both the FXIII-A-/- (8 weeks 0.8 +/- 0.5% 
fibrotic area p=0.0001 and 21 weeks 2.4 +/- 2.3% p=<0.0001) and DKO (8 
weeks 3.3 +/- 5.1% p=<0.0001 and 21 weeks 14.0 +/- 8.3% p=<0.0001) 
groups showed fibrotic changes, with the DKO mice showing significantly 
greater amounts of fibrosis than any of the other genotypes (Figure 3-11). 
Haemosiderin deposition in the cardiac tissue (a marker of red blood cell 
leakage into tissue) followed the same pattern as above whereby the DKO 
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mice showed significantly greater amounts of haemosiderin when compared 
to the wildtype at 21 weeks (WT 0.14 +/- 0.53%, DKO 0.76 +/- 0.35% 
p=<0.0001). This suggests that haemorrhage may be part of the pathological 
process which ultimately results in these (FXIII-A-/- and DKO) mice developing 
cardiac fibrosis. 
  
Figure 3-11 – Collagen deposition in the hearts of the knockout mice 
Representative images of sections of heart tissue (4x magnification) 
from the single and double knockout mice (n=12). Sirius red staining was 
used to detect collagen deposition (dark pink). The FXIII-A-/- and FXIII-
A-/-.TG2-/- mice showed significantly greater collagen deposition 
compared to the control TG2-/- mice (p=<0.0001). Scale bar denotes 1 
mm. 
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3.5.2 Abdominal Aortic Aneurysm 
A mouse model of vascular injury was established in the group to try and 
determine the effect (if any) that FXIII-A and/or TG2 have in tissue repair. 
Abdominal aortic aneurysms were induced in 8 week old mice by peri-aortic 
calcium chloride application by Dr Kathryn Griffin (Figure 3-12).  
A significant mortality was observed in both the FXIII-A-/- (41% mortality rate, 
23/56 died) and DKO (62% mortality rate, 47/77 died) (FXIII-A-/- vs DKO 
p=0.01 by T-test) groups compared to the wildtype and TG2 groups which 
showed a far lower mortality rate (9%, 6/70 died and 7%, 6/88 died 
respectively) (WT vs FXIII-A-/- p=<0.0001) meaning that this phenomenon was 
not a result of the aneurysm induction procedure. The majority of the FXIII-A-/- 
and DKO mice which had died prematurely exhibited cardiac pathology or 
other distal morphology upon post-mortem examination. Blackened, thrombus 
filled atria (Figure 3-13) were found suggesting that in these animals, non-
stable thrombi were produced which embolised to the heart causing sudden 
cardiac death.  
Figure 3-12 – CaCl2 induced AAA development in a C57BL/6 mouse 
A representative image from a C57BL/6 mouse before (left) and 6 
months after (right) AAA induction with CaCl2. Following injury, the artery 
dilates and becomes heavily calcified and inflamed. Scale bar denotes 
1 mm. 
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If TG2 and FXIII-A play a big role in repair, then it would be expected that a 
large effect would be seen following arterial insult. Images of the aorta were 
taken before AAA induction and before AAA excision. I measured the aortic 
diameters at both time points as a blinded observer and calculated a 
percentage change. No significant difference was seen in aortic diameter 
following AAA induction with CaCl2 between any of the single knockout or 
double knockout mice at 6 weeks post injury (Figure 3-15). However, if the 
animals were left for 6 months following injury (Figure 3-14) a significant 
increase in aortic diameter was seen in the TG2-/- when compared to the WT 
mice (WT 64% increase, TG2-/- 90% increase p=0.031). This finding suggests 
that the aneurysm had continued to develop in the TG2-/- mice and that TG2 
is perhaps involved in repair in the later stages of the aneurysm model.  
However, due to the mortality of the FXIII-A-/- and DKO mice, data at 6 months 
after injury was not available in these groups. 
Figure 3-13 – Post-mortem pathology of FXIII-A-/- and DKO mice 
Representative post-mortem image of a DKO heart isolated from a 
mouse that had undergone a sham procedure and was found dead on 
post-op day 2. Blood was found in the thoracic cavity and the atrium of 
the heart contained a large clot. 
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Figure 3-15 – Short term CaCl2 induced AAA – change in vessel diameter 
Graph shows the 6-week post-injury percentage change in aortic 
diameter compared to the pre-injury diameter. No significant difference 
(p=0.097) was seen between any of the genotype groups. Data is shown 
as mean +/- SEM and significance determined by 1-way ANOVA. 
Figure 3-14 – Long term CaCl2 induced AAA – change in vessel diameter 
Graph shows the summary data of the sham operated, 6-week post 
injury and 6-month post-injury changes in aortic diameter in the wildtype 
and TG2-/- groups. Significant increases were seen in the TG2-/- group 
between 6 weeks and 6 months (p=0.025) and the WT and TG2-/- groups 
at 6 months (p=0.03). Data is presented as mean +/- SEM and 2-way 
ANOVA used to determine significance. 
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3.6 Discussion 
3.6.1 Maternal FXIII-A is required for survival through 
pregnancy whilst embryonic FXIII-A supports foetal 
development 
The data presented in this chapter suggests that FXIII-A is required to 
maintain pregnancy, as with a previous study (Koseki-Kuno et al., 2003) 
spontaneous haemorrhage was observed late in pregnancy in all of the 
FXIII-A global knockout female mice who were allowed to breed. Congenital 
FXIII-A deficiency also causes spontaneous miscarriage in human females 
(Seitz et al., 1996). These findings signify that FXIII-A plays an important (if 
not crucial) role in pregnancy and is perhaps required for the extensive 
vascular remodelling. Whether the FXIII-A involved in this process is derived 
from the plasma or a tissue resident cell (such as a uterine macrophage), or 
is a mixture of both, is unknown, however, FXIII-A supplementation therapy is 
known to allow FXIII-A deficient humans to complete pregnancy. 
Further, FXIII-A knockout embryos stand a greater chance of death in utero 
than either FXIII-A+/- or FXIII-A+/+ littermates as the number of FXIII-A-/- (and 
DKO) pups was found to be significantly lower than expectation. Previously 
reported evidence on this subject has suggested that in FXIII-A-/- embryos 
there is a failure of blastocyst implantation that could represent a loss of an 
integrin crosslinking event which is normally catalysed by FXIII-A (Illera et al., 
2000).  
It may be that both of these explanations are true, and that as the FXIII-A-/- 
embryos begin to implant into the uterine wall something goes awry resulting 
in the death of the embryo which blocks the implantation site for other embryos 
and produces the smaller litter sizes seen. 
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3.6.2 Deficiency of both TG2 and FXIII-A may cause fibrosis of 
both the vessel and the heart 
The biochemical data presented in this chapter suggest that while the single 
and double knockout mice show no obvious gross phenotypic abnormalities, 
the DKO, and perhaps the FXIII-A-/-, mice show signs of both cardiac and 
vascular fibrosis and reduced vascular cellularity. While this fibrosis does not 
appear to pose an issue to these mice normally, vascular injury (e.g. CaCl2 
application to the aorta) in the FXIII-A-/- mice resulted in a significant mortality 
rate, this mortality was further increased in the DKO mice. While this may be 
explained by unstable clot formation in these mice, the fact that added 
deficiency of TG2 produced a far worse outcome argues for a second role 
beyond clotting, perhaps in microvascular structure and/or repair. 
The mechanism behind this spontaneous fibrosis development is unclear 
however, it may be a result of increased vascular leakage or permeability as 
both FXIII-A and TG2 have been implicated in maintaining the endothelial 
barrier (Noll et al., 1999; Lee et al., 2016). Further evidence for this hypothesis 
is provided from children undergoing open-heart surgery. It was shown by 
(Schroth et al., 2006) that children who showed increased pleural effusion had 
lower plasma FXIII-A levels than controls and when these children were given 
supplemental FXIII-A they showed rapidly decreased effusion for the first 24 
hours after surgery. 
Previous literature (Bakker et al., 2006) has shown that while there may be 
some compensatory action between FXIII-A and TG2, in TG2-/- mice there is 
no upregulation of FXIII-A. In this thesis, it is shown that the opposite is also 
true whereby in FXIII-A-/- mice, TG2 is not upregulated and is actually 
downregulated by 75%. While this finding suggests that any effects of FXIII-A 
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are not masked by overexpression of TG2 (or any other transglutaminase) it 
may be that the phenotype of the FXIII-A-/- mouse is exacerbated by the 
decrease in TG2 transcription. However, the evidence for this is provided only 
at the transcriptional level. While it usually holds true that an increase (or a 
decrease) in the amount of a specific protein associated with an increase (or 
decrease) in the amount of mRNA, the correlation between the two has 
recently been determined to only be ~40% (Vogel and Marcotte, 2012). It 
would therefore be important to confirm the findings of decreased enzyme 
levels by comparing the mRNA levels with measures of FXIII-A and TG2 
protein amount by western blotting for example.  
3.7 Conclusion 
This chapter focusses on the characterisation of mice with either single or 
double deficiency of FXIII-A and TG2. We have shown that FXIII-A is crucial 
for maternal survival through pregnancy and is also important for embryonic 
survival. Further to this, there appears to be no compensatory mechanisms 
for upregulating the transglutaminase family genes following deletion of either 
FXIII-A or TG2.  
Finally, loss of FXIII-A on its own produces cardiac fibrosis which is worsened 
by additional deficiency of FXIII-A and TG2 and insult in these mice causes 
significant mortality. 
These findings suggest that transglutaminases may play differing roles that 
are site and/or context specific. With FXIII-A and TG2 aiding vessel stability in 
microvessels (i.e. cardiac fibrosis) and in large vessels expression of FXIII-A 
is perhaps destined for secretion into the circulation to maintain the plasma 
pool rather than being involved in repair processes.  
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3.8 Summary of Key Findings 
 FXIII-A-/- and DKO pups are born at a lower rate and in smaller litter 
sizes than expected. 
 
 No gene upregulation or compensation of the other transglutaminases 
is seen in response to knockout of FXIII-A and/or TG2. 
 
 The FXIII-A-/- and DKO mice show development of spontaneous 
cardiac fibrosis at 8 weeks of age. 
 
 The DKO mice showed characteristic biochemical changes of vascular 
fibrosis (e.g. reduced cellularity and increased collagen deposition) by 
8 weeks of age (Table 3-1). 
 
 The FXIII-A-/- mice suffer a high mortality (41%) following injury, this 
mortality is further significantly increased in the DKO mice (62%) and 
suggests that this phenomenon is more than just a clotting defect. 
Genotype LDH:Protein DNA:Protein Elastin Collagen Elastin:Collagen
Wildtype --- --- --- --- ---
FXIII-A
-/-   --- --- ---
TG2
-/- --- --- --- --- ---
DKO   ---  
Table 3-1 - Overview of aortic biochemical data 
Findings from the biochemical assays showing decreased cellularity and 
increased collagen deposition in the DKO mice. 
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Chapter 4 – Identification of the cell type that 
maintains the pool of plasma FXIII-A 
4.1 Introduction 
The conclusion from our group that the platelet is not the cellular source of 
plasma FXIII-A was based on blood samples from Mpl-/- mice imported from 
Professor Benjamin Kile (Walter and Eliza Hall Institute, Australia) and from 
in-house breeding and characterisation of the Bcl-xplt20/plt20 mice. Both lines 
were previously reported by our group (Cordell et al., 2010) to have normal 
levels of plasma FXIII-A. To further confirm the findings in the Mpl-/- mice and 
to determine that platelet size and FXIII-A content were unchanged a new line 
of Mpl mice was established and characterised. 
In addition, cre-lox technology was used to allow production of mouse lines 
where the FXIII-A gene was inactivated in specific cell types. 
As macrophage-like cells in the heart had previously been seen to be 
expressing FXIII-A (Souri et al., 2008), as had blood monocytes (Henriksson 
et al., 1985; Töröcsik et al., 2005; Muszbek et al., 1985), macrophage specific 
cre constructs were used to resolve their role in maintaining the plasma pool. 
However, as monocyte/macrophages are known to be highly heterogeneous 
it was seen as necessary to use two independent and supposedly 
granulocyte/macrophage-specific promoters, CD11b and LysM. 
Finally, Flt3-cre was chosen to differentiate between primitive and definitive 
cells and determine if one (or both) were the source of plasma FXIII-A. Flt3 is 
required for differentiation of adult long term HSCs into short term HSCs. The 
use of Flt3-cre excludes all of the haematopoietic cell-types derived from the 
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bone marrow from contributing to the plasma pool (by recombining the FXIII-A 
gene in the HSC) whilst leaving any primitive cells alone (i.e. yolk sac-derived 
tissue resident macrophages in the heart, aorta and brain, amongst others). 
To complement the findings of the Flt3-cre mouse, bone marrow transplants 
were performed to determine if plasma FXIII-A could be restored by stem cell 
transplantation.
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4.2 Aims 
To find the cell responsible for maintaining and secreting plasma FXIII-A by: 
1. Breeding mice with tissue specific recombination of the FXIII-A gene 
using cre-lox technology. 
2. Determine the plasma and platelet FXIII-A levels in these mice and 
correlating them with tissue FXIII-A mRNA levels. 
3. Establish a method to allow quantification of the extent of genomic 
recombination in the cre-lox crosses. 
4. Perform bone marrow transplantation to determine the effect of 
resident macrophage turnover on the plasma FXIII-A activity. 
4.3 Hypothesis 
A cell type that is not the platelet maintains the circulating pool of plasma 
FXIII-A. 
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4.4 Results 
4.4.1 Plasma FXIII-A Assay 
Platelet depleted plasma was purified from whole mouse blood by serial 
centrifugation. Plasma FXIII-A activity was determined from these samples 
with allowance for the dilution with anticoagulant (as described in 2.7 above) 
in the wildtype, FXIII-A floxed, all cre-flox crosses, FXIII-A heterozygotes, 
FXIII-A global knockouts and Mpl knockout mice and the results are shown in 
Figure 4-3 below. 
The FXIII-A heterozygous mouse had a residual activity of 61% which 
suggests that the cell that maintains the plasma pool has no way of sensing 
the plasma concentration and therefore has no mechanism whereby the gene 
can be upregulated, which validates the cre-lox approach. 
Flow cytometry analysis of stained platelets from the thrombocytopenic (Mpl-/-) 
mice showed them to have a platelet count of ~6% compared to a wildtype, 
and to have normal levels of FXIII-A (95% of wildtype). The Mpl mice also 
showed normal platelet sizes and showed no compensatory mechanism for 
storing more FXIII-A in the residual platelets meaning that the platelet cannot 
be the cellular source of plasma FXIII-A. 
The mice in which FXIII-A deletion had been targeted to macrophages 
(CD11b-cre and LysM-cre) showed a residual plasma activity of 61% and 20% 
respectively. Despite exclusion of the platelet as the cellular source of plasma 
FXIII-A, the supposed megakaryocyte specific cre, PF4-cre, depleted the 
plasma pool of FXIII-A to a level of 18%. 
Individually, CD11b-cre and PF4-cre reduced the plasma pool to 61% and 
18% respectively. If taken as separate lineage-specific genes then in theory, 
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together they would deplete more than 100% of the plasma pool. In practice 
addition of both cre constructs into one mouse leaves a residual FXIII-A 
activity of 9% (however this is not significant over the single copy PF4-cre 
mouse, p=0.17). This suggests that at least 12% of the plasma pool originates 
from a cell line (most likely a tissue resident macrophage) expressing both 
platelet factor 4 and integrin alpha M (CD11b) with the remaining 9% coming 
from a separate PF4/CD11b-independent source. 
Two copy PF4-cre mice were bred to determine whether the residual 18% 
activity of the single copy PF4-cre mice was a result of suboptimal expression 
of the PF4-cre gene. As described in 2.11 above, the PF4-cre insertion site is 
unknown and therefore a real time PCR approach was employed to genotype 
2-copy PF4-cre mice.  
Figure 4-1 is an example of the results obtained and shows that mouse 
genotyping could be categorised into clearly distinct groups with a 2 copy 
mouse showing twice the fluorescence following qPCR than a 1 copy mouse. 
The copy number determination is supported by running known copy number 
controls alongside de novo samples and also by knowing the parental 
genotypes. Genotypes were confirmed by breeding mice suggested as 2-copy 
with each other followed by genotyping the offspring, which should all be 2-
copy. The genotype confirmed mice were then used for study. To aid copy 
number determination, breeding pairs were set up with known zygosity. 
- 112 - 
Figure 4-1 – PF4 copy number determination 
Results from the PF4 copy number assays. Parents with known 
genotypes were crossed to produce pups with either 1 copy of PF4-cre 
(litter 1, n=6, and 2, n=6) or 2 copies of PF4-cre (litter 3, n=8). The 
numbers shown are the average copy number +/- SEM for all of the pups 
in each litter and known copy number controls are included as visual 
normalisers. 
 
Addition of a second PF4-cre allele has a minor, but non-significant (p=0.77), 
effect on further depleting the plasma pool suggesting that a single cre allele 
produces a sufficiently high cre recombinase enzyme concentration to ensure 
complete recombination of the floxed locus in those cells within which PF4-cre 
is expressed. 
Flt3-cre depleted the plasma pool to a residual 34% in one case and left it 
totally intact in 10 other cases. It is known that Flt3-cre has variable 
penetrance in mice (Boyer et al., 2011) and this appears to be the case here. 
The one mouse that recombined ‘efficiently’ showed genomic recombination 
in the bone marrow by PCR (Figure 4-2) whereas the others did not. The 
above plasma FXIII-A activity results are summarised in Figure 4-3. 
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Figure 4-2 – Flt3-cre bone marrow recombination 
Isolated whole bone marrow was genotyped for the FXIII-A locus by 
standard PCR and showed that one mouse (1) recombined and this mouse 
showed efficient depletion of the plasma pool of FXIII-A. Whereas, the other 
Flt3-cre mice showed no evidence of genomic recombination (2-4). The last 
three lanes are known genotype samples used for visual comparison. 
Molecular weight guidelines are shown as base pairs (bp). 
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Figure 4-3 - Plasma FXIII-A activity assay 
Plasma FXIII-A activity levels were assayed in wildtype, Mpl-/- mice as 
well as the cre-lox crosses. Significant reductions in FXIII-A activity were 
seen in the FXIII-Aflox/flox (p=0.001), FXIII+/-, FXIII-A-/-, CD11b-cre, LysM-
cre, PF4-cre+, PF4-cre++ and CD11b-cre.PF4-cre (p=<0.0001) and also 
the Flt3-cre high efficiency group (p=0.001). No significant difference 
was seen in either the Mpl-/- (p=0.99) or Flt3-cre low efficiency (p=0.99). 
All results were compared to the wildtype group and are shown as mean 
+/- SEM, significance was determined by 1-way ANOVA. 
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As described earlier, human deficiency of FXIII-A is defined as <10% of the 
“normal” activity of the enzyme in the plasma. People with plasma activities of 
>10% FXIII-A usually show none of the phenotypes associated with deficiency 
(e.g. spontaneous brain haemorrhage) and do not require supplementation 
therapy. 
To try and explain the lack of clotting deficiency seen in the cre-lox mice, 
human plasma FXIII-A was assayed. The basal FXIII-A activity of the wildtype 
mouse was compared with that of four human platelet depleted plasma 
samples. Human plasma samples were diluted 1 in 5, 1 in 10 and 1 in 20 and 
mouse plasma samples diluted 1 in 10, 1 in 20 and 1 in 40 to bring assay 
readings into the sensitivity range of the assay. The assay results showed that 
human plasma FXIII-A activity was 392.3 +/- 67.3 ΔOD405 min-1 (n=4) and 
mouse C57BL/6 plasma FXIII-A was 2691.7 +/- 89.5 ΔOD405 min-1 (n=30) 
suggesting that mice have approximately a 7-fold greater excess of plasma 
FXIII-A activity when compared to humans. Data shown is the mean activity 
+/- SEM (Figure 4-4). 
- 116 - 
Figure 4-4 – Comparison of human and mouse plasma FXIII-A activity 
The results showed that mice have approximately 7 times more plasma 
FXIII-A per volume of plasma than humans (p=<0.0001). Data is shown 
as mean +/- SEM, an unpaired t-test was used to determine significance. 
 
Total mRNA was isolated from the livers of wildtype and global FXIII-A 
deficient mice. Real time PCR (Figure 4-5) showed no transcriptional changes 
in the acceptor B subunit of FXIII (fibrinogen chain genes shown for 
comparison). The results also confirmed that the liver does not produce any 
FXIII-A even though it contains a store of active HSCs left over from foetal 
haematopoiesis (Crosbie et al., 1999; Taniguchi et al., 1996) and has been 
suggested as a possible tissue source of FXIII-A by earlier studies. 
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Figure 4-5 – mRNA analysis of liver expressed clotting factors 
Liver mRNA isolated from wildtype and FXIII-A global knockout mice 
was assayed for gene transcripts relating to clotting factors. No 
significant differences were seen in any of the transcripts tested and 
of note no FXIII-A is made in the mouse liver, contrary to previous 
reports suggesting the liver maybe the tissue source of the plasma 
enzyme. Data is expressed as mean +/- 95% confidence intervals. 
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4.4.2 Platelet FXIII-A Assay 
Platelets were purified from mouse whole blood by centrifugation, lysed and 
the FXIII-A activity of these lysates was determined by kinetic assay. 
Figure 4-6 shows platelet FXIII-A activity per cell presented as mean +/- SEM. 
Of note, the Mpl knockout mice have a “normal” amount of FXIII-A per cell i.e. 
thrombocytopaenia does not in itself induce compensatory mechanisms to 
increase FXIII-A production. The single copy PF4-cre platelets are entirely 
depleted of their FXIII-A, showing that complete cre recombination has 
occurred in the megakaryocyte lineage and reinforcing the conclusion that the 
plasma pool cannot be maintained by the platelet. 
The unexpected recombination behaviour of the Flt3-cre mouse is also shown 
in this assay as evidenced by the normal FXIII-A activity in the platelets of 
these mice. In the single Flt3-cre mouse that did appear to recombine, i.e. 
recombination of FXIII-A in the bone marrow was evident by PCR, there was 
a marked depletion of platelet FXIII-A activity to 13% of the wildtype. 
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Figure 4-6 – Platelet FXIII-A activity 
Platelet FXIII-A activity was determined by kinetic assay and normalised 
to the platelet count as determined by FACS analysis. Significant 
decreases in FXIII-A activity/platelet when compared to the wildtype 
group were seen in the FXIII-A+/- (p=0.0009), FXIII-A and PF4-cre++ 
(0.0001) and Flt3-cre high efficiency (p=0.006) groups but not in the Mpl-/- 
(p=0.37) or Flt3-cre low efficiency groups (p=0.9997). Data is expressed 
as mean +/- SEM and significance determined using 1-way ANOVA. 
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4.4.3 Quantification of Genomic Recombination 
To be able to quantify the extent of genomic recombination in tissue samples 
from the cre-flox crosses it was necessary to design a novel PCR based 
method. This is outlined in 2.19 above and essentially compares the 
proportion of floxed FXIII-A allele to the knockout FXIII-A allele in a given 
sample. 
To test the efficacy of the method, samples of 60 ng/µL gDNA from spleens 
of FXIII-Aflox/flox and FXIII-A-/- mice were mixed in differing ratios to generate 
samples that would reflect experimental conditions (0-100% recombination in 
5% increments). Figure 4-7 verifies the utility of the method, which accurately 
estimated the extent of deletion at all ranges and has proven to be reliable 
and reproducible. The proportion of knockout loci to the floxed and knockout 
(FXIII-Aflox/flox x CMV-cre) loci was calculated to show the amount of 
recombination in that tissue. 
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Figure 4-7 – Calibration graph of defined mixtures of FXIII-A genomic 
DNA 
Genomic DNA isolated from spleens of FXIII-Aflox/flox and FXIII-A-/- mice 
were mixed in defined ratios from 0-100% in 5% intervals. Each sample 
was assayed using qPCR and the calculated amount of recombination 
compared to the expected amount. Linear regression showed a near 
perfect correlation (R2 = 0.9911) between the two groups of values. 
 
Figure 4-8 shows the calculated proportion of genomic recombination 
(assayed as described in 2.19) in both the PF4-cre+.FXIII-Aflox/flox and 
CD11b-cre+.FXIII-Aflox/flox mice. The data supports the notion that PF4-cre is 
specific and not promiscuous in its tissue specific recombination activity. The 
PF4-cre mice show low levels of cre recombination in all of the organs tested, 
3-4% in the heart and aorta, 2% in the liver and spleen and 0.5% in the brain. 
However, it does suggest that cell type(s) beyond the megakaryocyte express 
the endogenous PF4 gene and are therefore able to switch on the PF4-cre 
gene as haematopoiesis is not known to occur in the heart, aorta and brain 
and the tissues were perfused to remove circulating contaminating platelets. 
This finding of off-target recombination replicates that of (Pertuy et al., 2015) 
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who found that mice expressing PF4-cre show gene recombination in resident 
macrophage cells in all tissues. 
The CD11b-cre mice show larger amounts of genomic recombination and the 
results obtained appear to be in close agreement with the original report by 
(Ferron and Vacher, 2005) and also with the known proportion of macrophage 
cells living within those tissues.  
Figure 4-8 – Genomic recombination in the conditional cre-lox crosses 
Proportional recombination of the FXIII-A locus was determined in the 
heart, aorta, brain, liver and spleen of PF4-cre and CD11b-cre 
FXIII-Aflox/flox crosses. (A) PF4-cre appears to show limited and targeted 
recombination of <4% in the tissues tested whilst (B) CD11b-cre shows 
far higher amounts of recombination (10-40%), which may reflect the 
numbers of tissue resident macrophages within those tissues. Data is 
expressed as mean +/- SEM. 
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4.4.4 Messenger RNA Measurements 
Expression of the FXIII-A gene in whole mouse organs and fractionated cells 
was determined by qPCR. 
4.4.4.1 Gene Expression in Whole Organs 
Figure 4-9 shows the transcription of the FXIII-A gene in the heart, aorta, brain, 
liver, spleen and bone marrow. It was determined that all of these organs apart 
from the liver and spleen produce FXIII-A with the heart and aorta being the 
major sites of FXIII-A expression. 
No significant difference in FXIII-A transcription was found in either the aortas 
(74% of WT) or hearts (102% of WT) of the FXIII-Aflox/flox mice compared to 
the wildtype mice which agrees with the essentially normal plasma and 
platelet levels of FXIII-A in the floxed mice and shows that the targeting 
construct is not interfering with transcription of the gene. 
Figure 4-9 – FXIII-A gene expression in the organs of wildtype mice 
Gene transcription of FXIII-A was determined by qPCR in a number of 
organs in wildtype mice. The heart, aorta, brain and bone marrow all 
express FXIII-A whereas the liver and spleen do not. Data is shown as 
mean +/- 95% confidence intervals. 
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FXIII-A protein expression has previously been observed in the walls of both 
the heart and the vasculature (Figure 4-10). It had been expected that these 
cells would be identified as tissue resident macrophages and that this pool of 
cells expressing FXIII-A would be depleted in the CD11b-cre mice. However, 
FXIII-A mRNA levels in the aorta and heart of CD11b-cre+.FXIII-Aflox/flox were 
54% and 103% of wildtype, respectively. LysM-cre+.FXIII-Aflox/flox mice had a 
remaining FXIII-A mRNA signal of 37% in the aorta and 20% in the heart.  
  
Figure 4-10 – Immunofluorescent detection of FXIII-A in mouse heart 
Work in collaboration with Dr Paul Cordell in the group has shown FXIII-A 
in sections of mouse heart using an anti-sheep FXIII-A antibody 
(SAF13A-AP). The WT hearts show FXIII-A signal (red) in select cells 
whereas the FXIII-A-/- sections show no staining. In the WT heart, a 
proportion of labelled cells are nucleated (DAPI, blue, circled cell), 
whereas others adopt a spindle-shaped morphology that is distinctive of 
cardiac macrophages (arrow). Scale bar denotes 10 μm. 
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The FXIII-A mRNA signal in the PF4-cre+.FXIII-Aflox/flox mice was decreased to 
a residual 12% and 1% (aorta and heart respectively) when compared to the 
wildtype group. 
The residual signal in the aortas of the CD11b-cre.PF4-cre.FXIII-Aflox/flox mice 
is 9% and essentially 0% in the heart. This data suggests that the majority of 
cells expressing FXIII-A also express PF4; a smaller population of cells co-
express FXIII-A, PF4 and CD11b and a tiny proportion of the FXIII-A 
expressing cells express CD11b. 
The above data is summarised in Figure 4-11 and Figure 4-12. 
Figure 4-11 – Aortic FXIII-A mRNA in FXIII-A conditional and global 
knockout mice 
Figure shows FXIII-A mRNA expression in aorta. The results show 
significantly decreased gene expression in the FXIII-A (p=0.002), 
CD11b-cre (p=0.02), PF4-cre (p=0.0001), CD11b-cre.PF4-cre 
(p=0.0001) and LysM-cre (p=0.02) groups but no significant 
decrease was seen in the FXIII-Aflox/flox (p=0.34) group. Data is 
shown as mean +/- 95% confidence intervals and significance was 
determined by 1–way ANOVA. 
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To determine whether loss of the Mpl receptor affected the FXIII-A mRNA 
signal (i.e. which might be the case if platelets are trapped in the tissue or that 
the cells are produced through an Mpl dependent pathway) qPCR was 
performed on aorta and heart samples isolated from these mice. Mpl 
deficiency had no significant effect on FXIII-A mRNA signal in either the aorta 
or heart, however, there does appear to be a near doubling of FXIII-A mRNA 
in the aorta (235% of WT). The Mpl data is shown in Figure 4-14 and Figure 
4-13. 
  
Figure 4-12 – Cardiac FXIII-A mRNA in global and conditional FXIII-
A knockout mice 
The FXIII-A mRNA signal was seen to be significantly decreased 
in the FXIII-A-/- (p=0.0001), PF4-cre (p=0.0001), 
CD11b-cre.PF4-cre (p=0.0001) and LysM-cre (p=0.0001) groups 
but not significantly decreased in the FXIII-Aflox/flox (p=0.9996) or 
CD11b-cre (p=0.9982) groups. Data is expressed as mean +/- 95% 
confidence intervals and significance was determined by 1–way 
ANOVA. 
- 127 - 
The results above might be consistent with a macrophage origin of FXIII-A. 
Therefore, to determine if macrophages were able to be recombined by 
PF4-cre and to assess the level of endogenous expression of PF4 and 
CD11b, macrophages were cultured and mRNA isolated (as described in 
Figure 4-13 – Heart FXIII-A mRNA in Mpl knockout mice 
In the heart of the Mpl knockout mouse the amount of FXIII-A gene 
expression remained unchanged (p=0.62). Results are shown as 
mean +/- 95% confidence intervals and significance was determined 
by an unpaired t-test. 
Figure 4-14 – Aortic FXIII-A mRNA in Mpl knockout mice 
The Mpl knockout mouse appeared to cause an increase in FXIII-A gene 
expression in the aorta however this was not found to be significant 
(p=0.053). Data is shown as mean +/- 95% confidence intervals and 
significance was determined by an unpaired t-test. 
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2.13.2 above). Figure 4-15 shows that macrophages are able to express PF4 
which is in agreement with the view that PF4 (and therefore PF4-cre) is 
expressed outside the megakaryocyte lineage. 
In parallel studies to confirm the phenotype of this cell population, the cultured 
macrophage cells were shown to be strongly phagocytic towards zymosan 
coated beads and my work has shown that they are extensively killed by 
clodrosomes (6.2.2 below). 
  
Figure 4-15 – mRNA expression in cultured macrophages 
mRNA analysis of cultured wildtype bone marrow-derived macrophages 
which are known to express CD11b also express the supposedly 
platelet/megakaryocyte specific gene, PF4. Both genes are expressed 
at the same level. Data is shown as mean +/- 95% confidence intervals 
(n=7 per group). 
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4.4.4.2 Gene Expression in Fractionated Hearts 
We were aware that other groups within our Institute were fractionating heart 
cells and attempted to use this methodology to determine if the cells which 
produce the FXIII-A in heart were amenable to isolation.  
Heart cells isolated from 3-4 week old mice (obtained after removal of 
cardiomyocytes by a size exclusion filter) were fractionated with the mouse 
Neonatal Cardiac Fibroblast Isolation Kit (Miltenyi) and total mRNA was 
isolated by Dr Sumia Bageghni and colleagues. 
The hearts were fractionated into 4 pools, by cell number they were; 50% 
cardiomyocytes, which were discarded, 32% non-fibroblast (assumed to be 
endothelial cells), 16% fibroblast pool A (shown to be Thy-1 negative) and 2% 
fibroblast pool B (shown to be Thy-1 positive cells). The overall enrichment of 
the gene transcripts was shown by comparison with RNA samples isolated 
from whole hearts. 
Figure 4-16 depicts the results from each assayed fraction as 2-ΔCt (normalised 
to β-actin and RPL32) +/- 95% confidence intervals, all the results are 
normalised to the FXIII-A bar in fraction fibroblast pool B. Fibroblast pool B 
shows the greatest enrichment of FXIII-A over the whole heart along with both 
the endogenous genes PF4 and CD11b. This fraction was calculated to be 
2% of the entire cell number of a heart and corresponds closely with the 3% 
of heart cells that recombined their genomic DNA in the PF4-cre+.FXIII-Aflox/flox 
mice when assayed in 4.4.3 above. This suggests that these cells are most 
likely the rare FXIII-A positive cells of interest seen in the previous 
immunohistochemistry images (Figure 4-10). 
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While bone marrow-derived macrophages and THP-1 cells were not seen to 
be secretory in vitro, the spindle-like morphology of the in vivo cells may 
represent a cytoskeletal change within these cells when in situ which is 
associated with changes that allow secretion of FXIII-A. 
  
Figure 4-16 – Gene expression in fractionated hearts 
mRNA was extracted and analysed from hearts fractionated using the 
Miltenyi neonatal cardiac fibroblast isolation kit (n=4). The kit produces 3 
fractions of cells. FXIII-A, PF4 and CD11b transcript levels were 
determined in each fraction and compared to levels in a whole heart. 
Fibroblast fraction B showed the greatest enrichment of FXIII-A, PF4 and 
CD11b but only made up approximately 2% of the entire cell number. 
This number is in line with the percentage of recombination in the hearts 
of the PF4-cre mice and may point to the cell population being sought. 
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4.4.5 Bone Marrow Transplantation 
To further elucidate the contribution of the bone marrow to the plasma pool, 
bone marrow transplant experiments were performed. Bone marrow, isolated 
from wildtype mice, was transplanted into lethally irradiated wildtype and 
FXIII-A-/- mice and subsequently, plasma FXIII-A activity, platelet FXIII-A 
activity and organ FXIII-A mRNA levels were determined. 
The plasma FXIII-A activity (Figure 4-17) was shown to be maintained but not 
increased in the WT into WT group (100%) and plasma FXIII-A was 
reconstituted to 74.6% in the WT into KO group. The platelet FXIII-A activity 
(Figure 4-18) showed near 50% reconstitution in the WT into WT group and 
78% in the WT into KO group. Taken together, this data suggests that the 
majority of plasma FXIII-A, in mice, is maintained by a bone marrow-derived 
cell which can be displaced by irradiation and restored by cell transplantation. 
Both the hearts and brains of the FXIII-A-/- mice were repopulated with 
FXIII-A+/+ expressing cells whereas the aorta showed incomplete 
reconstitution (25%). However, the real time PCR assay that determined the 
repopulation within the aorta showed very high Ct values for both the FXIII-A 
and housekeeper transcripts so this value may underestimate the actual 
repopulation that took place. 
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Figure 4-17 – Reconstitution of plasma FXIII-A activity in the bone 
marrow transplant recipient mice 
Plasma FXIII-A was assayed in both wildtype and FXIII-A-/- mice that had 
been lethally irradiated and injected with bone marrow isolated from 
wildtype mice. The plasma FXIII-A activity was restored to 74.6% in the 
wildtype bone marrow into FXIII-A-/- group which is significantly lower 
than the WT into WT group (p=<0.0001). Data is shown as mean +/- 
SEM and significance determined using an unpaired t-test. 
Figure 4-18 – Reconstitution of platelet FXIII-A activity in the bone 
marrow transplant recipient mice 
Platelet FXIII-A was measured in bone marrow recipients (WT and 
FXIII-A-/-) that had received WT bone marrow. The platelet FXIII-A 
activity was returned to 50% in the WT into WT group and 78% in the KO 
into KO group. Data is expressed as mean +/- SEM and significance 
determined using an unpaired t-test. 
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Figure 4-19 – Reconstitution of FXIII-A mRNA in bone marrow transplant 
assays 
Organs were harvested from wildtype and FXIII-A-/- mice that had been 
lethally irradiated and injected with bone marrow harvested from healthy 
wildtype mice. In the FXIII-A-/- mice, the heart and brain showed near 
perfect reconstitution of FXIII-A mRNA (heart 97.7%, p=0.99 and brain 
73.6%, p=0.99) whilst the aorta showed incomplete reconstitution 
(25.8%, p=0.03). Data shown as a percentage of the control group 
(wildtype bone marrow transplanted into lethally irradiated wildtype 
mice). Inset is PCR genotyping of liver tissue from WT and FXIII-A-/- bone 
marrow recipients of WT bone marrow showing that the mice were 
originally FXIII-A-/- but now contain WT FXIII-A after transplantation 
suggesting haematopoietic cells in the liver had converted to the donor 
genotype. Molecular weight scale is shown as base pairs (bp). 
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4.4.6 Plasma FXIII-A and Clot Structure 
An unresolved question in the literature regards whether FXIII-A is a potential 
anti-thrombotic target. Mouse lines were generated in this thesis that 
expressed different levels of FXIII-A and this allowed us to examine the effect 
of lowering plasma FXIII-A concentration on clot strength. This involved in vitro 
testing of mouse whole blood samples by rotational thromboelastometry which 
provides a real time output of clot strength as the clot forms. A caveat of this 
study however (as shown in Figure 4-4) is that mice have a greater activity of 
plasma FXIII-A than humans (approximately 7-fold higher). 
The thrombocytopenic Mpl mice showed the same rate of increase of clot 
firmness compared to the wildtype but overall have a lower maximal firmness 
which is presumably a result of having less platelet material incorporated into 
the clot. The FXIII-A-/- mice also showed a greatly perturbed clotting 
phenotype both in terms of clot firmness and formation time, which is in line 
with human reports of FXIII-A deficiency (Figure 4-20A). 
Finally, neither clot firmness nor formation time is affected in the conditional 
knockout mice compared to the wildtype (Figure 4-20B&C) suggesting that a 
residual FXIII-A activity of 9% may be enough to form a ‘normal’ clot. This is 
unlike the human condition whereby a person with <10% FXIII-A has 
significantly impaired clotting parameters and this may be due to mice having 
a greater activity of plasma FXIII-A than humans. 
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Figure 4-20 – ROTEM 
Whole blood ROTEM was performed to determine clotting parameters. (A) 
shows the amplitude (clot stiffness) at 6 time points. Significant decreases 
in clot stiffness were seen in the FXIII-A-/- and Mpl-/- groups at all time points 
(p=<0.0001). (B) None of the conditional FXIII-A knockouts showed any 
statistical difference in clot formation. Data is shown as mean +/- 95% 
confidence intervals. (C) shows the clot formation time for each genotype 
and significant increases were seen in the Mpl-/- (p=<0.001), FXIII-A+/- 
(p=<0.05) and FXIII-A-/- (p=<0.001) mice compared to the wildtype. Data 
is expressed as mean +/- SEM and significance determined by 2-way 
ANOVA for A and B and 1-way ANOVA for C. 
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4.5 Discussion 
4.5.1 Platelets do not maintain the plasma pool  
The plasma FXIII-A activity assay data shows that the PF4-cre mice, 
(supposedly a megakaryocyte specific cre construct) depleted almost all of 
the plasma FXIII-A. The thrombocytopenic Mpl-/- mice on the other hand 
(which have ~6% of the normal platelet number) were found to have normal 
levels of plasma FXIII-A. This is consistent with previous reports from our 
group of plasma FXIII-A in two different lines of thrombocytopenic mice 
(Cordell et al., 2010). FACS analysis of platelets derived from Mpl-/- mice show 
no changes in cell size or volume compared to the wildtype and when equal 
numbers of platelets are assayed from both groups identical FXIII-A activities 
are seen. This suggests that there are no compensatory mechanisms involved 
(e.g. larger platelets containing more FXIII-A or normal sized platelets 
containing a higher concentration of FXIII-A) and therefore refutes the notion 
that platelets are the cellular source of FXIII-A. 
Analysis of genomic recombination in the PF4-cre mice shows that the 
targeting construct is specific and not simply recombining in every cell. 
However the mRNA data demonstrates that cultured bone marrow-derived 
macrophages can express the endogenous PF4 gene under normal 
conditions further confirming that this construct is able to be expressed outside 
of the megakaryocyte lineage. 
Previous reports, which had suggested an extrahaematological source of 
plasma FXIII-A had hypothesised that the liver could be the source of plasma 
FXIII-A (Poon et al., 1989; Pihusch et al., 2002). The results of our mRNA 
assays show that the liver, spleen, brain and bone marrow (which contain 
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FXIII-A positive macrophages) contain negligible amounts of FXIII-A mRNA 
and therefore would be unlikely sources of plasma FXIII-A production. In 
contrast, the heart and aorta do contain high quantities of FXIII-A mRNA. 
Immunohistochemistry data has previously shown that the heart contains 
spindle-like cells which stain positively for FXIII-A antigen, which are believed 
to be tissue resident macrophages (Souri et al., 2008) and account for 
approximately 3-5% of the total cell number. 
4.5.2 Fingerprinting of cre-lox mice suggests the aorta is the 
site that maintains the plasma pool of FXIII-A 
Figure 4-21 is an overview of the results produced from real time PCR assays 
of heart and aorta mRNA samples from the cre-lox crosses and Mpl-/- mice 
and shows FXIII-A gene transcript level and plasma FXIII-A activity assay 
results for each of the genotypes. 
The data presented in this thesis suggests that tissue resident macrophages 
express PF4, which has been shown previously by (Schaffner and Rhyn, 
2005), with a minority also expressing CD11b. These cells can be readily 
isolated from heart tissue using cardiomyocyte depletion and what is 
presumed to be positive selection with an anti-Thy1.2 antibody. This may also 
be possible to achieve in aortic samples; however, this has not yet been 
attempted. 
From this overview of the data, it appears that the aorta is the prime candidate 
for the tissue source of plasma FXIII-A, the heart seems less likely or perhaps 
plays a lesser role in maintaining the plasma pool. The reasons for discounting 
the heart are; 1) PF4-cre almost entirely depletes the FXIII-A mRNA signal in 
the heart but does not completely deplete the plasma protein whereas the 
aorta is not completely exhausted, this is the same story with the 
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CD11b-cre.PF4-cre mice; 2) The CD11b-cre+.FXIII-Aflox/flox mouse shows a 
parallel decrease in both aortic mRNA and plasma FXIII-A activity but the 
cardiac mRNA does not fall to the same level; 3) in the LysM-cre mice aorta 
mRNA and plasma activity levels match but the heart again shows a decrease 
greater than that seen in plasma activity; 4) the bone marrow transplant 
assays show complete restitution of FXIII-A mRNA in the heart but both the 
plasma FXIII-A activity (74.6%) and aorta also show incomplete reconstitution 
of FXIII-A mRNA; 5) the non-recombined floxed mouse shows a reduction in 
plasma FXIII-A activity but no commensurate drop in heart mRNA signal 
whereas the aorta does show a reduction, which may suggest a different 
transcriptional mechanism for FXIII-A destined for the plasma (i.e. the aortic 
cells) and that destined for repair (i.e. the cardiac cells). 
When taken together these results build a picture of the aorta playing the 
primary role in maintaining the levels of plasma FXIII-A. It may also be true 
that this isn’t just taking place in the aorta but in the entire vasculature due to 
the large concentration of FXIII-A in the plasma and its apparent short half-
life. However, due to the difficulties in isolating mRNA from the aortas of mice 
due to the small size of the vessel, it was not possible to look at other sites, 
an example being the carotid arteries where unsuccessful attempts were 
made in trying to extract mRNA. 
In the future, extraction of RNA from smaller vessels or from other species 
(e.g. rat or rabbit) will be attempted using the methodology described in 2.16.2 
above using silica columns. It would also be pertinent to test the lungs for 
expression of FXIII-A as this was suggested previously as an 
extrahaematological source of plasma FXIII-A. 
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Figure 4-21 – Fingerprinting of FXIII-A mRNA and plasma activity 
following cre-lox deletion 
An overview of the data from the plasma FXIII-A activity assays and 
FXIII-A gene transcription in the heart and aorta. When comparing the 
two tissues to the plasma activity, the data points to the aorta being the 
tissue source of FXIII-A as the aortic mRNA appears to mirror the plasma 
activity more closely than the heart mRNA does. 
 
4.5.3 Tissue resident macrophages are the probable cellular 
source of FXIII-A 
Figure 4-22 summarises the above work into a working hypothesis of how the 
plasma and platelet cellular sources of FXIII-A arise. The results suggest that 
the cellular source of plasma FXIII-A is maintained by a population of resident 
tissue cells, which appear to be macrophages, in the aorta and possibly the 
heart. 
- 140 - 
Tissue resident macrophages in the aorta and heart, as well as those in the 
brain, skin, lungs and liver, arise initially from the foetal yolk sac. These cells 
originate from primitive (Flt3-independent) haematopoiesis and migrate to the 
early dorsal aorta (aorto-gonadal mesonephros) (Medvinsky et al., 2011; 
Perdiguero et al., 2014) which perhaps makes the finding that the aorta may 
serve as the tissue source less surprising than it first appears. These cells are 
able to undergo local proliferation within the tissue in order to maintain their 
numbers and can also be replaced by circulating monocytes from the bone 
marrow which appear to differentiate into tissue resident macrophages when 
in situ (Epelman et al., 2014; Molawi et al., 2014). These bone marrow-derived 
cells arise through definitive haematopoiesis which differentiate from a stem 
cell derived from the HSC (Flt3-dependent) but not from a cell-type that is a 
precursor to the megakaryocyte (Mpl independent). 
As the animal ages, these cells can be displaced by invading adult bone 
marrow-derived macrophages naturally as a result of cell turnover (Molawi et 
al., 2014), or as a result of injury (Epelman et al., 2014). Fms-like tyrosine 
kinase 3 (Flt3) is required for the differentiation of long-term haematopoietic 
stem cells (LT-HSCs) into short-term haematopoietic stem cells (ST-HSCs). 
These ST-HSCs are the cells which are able to differentiate into the many 
lineages of cells that the bone marrow produces (namely, megakaryocytes 
and monocytes) through the common myeloid precursor. 
These resident tissue cells, both yolk sac- and bone marrow-derived, appear 
to express the genes PF4 in the aorta and heart and potentially Thy1.2 in the 
heart. This is reinforced by calculating the recombination efficiency of the 
PF4-cre mouse in the heart and aorta, which reports that approximately 3-4% 
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of cells in the aorta and heart have undergone cre-lox recombination. 
Fractionation of 3-4 week old mouse hearts using a positive selection strategy 
involving what is believed to be an anti-Thy1.2 antibody produced a cell 
fraction that accounts for approximately 2% of the entire cell number of the 
heart and these cells show the greatest enrichment of FXIII-A, PF4 and 
CD11b transcripts over a whole heart. 
There are differing reports of what happens after birth to the yolk-sac derived 
macrophages. There are three hypotheses with good evidence supporting 
each of them; 1) the yolk-sac cells persist and divide but are not replaced by 
adult cells (Hashimoto et al., 2013; Schulz et al., 2012; Yona et al., 2013; 
Guilliams et al., 2013; Epelman et al., 2014); 2) the yolk-sac cells are replaced 
entirely at birth or following injury by bone marrow-derived cells (van 
Amerongen et al., 2007; Nahrendorf et al., 2007); 3) the yolk-sac cells persist 
and divide, but are slowly displaced by, and co-exist alongside, bone marrow-
derived macrophages (Ensan et al., 2016; Perdiguero and Geissmann, 2016; 
Molawi et al., 2014). 
The results presented here suggest that hypothesis 3 is the most likely as the 
Flt3-cre FXIII-A assays which show that the plasma activity is depleted to 34% 
of the wildtype which would mean that by around 8 weeks of age a C57BL/6 
mouse has displaced approximately 65% of its (yolk sac derived, 
Flt3-independent) FXIII-A secreting cells with bone marrow-derived 
(Flt3-dependent) cells.
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Figure 4-22 – Proposed mechanism by which FXIII-A positive resident tissue macrophages arise in the heart and 
aorta 
Diagram summarising the origins of tissue resident macrophages in the heart and aorta and how they contribute to the 
plasma pool of FXIII-A. These cells originate from the embryo and are generated from flt3-independent primitive 
haematopoiesis which takes place in the yolk sac. These cells then migrate into the early aorta and heart and persist 
throughout embryogenesis. It is known that these cells can undergo self-renewal and maintain their numbers by mitosis 
but also can be displaced by bone marrow-derived macrophages produced by flt3-dependent adult haematopoiesis. 
HSC = haematopoietic stem cell 
CMP = common myeloid progenitor 
GMP = granulocyte/macrophage progenitor 
MEP – megakaryocyte/erythrocyte progenitor 
MP = megakaryocyte precursor 
Meg = megakaryocyte 
AGM = aorta-gonad-mesonephros 
PF4 = Platelet factor-4 
Mpl = thrombopoietin receptor 
Flt3 = Fms-like tyrosine kinase-3.  
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4.5.4 Differing expression of Flt3-cre between pups 
Flt3-cre, peculiarly, has been reported to have variable penetrance in mice. 
(Boyer et al., 2011) described two groups of mice derived from Flt3-cre 
mediated recombination of the dual-colour reporter mT/mG mouse. They 
coined the terms “high-efficiency” and “low-efficiency” floxers. The high-
efficiency mice showed recombination and therefore expression of the GFP 
reporter in all haematopoietic lineages whereas the low-efficiency mice 
showed switching on of the reporter in lymphoid cells only. This thesis reports 
similar findings whereby FXIII-A was not recombined in the platelets of the 
majority of the Flt3-cre offspring and recombination was only detected in one 
of eleven pups. To date, no one has established why this variable 
recombination occurs and in the future a new line of Flt3-cre mice, which are 
known to produce high-efficiency pups, would have to be imported. 
A potential reason for this difference in cre expression in these mice may be 
due to epigenetic silencing of the transgene. While it has been generally 
assumed that all epigenetic modifications are erased from the germline, it has 
been shown that certain epigenetic modifications of gene loci can be inherited 
in mice an example of this being the agouti locus. (Morgan et al., 1999; 
Roemer et al., 1997). 
4.5.5 Mice have limitations for modelling human FXIII-A 
deficiency 
FXIII-A deficient mice were generated by cre-lox recombination using tissue 
specific cre constructs. This allowed depletion of circulating FXIII-A from 100% 
(FXIII-A+/+) down to 61% (CD11b-cre and FXIII-A+/-), 18% (PF4-cre), 9% (PF4-
cre.CD11b-cre) and 0% (FXIII-A-/-). 
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An in vitro assessment of clot formation was performed using ROTEM in all 
mouse lines and while differences were found in the global FXIII-A knockout 
and Mpl-/- groups, which was expected, no differences were found in any of 
the conditional knockout mice. The reduction in firmness in the Mpl knockout 
group is probably a result of the lack of platelet mass in the clot and as 
platelets have a wide range of functions in clotting (e.g. retraction and as a 
source of clotting factors) it is unsurprising that these mice have perturbed 
clotting function. 
The strong sequence homology between mouse and human FXIII-A suggest 
that there will be no difference in the specific activities of enzymes between 
the two species. This would imply that mice have approximately 7 times more 
enzyme molecules of FXIII-A than humans per volume of blood. If the effects 
of clinical human deficiency begin to be apparent at 10% of “normal” FXIII-A 
(i.e. an activity of ~40 in the assay) then an equivalent “human deficient” 
mouse model would require a residual enzyme activity of approximately 1.5% 
or lower in order to mimic this. 
(39.2 ÷ 2691.7) × 100 = 1.45% 
This means that the PF4-cre+.CD11b-cre+.FXIII-Aflox/flox mouse, which has 9% 
residual FXIII-A when compared to a wildtype mouse, is actually equivalent to 
a human with approximately 70% plasma FXIII-A assuming that other blood 
parameters are unchanged. Such an individual would be asymptomatic, and 
this would therefore explain the results of the ROTEM assays. The excess of 
plasma FXIII-A in mice could be explained by a need to clot quickly due to 
their small blood volume but this would have to be balanced by rapid clot lysis 
as most blood clots would presumably be occlusive. This may be a result of 
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mice having blood cells which are of a comparable size to humans (mice 
RBCs are 6 μm in diameter, human RBCs are 7.9 μm in diameter) (Milo et al., 
2010) but smaller vessels. 
It may be that using mice to model human FXIII-A deficiency is impractical as 
a mouse with a residual activity of 1.5% (i.e. a mouse with <10% “human” 
FXIII-A activity) is beyond the limits of cre-lox recombination even with the use 
of a tamoxifen-inducible cre recombinase (e.g. ROSA26). 
A future line of enquiry which could prove interesting would be to investigate 
whether the plasma activity of FXIII-A is inversely proportional to the blood 
volume of the animal by looking at other small (e.g. hamsters), and large 
rodents (e.g. rats) as well as larger mammals such as pigs and sheep. 
4.6 Conclusion 
The aim of this project was to define the role that platelets play in maintaining 
the circulating source of plasma FXIII-A. The results presented here not only 
provide substantial evidence to refute the idea that platelets maintain the 
plasma pool but also suggests that yolk sac-derived and later bone marrow-
derived tissue resident macrophages, most likely present in the aorta (and 
perhaps the entire vasculature), are the cellular source which maintains the 
plasma pool of FXIII-A. 
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4.7 Summary of Key Findings 
 Normal plasma FXIII-A activity and lack of compensation in platelet size 
or platelet FXIII-A content in the Mpl-/- mouse discounts the platelet as 
the cellular source of plasma FXIII-A (Table 4-1). 
 
 Cultured bone marrow-derived macrophages were seen to express 
PF4 and therefore depletion in the PF4-cre may suggest a macrophage 
origin for plasma FXIII-A. 
 
 Fingerprinting of the cre-lox crosses shows that plasma FXIII-A closely 
matches the aortic FXIII-A mRNA profile. 
 
 BMT of FXIII-A+/+ bone marrow cells into FXIII-A-/- mice restores plasma 
and platelet FXIII-A but also organ FXIII-A mRNA. 
 
 Mice have 7 fold more plasma FXIII-A than humans hence modelling 
FXIII-A deficiency in mice may be impractical. 
Genotype
Plasma 
Activity
Platelet 
Activity/Cell
Cardiac 
mRNA
Aortic 
mRNA
Wildtype 95% 75% 102% 74%
Mpl-/- 95% 81% 93% 236%
CD11b-cre+.FXIII-Af lox/f lox 61% 63% 103% 54%
LysM-cre+.FXIII-Af lox/f lox 20% 71% 20% 37%
PF4-cre+.FXIII-Af lox/f lox 18% 0% 1% 12%
CD11b-cre+.PF4-
cre+.FXIII-Af lox/f lox
9% 0% 0% 9%
Flt3-cre+.FXIII-Af lox/f lox 34% 13% n.d. n.d.
FXIII-A-/- 0% 0% 0% 0%
Table 4-1 - Summary of the cre-lox fingerprinting data 
Table showing residual plasma and platelet FXIII-A activity and 
expression of FXIII-A mRNA in the heart and aorta of the cre-lox crossed 
mice. All data is shown as the average value normalised to the wildtype. 
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Chapter 5 – Examining the effect of TG2 
deficiency on apoptosis 
5.1 Introduction 
So far, no large vessel repair deficit has been seen in the experimental 
aneurysm studies of the TG2-/- mice. Is this because TG2 does not have a 
repair role or is it due to it having an equally important role in cell apoptosis? 
Previous reports have suggested that a transglutaminase is able to increase 
the activation of MAPK through interaction with the first kinase in the cascade, 
DLK. This interaction has been suggested to be a crosslinking reaction 
whereby DLK oligomerises and is stabilised by a transglutaminase which 
results in increased apoptotic potential of the cell (Robitaille et al., 2004; 
Robitaille et al., 2008; Hébert et al., 2000). 
Activation of apoptosis typically involves a rapid influx of calcium and hence, 
to mimic this, calphostin C was used to induce apoptosis in our cellular 
models. Calphostin C is a potent, light dependent, inhibitor of protein kinase 
C which results in rapid mobilisation of intracellular calcium stores resulting in 
activation of the typical caspase-dependent apoptosis cascade. 
Vascular smooth muscle cells were chosen as the model system for this study 
due to their particular relevance in aortic aneurysm disease. Vascular smooth 
muscle cell apoptosis is a key component of aneurysm pathology (McCarthy, 
2000; Rowe et al., 2000). Since VSMCs also represent the bulk cell population 
of the artery wall their isolation and culture is relatively straightforward and 
well described in the literature (Bochaton-Piallat et al., 1992; Ray et al., 2001). 
- 148 - 
5.2 Aims 
To define the effects of TG2 deficiency on JNK activation and gene expression 
by: 
1. Culturing vascular smooth muscle cells derived from the aortas of 
wildtype and TG2-/- mice. 
2. Determine the phospho-JNK antigen levels and total JNK activity in 
these cells as a readout of MAPK activation. 
3. Measure the transglutaminase activity levels under apoptotic 
conditions. 
4. Examine the protein sequence of DLK to try and identify any potential 
TG2 crosslinking sites. 
5.3 Hypothesis 
Transglutaminase 2 is involved in the activation of c-Jun N-terminal kinase 
(JNK) therefore TG2-null vascular smooth muscle cells will show defects in 
JNK activation and apoptosis. 
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5.4 Results 
5.4.1 Vascular Smooth Muscle Cell Culture and Phenotype 
Mouse aortic vascular smooth muscle cells were isolated from whole aortas 
(aortic arch to iliac bifurcation). The culture conditions were optimised to 
provide maximum cell numbers for study. To determine this, cells were split 
at 1 in 4, 1 in 8 and 1 in 16 and it was found that splitting at a density lower 
than 1 in 4 did not establish viable cultures. Therefore, the culture conditions 
used were a total culture time of 10 days and a single passage at a 1 in 4 ratio. 
The cultured cells grew as monolayers, as examined by phase contrast 
microscopy, and took on the characteristic ‘hill-and-valley’ morphology as 
expected of smooth muscle cells (Endlich et al., 2000) following fixation and 
confocal microscopy. They also showed features of both the synthetic 
(rhomboidal) and contractile (elongated) phenotypes both of which stain 
positively for alpha-smooth muscle actin (Figure 5-1). 
Real time PCR of total mRNA data from these cells confirms that they are 
indeed vascular smooth muscle cells (αSMA positive) and not endothelial cells 
(CD31 negative). This is in agreement with the <1% contamination of 
endothelial cells reported in the original published method (Ray et al., 2001). 
This data also confirms that VSMCs express the pro-apoptotic MAP kinase 
pathway (DLK and JNK) and also TG2 (but as expected, not FXIII-A). 
However, in the TG2-/- cells, the transcripts relating to the MAPK pathway 
appear to be transcribed at lower levels than in the wildtype cells and therefore 
these cells may have lower amounts of those proteins (Figure 5-2). 
Whilst synthetic VSMCs are known to express MMP-2 and -9 it has also been 
shown that VSMCs are able to express the macrophage metalloelastase, 
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MMP-12 (Wu et al., 2003; Harris et al., 2010). This was confirmed in this work. 
Macrophage metalloelastase, as its name suggests, was first characterised in 
invading inflammatory macrophages and contributes to the excessive 
degradation of the elastic ECM seen in numerous inflammatory disorders (e.g. 
aortic aneurysm and emphysema). Its constitutive expression in VSMCs 
further implicates these cells as important drivers of the destructive process 
within the vessel. 
VSMCs in culture also express the ECM synthesis machinery (e.g. lysyl 
oxidase, collagens and elastin) suggesting a wider role for VSMCs in 
remodelling the vasculature, and not just in modulating vessel tone and ECM 
turnover. 
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Figure 5-1 – Confocal micrograph of VSMCs 
200x magnification of VSMCs cultured without calphostin C on coverslips, fixed with paraformaldehyde, permeabilised with Triton 
X-100 and stained with DAPI (nucleus, blue) and an Alexa Fluor 488 conjugated α-smooth muscle actin antibody (clone 1A4, 
green). Image analysis of the cultured cells showed that they grew in monolayers and that all cells were nucleated and reacted 
with the 1A4 antibody suggesting that the cells were VSMCs and not endothelial cells or other contaminating cells. A mixed 
population of VSMCs were seen, containing both rhomboidal synthetic cells (circled) and elongated contractile cells (arrow). Scale 
bar denotes 5 μm. 
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Figure 5-2 – Real time PCR of VSMCs 
Bar graphs showing real time PCR data from WT and TG2-/- VSMCs.  
Data is shown as mean +/- 95% confidence intervals. 
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5.4.2 JNK Antigen and Activity 
The ability of a cell to undergo programmed cell death (apoptosis) depends 
upon sustained activation of one or more of a number of receptors, all of which 
funnel through JNK, which is the final kinase in the MAPK pathway. A 
commercial activity assay was used to determine the activity of phospho-JNK 
(the active form) immunoprecipitated from cell lysates. 
In 80% confluent TG2-/- cells it was found that total JNK activity was 
significantly decreased to 30% of the wildtype group (p=0.01). Phospho-JNK 
immunoblot levels in the same cells were decreased to 38% for p54 JNK 
(p=0.001) and 42% for p46 JNK (Figure 5-3). 
Figure 5-3 – JNK Activity and Antigen 
Cell lysates from WT and TG2-/- VSMCs cultured without calphostin C 
were assayed for (A) JNK activity and (B) phospho-JNK antigen. TG2-/- 
were shown to have significantly less basal JNK activity (p=0.01) and 
phospho-p54 JNK (p=0.001) and a trend towards less phospho-p46 JNK 
(p=0.18) when compared to WT. Data is presented as mean +/- SEM 
(with western blot images inset) and significance determined by unpaired 
t-test for A and 1-way ANOVA for B. 
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5.4.3 Transglutaminase Activity 
It has been postulated on the basis of inhibitor studies, but not formally shown, 
that TG2 is involved in potentiating apoptosis. Therefore, VSMCs from 
wildtype and TG2-/- mice were labeled with 2 mM biotinpentylamine, a 
transglutaminase substrate, and challenged with 100 nM calphostin C for 2 h 
to induce apoptosis.  
Transglutaminase activity was determined by detection of biotinylated 
proteins from cultured VSMCs which were immobilised on a 96-well plate. Cell 
lysates were also ligand blotted using horseradish peroxidase labelled 
streptavidin to visualise biotinpentylamine labelled proteins.  
Figure 5-4 shows the results of this activity assay and ligand blot. The activity 
assay is presented as the mean reaction velocity normalised to the non-
apoptotic control. This value is the fold induction of total cell transglutaminase 
activity under apoptotic conditions. There is a significant difference in 
transglutaminase activity between the wildtype and TG2-/- groups (13-fold 
induction vs 3-fold, p=0.004) which supports the idea that this process is a TG 
mediated pathway and that the principal transglutaminase involved is TG2, 
rather than TG1 or TG4, both of which have been shown to be expressed by 
VSMCs (Johnson et al., 2012). It is also possible that this process is universal 
to all cells as TG2 is ubiquitously expressed. 
The ligand blot (inset) shows transglutaminase crosslinking substrates in 
apoptosis (+/- calphostin C treatment). Interestingly, the number of bands 
appears to be limited, when compared to an SDS-PAGE gel of total 
intracellular protein, suggesting that TG2 is not indiscriminately crosslinking 
acceptor proteins together, and rather that there is selection in the glutamine 
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residue of substrate proteins. This signifies that the action is targeted and 
therefore is not just protecting against spillage of intracellular proteins into the 
extracellular space as has previously been suggested (Piredda et al., 1997).  
Future work will aim to identify these labelled proteins which should be 
amenable to enrichment by magnetic streptavidin beads prior to identification 
by LC-MS.
Figure 5-4 – TG2 activity and western blot of crosslinked proteins 
Apoptosis was induced, by addition of calphostin C, in cultured VSMCs 
which had the transglutaminase substrate, biotinpentylamine, 
supplemented in the cell media. After 2 h of apoptotic stimuli, cells 
were lysed and (A) assayed for transglutaminase activity, (B) ligand 
blotted with streptavidin conjugated alkaline phosphatase to show 
crosslinked proteins and (C) SDS-PAGE gel of total intracellular 
proteins. Data in A is expressed as mean +/- SEM and an unpaired t-
test used to determine significance. 
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5.4.4 Transglutaminase Activity in Apoptosis 
Figure 5-5 shows the proportion of dead cells based upon an assay of protein 
mass after 2 h of calphostin C treatment.  
TG2 knockout cells appear to resist apoptosis, as after 2 h of calphostin C 
treatment only 5% of cells had undergone apoptosis whereas 21% (p=0.03) 
of the wildtype cells had died. 
  
Figure 5-5 – VSMC death following apoptosis 
The numbers of dead cells following calphostin C treatment was 
estimated by protein concentration of the harvest cell lysates (BCA 
assay) which were normalised to control cells (not treated with 
calphostin C). The data shows that significantly more WT cells had died 
than TG2-/- cells after 2 h (p=0.03). Data is shown as mean +/- SEM and 
significance determined by unpaired t-test. 
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5.4.5 DLK Protein Sequence Alignment 
As it is known that TG2 preferentially crosslinks glutamines residing in 
Q-x-P-Φ motifs, protein alignment of the DLK amino acid sequence was 
performed. Figure 5-6 shows the findings of the alignment which revealed a 
conserved consensus TG2 crosslinking motif (QAPC) in all 28 animal species 
on Uniprot which contain a DLK homolog. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-6 - Sequence alignment of DLK 
Alignment of the DLK protein sequence of the 28 animal species 
available on the Uniprot database reveals a conserved TG2 recognition 
motif proximal to the kinase domain (QAPC). 
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Sequence annotation of the mouse homolog of DLK reveals that this potential 
crosslinking site resides within the protein kinase domain between the ATP 
binding and active sites. This crosslink could serve to either simply tether DLK 
molecules together or to promote cooperativity between the monomers and 
therefore greatly increase activity. Figure 5-7 shows the sequence alignment 
of mouse DLK and highlights the protein kinase domain (residues 137-405, 
yellow), the ATP binding site (K185, red), the active site (D269, pink) and the 
proposed TG2 crosslinking site (QAPC, 215-218, green). 
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Figure 5-7 – Protein sequence annotation of mouse DLK 
Consensus protein sequence of mouse DLK (MAP3K12) with the protein 
kinase domain highlighted in yellow (137-405), ATP acceptor (K185) in 
red, active site (D269) in pink and the potential TG2 crosslinking motif 
(QAPC, 215-218) highlighted in green. 
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5.5 Discussion 
5.5.1 Transglutaminase 2 interacts with the apoptotic MAPK 
cascade 
It has previously been proposed that a transglutaminase is involved in the 
activation and/or potentiation of apoptosis and studies utilising non-specific 
inhibitors (which among other actions would inhibit transglutaminase activity) 
have shown a commensurate reduction in the formation of DLK oligomers 
(and therefore MAPK activation) and caspase cleavage following initiation of 
apoptosis with calphostin C (Robitaille et al., 2008). 
The results presented here corroborate those put forward by (Robitaille et al., 
2008) and identify that TG2 is the main transglutaminase that potentiates 
apoptosis through the MAPK cascade. Aortic VSMCs derived from global TG2 
knockout mice show defects in JNK activity as a result of lower levels of 
phosphorylation at the activating TPY motif in JNK. Further to this, protein 
alignment of DLK homologs revealed a conserved TG2 crosslinking site within 
DLK which is located in the protein kinase domain. This oligomerisation and 
subsequent crosslinking may serve to promote cooperativity between the 
active sites of the DLK molecules thereby resulting in the increased activity 
seen when oligomerised in previous reports (Robitaille et al., 2004). 
However, the decrease in JNK phosphorylation, activity and amount of cell 
apoptosis seen in the TG2-/- VSMCs could be due to the decrease in the 
concentrations of the target molecules (i.e. DLK and JNK) as seen in the 
qPCR measurements and not necessarily due to a lack of TG2 catalysed 
crosslinking of DLK oligomers. In order to clarify this total JNK (and DLK) 
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antigen levels, for which antibodies are available, would need to be 
determined in the same samples. 
The previous studies into TG2’s involvement with the MAPK pathway have 
used caspase cleavage assays to determine the amount of apoptosis 
(Robitaille et al., 2004; Robitaille et al., 2008). This thesis used intracellular 
protein concentration as a surrogate for measuring intact cells. This method 
is not a measure of apoptosis and other methods would need to be employed 
in order to determine this. Examples of such assays would be the use of 
quenched-fluorescent caspase substrates (e.g. DEVD peptides) which tether 
a DNA binding dye to the cytosol until activation of caspase 3 and/or 7 which 
cleave the peptide and release the dye resulting in a measureable 
fluorescence signal, quantitation of the amount of DNA laddering and nuclear 
condensation as a result of nuclease activation and Annexin V staining of the 
outer cell membrane as a result of phosphatidylserine being externalised as 
part of the apoptotic cascade. 
A potential therapeutic avenue could be explored by developing inhibitors of 
DLK oligomerisation. If this oligomerisation and covalent stabilisation occurs 
purely in apoptotic states when TG2’s transamidation activity is activated, then 
this pathway would be a more preferable target for slowing cellular apoptosis 
than global JNK inhibition as it would not disturb JNK-dependent proliferation. 
Figure 5-8 depicts this pathway as a flow chart, with the dotted horizontal line 
representing TG2 transamidation activity and vertical lines labelled with ATP 
signifying kinase activity. 
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Figure 5-8 – Proposed mechanism of apoptotic MAPK activation 
The data from this study and others suggests that TG2 is able to potentiate 
apoptosis through the MAPK pathway. Previous work suggested a 
transglutaminase was able to covalently oligomerise the MAPKKK, DLK, 
resulting in greater activation of the downstream cascade and therefore a 
greater activation of apoptotic signalling. Solid vertical arrow represents 
kinase activity and the dotted horizontal arrow shows transamidation 
activity. 
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5.6 Conclusion 
This study aimed to build on the previously reported findings that a 
transglutaminase is involved in potentiating apoptosis through the MAPK 
pathway (Robitaille et al., 2004). 
From the results presented above, it can be concluded that TG2 is the 
principal transglutaminase involved in potentiating apoptosis and that TG2 
deficient cells show less ability to be able to undergo apoptosis. 
This observation may be a result of either lower target concentrations of 
signalling molecules or a lack of TG2-catalysed stabilisation of DLK oligomers 
(Robitaille et al., 2004). 
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5.7 Summary of Key Findings 
 Previous reports suggested that a transglutaminase (potentially TG2) 
crosslinks an upstream MAPK pathway kinase (DLK) resulting in an 
increased activation of the pathway and an increased potential for the 
cell to undergo apoptosis. 
 
 TG2-/- VSMCs show reduced JNK activity and phospho-JNK levels. 
 
 TG2 is the main transglutaminase involved in calphostin C-induced 
apoptosis and TG2-/- cells show resistance to apoptosis. 
 
 Bioinformatics analysis of DLK reveals a conserved potential TG2 
crosslinking site proximal to the kinase domain. 
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Chapter 6 – Preliminary Data and Suggestions for 
Future Work 
6.1 Introduction 
This thesis has provided evidence for a role for arterial FXIII-A in maintaining 
the plasma pool and also a role for TG2 in potentiating cellular apoptosis. 
However, some questions still remain unanswered. 
This chapter describes work that has been carried out during the PhD study 
which require further attention and discusses some potential avenues for 
future work. 
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6.2 Results 
6.2.1 Identification of TG2 Substrates 
The literature suggests several important roles for TG2 but very little evidence 
in the way of identified in vivo substrates. The two roles of interest probed in 
this thesis relate to the promotion of apoptosis and the crosslinking of proteins 
in the extracellular space. Within the extracellular space there are two 
potential functions for TG2; the first is in the basal structure of the ECM and 
some potential in vitro substrates have been identified for this (shown earlier 
in 1.1.3), and the second is in repair whereby TG2 potentially becomes 
activated following tissue damage. 
6.2.1.1 Substrates in Apoptosis 
Proteins extracted from VSMCs (in 5.4.3 above), in which apoptosis had been 
induced with calphostin C, were labelled with biotinpentylamine, which was 
crosslinked into cellular proteins. These proteins were selectively enriched 
using streptavidin magnetic beads, trypsinised and peptide spectra identified 
by LC-MS. This methodology was seen as a viable strategy to allow efficient 
identification of TG2-crosslinked proteins due to the limited number of 
crosslinked bands detected by ligand blotting and a recent report 
(Schiapparelli et al., 2014) that suggested that direct trypsinisation of the 
biotin-streptavidin complexes produced more identifiable peptides in 
biotinylated HEK 293T cells than with traditional elution. 
While the presence of biotinpentylamine was determined in the cell lysates 
the mass spectrometer detected no peptide peaks that were not derived from 
streptavidin. This is more than likely due to the amount of streptavidin 
magnetic beads used, which in retrospect will have been in too great an 
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excess for the amount of biotinylated proteins in the sample. Therefore, when 
the beads were trypsinised the resulting cellular peptides were swamped by 
the over abundant streptavidin peptides, thus masking the signal. 
6.2.1.2 Substrates in the Extracellular Matrix 
While the work presented earlier in this thesis identified a role for TG2 in the 
intracellular space (namely, in apoptosis), it is also known that TG2 is present 
in the ECM and in certain circumstances may become active in the 
extracellular space. Hearts were chosen to try and identify substrates because 
of their large relative size and amount of protein available compared to smaller 
tissues and also due to the link with a possible repair role for TG2 in 
myocardial fibrosis (3.5.1 above). To try and identify some novel extracellular 
TG2 substrates heart proteins were fractionated; 
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1. PBS soluble – extracellular, non-electrostatically bound, non-covalently 
bound proteins. 
2. 0.5 M NaCl soluble – extracellular, electrostatically bound, 
non-covalently bound proteins. 
3. Detergent soluble – intracellular and membrane proteins. 
4. 0.25 M oxalic acid soluble – extracellular, elastin-bound proteins. 
This scheme was based upon approaches described by others (de Castro 
Brás et al., 2013; Kim et al., 2014) and the expectation that TG2 crosslinks 
proteins that are already associated with the ECM (most likely by forming an 
initial electrostatic interaction). Therefore, the fractions containing the 
crosslinked proteins of interest would be the salt and acid soluble fractions 
with the salt fraction showing a greater abundance of protein in the TG2-/- 
mouse. 
To characterise the fractions, several assays were performed; protein 
concentration was determined, SDS-PAGE to see any gross changes in 
abundant proteins, agarose gel electrophoresis to confirm the extracellular 
fractions were free of gDNA, and finally, protein identification by LC-MS. 
Figure 6-1A shows the results of the BCA assay which provides evidence that 
the TG2-/- hearts have more protein electrostatically attached to the ECM (salt 
fraction, TG2-/- had 272.5 +/- 29.6 µg/mL vs 149.2 +/- 5.8 µg/mL for the WT) 
but less elastin crosslinked protein (oxalic acid fraction, TG2-/- 208.3 +/- 10.2 
µg/mL, WT 266.7 +/- 8.0 µg/mL) compared to the wildtype.  
The SDS-PAGE analysis of the salt fractions of the two groups (Figure 6-1B), 
showed that a ~250 kDa protein was differentially expressed in the TG2-/- 
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hearts (brighter band, which does not appear in the wildtype). This may well 
be a protein that is usually crosslinked to the ECM by TG2 but in the knockouts 
has remained electrostatically associated to the ECM. Alternatively, the 
protein highlighted by SDS-PAGE could have been induced to compensate 
for the lack of TG2.
Figure 6-1 – Characterisation of heart protein fractions 
Mouse hearts were fractionated using different conditions to 
sequentially extract groups of proteins potentially crosslinked by TG2. 
Four fractions of proteins were produced, PBS soluble, 0.5 M NaCl 
soluble, detergent soluble and 0.25 M oxalic acid soluble. (A) Protein 
concentrations were determined using the BCA assay. (B) SDS-PAGE 
analysis of the salt soluble fractions. 
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Because the BCA assay consistently showed an increased protein 
concentration in the salt fraction and there was evidence of a difference in 
protein composition, this fraction was further analysed. 
Fifty micrograms of total protein was precipitated with 100% acetone and 
washed once with 100% acetone. These samples were then sent for protein 
identification by LC-MS. Table 8-4 details the results of the mass spectrometry 
which identified 50 proteins in the fractions. However, the proteins identified 
did not appear to be ECM derived proteins, with the most abundant being 
serum albumin. Amongst the remaining proteins many were identified as 
intracellular with numerous enzymes of the glycolytic pathway being found, 
thus suggesting that cell lysis had occurred and contaminated the samples. 
These proteins are so abundant that they mask the signal from any less 
abundant proteins and therefore no novel TG2 substrates were identified. 
To try and establish if cellular damage had occurred during sample 
preparation, agarose gel electrophoresis (Figure 6-2) was performed on both 
the salt (NCP) and detergent (ICP) fractions to detect the presence of genomic 
DNA. As expected, large amounts of high molecular weight nucleic acid were 
found in the ICP fraction as cell and nuclear membranes are detergent 
soluble. Small amounts of nucleic acid were seen in the salt fractions along 
with light smears of ethidium bromide stained material (presumably 
fragmented gDNA) which suggests that a number of cells had indeed lysed 
and released intracellular material into the extracellular space, thus removing 
any expectation of detecting any of the extracellular, potentially crosslinkable, 
proteins. 
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Figure 6-2 – Localisation of gDNA in heart fractions 
Image of ethidium bromide stained 2% agarose gel electrophoresis of 
wildtype (WT) and TG2-/- salt and detergent soluble heart protein 
fractions. LM = DNA ladder, NCP = non-covalently bound protein 
fraction, ICP = intracellular protein fraction. 
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6.2.2 Clodronate 
To determine if resident macrophages maintain the plasma pool of FXIII-A we 
attempted to selectively kill these cells by delivering the cytotoxic drug 
clodronate encapsulated within liposomes to mice and cultured bone marrow-
derived macrophages. Only phagocytic cells exposed to these liposomes will 
engulf them, and be affected by the drug and die. 
6.2.2.1 In vitro 
Figure 6-3A shows cultured macrophages efficiently ingesting the DiI-labelled 
clodrosomes (red) and cells (blue). Once ingested, cells rapidly underwent 
apoptosis as expected. These cells showed the characteristic morphological 
changes associated with apoptosis, cell shrinkage, membrane blebbing and 
chromatin condensation followed by DNA fragmentation. As the DNA 
fragments, more sites for Hoechst dye binding are revealed resulting in a 
direct increase in fluorescence, this is shown in Figure 6-3B (green spots). 
Cells 1, 2 and 3 (labelled) show a time-dependent increase in fluorescence 
whereas cell 4 does not change its fluorescence throughout imaging. 
Figure 6-3C&D show the characterisation of the clodrosome preparations and 
hence confirms that 3-5 mg of clodronate is encapsulated per mL of liposomes 
which is in line with expectation from the published method.
- 173 - 
 
Figure 6-3 – In vitro testing of clodrosomes 
Clodrosomes, clodronate-encapsulated liposomes, were given to phagocytic bone marrow-derived macrophages (BMDM) to test 
their cytotoxic potential. (A) shows a BMDM (nuclei, blue) phagocytosing a clodrosome (red) and then undergoing apoptosis and 
shows the characteristic cell shrinkage, membrane blebbing and intracellular vesicle formation. (B) is a fluorescence image showing 
Hoechst 33258 stained nuclei (green), as the chromatin condenses (in apoptosis) more sites for dye binding become accessible and 
fluorescence intensity increases. Cells 1, 2 and 3 show increases in fluorescence whilst 4 does not. (C) shows the clodronate 
encapsulation efficiency of the liposomes and demonstrates that the clodrosomes contain 3-5 mg/mL of clodronate. 
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6.2.2.2 In vivo 
Literature in this area suggested that resident tissue macrophages living in the 
liver, spleen and bone marrow (Rooijen and Sanders, 1994) are all susceptible 
to clodronate treatment and there is evidence that cardiac macrophages are 
accessible too (Epelman et al., 2014; Fujiu et al., 2014) even though they do 
not contain fenestrated capillaries. However, as the liposomes cannot cross 
the blood-brain barrier (unless mannosylated), the brain microglial cells are 
not affected and can therefore serve as a negative control of cell death. The 
liver is known to be well targeted by the clodrosomes as a result of it containing 
fenestrated capillaries and can act as a positive control of cell death. We 
chose Mpl-/- mice for this experiment as any fall in plasma FXIII-A would be 
easier to see as the platelet contribution to the FXIII-A background is 
significantly reduced (as described in 4.4.2 above). 
Either PBS-liposomes or Clodrosomes were injected via the tail vein 3 times 
per week for 2 weeks into Mpl-/- mice. Terminal blood samples were taken 
from these mice and age matched C57BL/6 controls for plasma FXIII-A activity 
determination and tissue was taken for mRNA determination. 
Macrophage cell death in the in vivo assays was determined by assaying gene 
transcripts of cell differentiation markers, namely, the macrophage markers; 
CD163, heme oxygenase-1, F4/80 and CD68; the dendritic cell marker, 
CD11c; and CCR2 which is the receptor that allows the uptake of 
mononuclear cells into the tissue space. Alongside these markers the FXIII-A 
gene transcript was assayed to see if a proportional drop was seen. A wide 
range of supposedly pan-macrophage markers were chosen as a result of the 
large heterogeneity seen within a population of cells known as ‘macrophages’. 
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A dendritic marker was included as these cells are known to be tissue resident 
and also phagocytic and CCR2 was chosen as a reuptake marker to see if 
clodronate treatment induced macrophage flux into the tissue from the blood. 
Figure 6-4 shows the real time PCR results of the above transcripts in heart 
(a), aorta (b), brain (c), liver (d), spleen (e), and bone marrow (f). 
Of note, the highest transcribed macrophage marker was CD68, a surface 
glycoprotein which binds oxidised low density lipoprotein and is supposed to 
be a common marker representing all monocytes and macrophages (Heidt et 
al., 2014; Deonarine et al., 2007; Côté et al., 2013) and is therefore best 
placed to show a reduction if these cells are cleared by the clodrosomes. 
The results show that the brain is unaffected by the clodrosomes, as expected, 
because the liposomes were not made with mannosylated reagents. The liver, 
which is expected to be sensitive to clodrosomes, showed a distinct drop in 
CD68 and HO-1, however not to zero. The heart appeared to be susceptible 
to clodrosomes and showed a drop in CD68 and was the only organ to show 
a demonstrable drop in FXIII-A. The spleen was also supposed to be sensitive 
to clodrosomes but it is arguable as to whether there is a drop in CD68 level.  
Whereas, the aorta and bone marrow appeared insensitive to clodrosome 
treatment. Of these, the bone marrow result appeared unpredicted as the 
clodrosomes are meant to be taken up through fenestrated vessels, which the 
bone marrow contains (as this is how cells are released from the bone marrow 
into the circulation, e.g. platelets). 
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Figure 6-4 – mRNA data from clodrosome-treated mice 
FXIII-A and cell marker mRNA expression in (A) heart, (B) 
aorta, (C) brain, (D) liver, (E) spleen and (F) bone marrow. 
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Blood samples from the clodrosome and control treated mice were taken and 
Figure 6-5 shows the results of the plasma FXIII-A activity assay. No reduction 
was seen in the clodrosome treated group when compared to either the PBS-
liposome treated or wildtype control groups.  
The in vivo use of the clodrosomes was to try and determine whether or not 
there was an easy option for depletion of tissue resident macrophages and 
whether or not they contribute to the circulating levels of FXIII-A. However, the 
results presented here suggest that while the clodrosomes did kill 
macrophages in vitro, sporadic depletion was seen in vivo, and therefore 
future use of the clodrosomes will have to be carefully considered and if 
pursued would require further optimisation. 
Figure 6-5 – FXIII-A plasma activity assay in clodrosome-treated mice 
Mpl-/- mice were given intravenous injections of cytotoxic clodrosomes to 
deplete blood and, hopefully, tissue resident macrophages. Following 
treatment, plasma FXIII-A assay was determined and compared to the 
control liposome treated mice. No difference in plasma FXIII-A activity 
was seen between the two groups. Data is shown as mean +/- SEM. 
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Ideally, to assay the in vivo effectiveness of the clodrosomes, circulating 
monocyte numbers should have been assayed as these cells readily ingest 
the liposomes and would have provided an index of cell depletion.  
6.2.3 Carotid Injury 
It remains unclear whether or not the lack of a clotting defect seen in the 
conditional knockout mice in the ROTEM assays fully represent the in vivo 
situation. It might still be expected that the FXIII-A-/- mouse would show an 
effect in clot formation in this model. 
Several preliminary carotid injury procedures were carried out in wildtype mice 
to establish the technique. The procedure itself is summarised visually in 
Figure 6-6.
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Figure 6-6 – In vivo carotid injury model 
  Eight week old C57BL/6 mice were anaesthetised using inhaled Isoflurane and maintained using a face mask. 
Once asleep, the mouse was placed on its back and the hair removed from the neck using an electric razor and 
dilapidating cream. The right carotid artery was exposed by making an incision to the right of the trachea and 
blunt dissecting away the soft tissue. 10% FeCl3 on a 1 x 2 mm2 piece of filter paper was placed on the artery for 
3 min to induce thrombosis. The filter paper was then removed and the site washed with sterile PBS. The 
incision was then sutured using 6/0 vicryl and the mouse allowed to recover in a heated hospital cage. 
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The findings of (Evans et al., 2009) suggested that a clot in the common 
carotid artery of a wildtype C57BL/6 mouse has an area of 39 μm +/- 6 μm. 
Based upon this data, this study would require large group sizes to have the 
power to see differences in this parameter between the genotypes (n=6 per 
time point to have the power to see a 50% drop in clot area). In order to try 
and reduce the numbers of mice required for this study other methodologies, 
besides serial sectioning of the carotid artery, were explored including 
contrast-enhanced ultrasonography utilising fibrin-targeted microbubbles as 
well as standard ultrasonography (Figure 6-7). 
  
Figure 6-7 – Ultrasound imaging of a carotid thrombus 
(A) shows an ultrasound 3D reconstruction of the right carotid artery of 
a FXIII-A+/+ mouse following FeCl3-induced thrombosis. (B) is individual 
1 mm short-axis non-contrast enhanced ultrasound sections through the 
vessel with colour Doppler overlaid (red = flow towards probe, blue = flow 
away from probe). 
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6.3 Discussion 
6.3.1 Composition of the extracellular matrix in the TG2-/- mice 
While the presence of TG2 in the intracellular and extracellular spaces is 
unquestioned, the enzyme itself appears dormant under most conditions. Little 
is known about the substrates of TG2 and while this appears to be an obvious 
question, to date there are no reports that identify them in vivo. Therefore, as 
part of this thesis, work was undertaken to try and develop a method to be 
able to identify some potential targets. 
While it was expected that the ECM-derived salt fraction in the TG2-/- mice 
would contain a greater concentration of protein, and the oxalic acid fraction 
less, when compared to the wildtype, it is unclear as to what this represents. 
The simplest explanation would be that the proteins usually crosslinked to the 
matrix in the wildtype are not crosslinked in the TG2-/- mice and therefore 
appear in the salt fraction. However, the mass spectrometry data does not 
reflect this notion. Instead, what this may suggest is that either the tissue is 
softer and therefore easier for sample preparation to cause cell lysis (as 
evidenced by protein identification of intracellular proteins) or it could 
represent an increase in vascular permeability in the TG2 knockouts (seen as 
an increase in albumin in the ECM). 
These possibilities could be tested by techniques already established in the 
literature. Tissue strength can be determined through mechanical testing such 
as resistance to stretching and crushing (Miller, 2005) and calorimetry (Sun 
and Leung, 2008), whereas vascular permeability can be assayed by 
intravenous injection of Evan’s blue dye into mice and subsequent 
measurement of the dye in excised tissues (Radu and Chernoff, 2013). 
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6.3.2 Clodronate did not deplete the cells that maintain the 
plasma pool 
On review of the literature it became apparent that groups were attempting 
and reporting success in using clodronate-encapsulated liposomes to deplete 
both circulating monocytes as well as more importantly already established 
tissue resident macrophages. It was known that liver, spleen and bone marrow 
could be readily targeted by these clodrosomes (Rooijen and Sanders, 1994; 
Rooijen and Hendrikx, 2010) but more surprisingly that also cardiac (Epelman 
et al., 2014) and aortic cells (Psaltis et al., 2014) could be depleted. 
Clodrosomes are made available to the tissue as they are able to travel out of 
the capillary through fenestrations in the wall of the vessel (Sercombe et al., 
2015). The liver, spleen and bone marrow should all be targeted by 
clodrosomes as they all contain these discontinuous, fenestrated, capillaries. 
How the aorta and heart were targeted was more curious as they do not 
contain fenestrated capillaries and therefore the clodrosomes should have no 
access to the cells residing within the tissue. The brain is protected from 
clodrosome depletion as they cannot be transported across the blood-brain 
barrier unless mannosylated (Rooijen and Sanders, 1994).  
The results presented in this thesis suggest that the clodrosomes, as 
expected, contained 3-5 mg/mL clodronate and that only the liver and heart 
are susceptible to clodrosome treatment through intravenous administration. 
However, the aorta, spleen and bone marrow show no depletion which 
contradicts the previous literature on the subject and suggests that the 
clodrosomes produced do work in vitro but were not evenly distributed in vivo. 
However, if the clodrosomes had spared cardiac macrophages and plasma 
FXIII-A but depleted bone marrow resident macrophages and monocytes then 
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this would have been good evidence for a role of resident macrophages in 
maintaining the plasma pool of FXIII-A. 
A further question is raised as to how plasma proteins are degraded and 
removed from the circulation. This degradation may in part be mediated by 
blood monocyte/macrophages which if depleted by the clodrosomes may 
result in the circulating levels of FXIII-A not falling at the expected rate based 
on the known half-life of FXIII-A. This would make interpretation of the residual 
plasma FXIII-A activity levels following clodrosome treatment difficult as the 
levels of FXIII-A may remain “normal” for an extended period of time. 
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6.4 Future Work and Direction 
While the work presented in this thesis lends evidence to arterial cells being 
involved in the maintenance of the plasma FXIII-A pool and intracellular TG2 
playing a key role in apoptosis, there are still many unanswered questions. 
The ideas for future work are described below and concern the elucidation of 
the cellular source of plasma FXIII-A and the secretory mechanism as well as 
identifying novel substrates of TG2 both in the intracellular and extracellular 
spaces.  
6.4.1 Macrophage Adoptive Transfer 
In view of the failure of the clodronate assays but the success of bone marrow 
transplantation; two experiments would be worth carrying out. 
The first is the reverse experiment to the one described earlier whereby 
FXIII-A-/- bone marrow would be transplanted into lethally irradiated FXIII-A+/+ 
recipients to determine the cell displacement efficiency within the bone 
marrow as well as the organs of interest. 
The second is to attempt adoptive transfer of wildtype cultured or isolated 
macrophages into FXIII-A-/- mice to see if the FXIII-A secreting niches can be 
repopulated without bone marrow ablation by irradiation and if they are able 
to reconstitute the plasma levels of FXIII-A. This would provide useful 
evidence as to the mechanism by which tissue macrophage niches are turned 
over as well as testing a possible treatment option for human patients deficient 
in FXIII-A. Adoptive transfer of macrophages has been established by other 
groups who have shown that macrophage adoptive transfer; prevents type 1 
diabetes in NOD mice (Parsa et al., 2012), ameliorates renal fibrosis (Nishida 
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et al., 2005) and alleviates bronchial hyperresponsiveness (Careau and 
Bissonnette, 2004). 
6.4.2 Purification of FXIII-A Secreting Cells 
This thesis reports on a method to potentially purify these cells from 3-4 week 
old mouse heart tissue using (what is thought to be) an anti-Thy1.2 antibody, 
and if the same cells that colonise the early aorta are the same as the cells 
that are present in the heart then this methodology may be applicable to 
isolating those as well. 
Beyond this, the evidence points toward the cells of interest in the aorta and 
heart expressing PF4. (Pertuy et al., 2015) described that F4/80+ 
macrophage-like cells in the lung, kidney, brain, heart, liver and stomach are 
able to be recombined by PF4-cre using an mT/mG mouse. The mT/mG 
mouse is a dual colour reporter whereby a stop codon placed downstream of 
the first colour reporter (Tomato) are flanked by LoxP sites. Upon cre 
recombination the Tomato and stop codon are cut out therefore allowing the 
GFP gene to be expressed. Therefore, when crossed with the PF4-cre mouse, 
this system would produce pups in which all of the cells express Tomato (red) 
fluorescing cells except for the PF4 expressing cells which would express 
GFP (green). Using the methodology described by Pertuy et al, these green 
fluorescing cells could be identified in the aorta (which the original study did 
not examine) and fluorescent cells isolated from organs using FACS and 
either cultured or assayed directly for FXIII-A expression and evidence of 
FXIII-A secretion. 
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6.4.3 Clodronate 
The data presented in 6.2.2 above shows that in vitro cultured macrophages 
are phagocytic however no characterisation of these cells was carried out. It 
would be pertinent to characterise these cells in terms of FXIII-A mRNA and 
expression of PF4 and Thy1.2 and to verify that the FXIII-A mRNA disappears 
with clodronate treatment. It would also be important to determine if the heart 
cells from fibroblast B fraction isolated in 4.4.4.2 above are able to be cultured. 
If they are then two questions would need to be answered. The first, does 
treatment with clodrosomes cause apoptosis in this cell population which 
would suggest that they are capable of phagocytosis and therefore provide 
evidence that they are macrophages. The second question would be does 
clodrosome treatment result in a reduction of the FXIII-A mRNA signal 
implying that the population may represent a cell type capable of secreting 
FXIII-A. 
Due to the findings of the in vivo assays whereby the clodrosomes did not 
produce the same findings as presented in the literature there are no 
immediate plans for attempting more in vivo clodronate assays. 
A more effective way to determine the role that bone marrow-derived 
monocytes and macrophages have in maintaining the plasma pool of FXIII-A 
may be to characterise a mouse line that is monocytopenic. The Csf1op/op 
mouse carries a homozygous mutation in the colony stimulating factor-1 gene 
and therefore shows defects in producing monocytes through definitive 
haematopoiesis. As a result, this mouse produces 10% of the number of total 
leukocytes compared to a wildtype (Yoshida et al., 1990). It would be 
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predicted that these mice would show the same plasma FXIII-A levels as the 
Flt3-cre mice but with intact platelet FXIII-A. 
6.4.4 Quantitation of Apoptosis in an Injury Model 
Whilst the data presented in this thesis show that in vitro TG2 plays a role in 
cell death there is no substantive in vivo evidence as yet. A model of AAA has 
been established within the group as described in 3.5 above and it would be 
interesting to determine if there is a difference in apoptosis between the 
wildtype and TG2-/- groups by looking at DNA fragmentation levels using 
TUNEL staining in sectioned aneurysmal tissue. To balance this, staining 
would also be carried out using an anti-Ki67 antibody to determine any 
difference in cellular proliferation within the aneurysmal tissue. 
A simple method for validating the idea that TG2 can slow apoptosis in vivo 
would be to utilise the mouse paracetamol overdose model. Cell death 
following paracetamol overdose is known to occur through a JNK dependent 
pathway (Win et al., 2011) and is relatively straightforward to carry out. 
Paracetamol is metabolised to the toxic product NAPQI in the liver and further 
reduced to a non-toxic product requiring glutathione. As the cellular stores of 
glutathione are depleted NAPQI builds up within the cell and beings binding 
mitochondrial proteins and inhibiting function leading to cell death. This 
methodology requires male C57BL/6 wildtype and TG2-/- mice (10-12 weeks 
old) which have been fasted for 12 hours (to normalise liver glutathione levels 
between mice). Following fasting, 300 mg/kg paracetamol (15 mg/mL in 
saline) is injected intraperitoneally and access to food is given. Mice are then 
sacrificed at 4 hours and 12 hours after injury and serum levels of alanine 
transferase are determined to show liver injury, liver lysates used to show 
- 188 - 
 
activation of the MAPK pathway, transglutaminase activity and caspase 
activation and sectioned tissue used for Annexin V staining (Mossanen and 
Tacke, 2015). 
6.4.5 Cell Apoptosis 
It has been suggested in this thesis that TG2 promotes the pro-apoptotic 
pathway and a potential crosslinking site within DLK, which is proximal to the 
kinase domain, has been identified in this work but has not been previously 
reported. Work will be undertaken to confirm that this site is crosslinked by 
TG2, both by in vivo cell labelling with biotinpentylamine and mass 
spectrometry identification of crosslinked DLK and also by recombinant 
protein methods. 
As previously stated, TG2 is a ubiquitously expressed enzyme and therefore 
its role in apoptosis could be global. Further work is planned to determine if 
this pro-apoptotic function is present in other vascular cells e.g. fibroblasts, 
macrophages and endothelial cells. 
A number of cell types, e.g. monocytes, macrophages and megakaryocytes, 
express FXIII-A. While FXIII-A is known to be secreted, albeit by an unknown 
mechanism, and is present in μg/mL quantities in the plasma it has also been 
shown to be retained intracellularly by some cell types (Adány and Bárdos, 
2003; Cordell et al., 2010; Muszbek et al., 2011). FXIII-A, like TG2, is activated 
by increased Ca2+ ion concentration and carries out the same catalytic 
transglutamination reaction. 
The vascular smooth muscle cells described here in this thesis were shown 
by real time PCR to not express FXIII-A however it would be interesting to see 
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if in cultured monocytes, which do express FXIII-A, there is a redundant role 
for FXIII-A in crosslinking DLK in apoptosis in the TG2-/- mice. 
6.4.6 Substrates of TG2 in the ECM and within Apoptotic Cells 
TG2 plays a role in cell apoptosis and it was shown in 5.4.4 above that proteins 
could be labelled with a small biotinylated molecule by TG2 which could 
potentially be enriched using streptavidin magnetic beads. Mass spectrometry 
will then be used to identify proteins crosslinked by TG2 in apoptosis. 
In the ECM, isolation of crosslinkable proteins proved more challenging due 
to the highly crosslinked and insoluble nature of the matrix. In the future, 
decellularised hearts will be subjected to cyanogen bromide digestion to 
produce peptides of crosslinked proteins which should be suitable for mass 
spectrometry. Contamination with elastin should be avoided as it contains no 
methionine residues (which cyanogen bromide cleaves after) however 
collagen derived peptides may prove to be an issue. If this endeavour proves 
successful then TG2’s role in repair could be studied by performing proteomic 
analysis on fibrotic hearts for example. 
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Chapter 7 – General Discussion and Conclusion 
For quite some time the general consensus in the literature has been that the 
plasma pool of FXIII-A is maintained by the platelet. The work presented in 
this thesis describes the generation of a novel FXIII-A floxed mouse and not 
only discounts the platelet as the cellular source (as suggested by previous 
reports) but puts forward substantial evidence that circulating FXIII-A is 
secreted from a cell identical to, or closely resembling, the aortic tissue 
resident macrophage. Several experiments presented here suggest that these 
cells express the cell marker, PF4 and also perhaps Thy1.2. There is an 
emerging theory in the literature that tissue resident macrophages are seeded 
into the developing organs during embryogenesis, the earliest of which 
originate from the yolk sac. These cells then remain within the organs until 
long after birth and the majority of the reports suggest that while these cells 
are able to maintain their own cell numbers, they are slowly displaced by bone 
marrow-derived macrophages throughout life. 
The evidence from the bone marrow transplantation studies presented in this 
thesis suggests that these resident cells can be displaced by irradiation and 
the results from the Flt3-cre mice show that these cells undergo simple 
turnover as the mouse ages. While FXIII-A deficiency in humans is rare, those 
that suffer with it require regular injections of recombinant protein to mitigate 
their symptoms. For these patients, transfer of cells expressing wildtype 
FXIII-A could serve as a long term therapy. What remains to be seen is 
whether or not tissue resident cells can be displaced by adoptive transfer (i.e. 
cell transfer without radiation) as this would allow restoration of the plasma 
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pool without the side-effects of bone marrow ablation therapy. However, 
further work is needed to confirm these findings. Once the cellular source is 
defined and a method designed to isolate the cells, substantial effort will need 
to be expended to elucidate the unknown mechanism of secretion from the 
cell. 
While there does appear to be a convincing role for FXIII-A in microvascular 
repair (e.g. fibrosis) the results reported in this thesis and those from our group 
seem to discount the notion that TG2 and FXIII-A play a cooperative role in 
bone formation or macrovascular protection. However, there does appear to 
be a role for maternal FXIII-A in pregnancy which may well prove to be a 
macrovascular function, e.g. remodelling of the placental artery. 
Despite the finding that TG2 is involved in apoptosis in vitro, which has been 
suggested previously, little in the way of in vivo evidence for this role has been 
shown. The work presented here reaffirms and builds on those findings and 
while it is known that apoptosis is required for a number of crucial 
developmental processes such as finger and toe formation, brain growth and 
septum formation in the heart (Haanen and Vermes, 1996; Watanabe et al., 
2001), the TG2-/- mouse used in this thesis showed no gross phenotypic 
differences compared to the wildtype. This leads to the possible concern that 
a decreased apoptotic potential is incompatible with an otherwise 
phenotypically normal mouse. However, both of these could be rationalised if 
developmental apoptosis is controlled through a separate pathway to the TG2-
JNK “stress” pathway. There are several previous reports detailing apoptosis 
during embryogenesis (Nelson, 1996; Uckan et al., 1997; Brill et al., 1999) 
- 192 - 
 
which suggest that this process is driven by Fas signalling which does not 
require JNK or any of the other MAPK components. 
While global JNK inhibitors are in development for clinical use with the hope 
of efficacy in treating numerous conditions, it may be that this is ill-advised 
due to the findings in the compound knockout mouse that JNK is involved in 
proliferative signalling. It may well instead be prudent to target an upstream 
kinase in the MAPK pathway, of which DLK is identified as pro-apoptotic, and 
either inhibit its kinase activity directly or the potential oligomerisation sites, 
thus inhibiting apoptotic MAPK signalling without disturbing potential 
proliferative pathways. 
Finally, while FXIII-A and TG2 appear to have distinct roles in biology, they do 
appear to have some cooperative function in protection against the 
development of both cardiac and vascular fibrosis, a deficit which is only seen 
in the double knockout mice and not in the single knockouts. Beyond this, it 
was shown in a model of aortic aneurysm that the double knockout mice were 
less susceptible to aneurysm formation at 6-weeks post injury which may be 
a result of the underlying fibrosis protecting the vessel from dilatation. 
In summary, this thesis presents some common and distinct functions of the 
transglutaminases FXIII-A and TG2, for example in pregnancy and the 
development of cardiac and vascular fibrosis. Beyond this, significant 
exploration of the cellular source of plasma FXIII-A was undertaken and as a 
result plasma FXIII-A is suggested to originate from the aorta. Finally, the role 
of TG2 in potentiating apoptosis was investigated and TG2 was found to be 
the main transglutaminase involved in calphostin C-induced apoptosis in 
VSMCs. Also, a potential novel crosslinking site was identified in DLK, an 
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upstream MAPK component previously reported to be crosslinked by a 
transglutaminase, and this site could potentially be exploited as an avenue for 
therapy to better treat those conditions currently targeted by JNK inhibitors.
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Chapter 8 – Appendices 
8.1 Routine PCR Genotyping Conditions 
  
… 
Genotype Primer Name Sequence (5'-3') TM (
o
C)
FXIII-A F13-intron8FL TCTGGGCCAAACCAAGTACCTGG
F13-intron8R2 CAAGACCAGACTGTGCAAAGGG
F13-intron9R2 GGGGACTTGCTCCCATGTAAA
PF4-cre PF4common CATTGGAGATGTGGATCCTGCT
PF4endog_rev CATGTCAAGAGGGTGCCACTGGA
PF4transgene ATGTCCATCAGGTTCTTCCTGAC
CD11b-cre CD11b_F CGACCAGGTTCGTTCACTCA
CD11b_R CAGCGTTTTCGTTCTGCCAA
ApoE_F CTCTGTGGGCCGTGCTGTTGGTCACATTGC
ApoE_R CTCGAGCTGATCTGTCACCTCCGCTCTCC
TG2 TG2_P1_Long GGAGCACACAGGCCTTATGAGCTGAAG
TG2_P2_Long GCACAGATAGGGATACAAGAACATTGAAG
TG2_P3_Long GTCCTCGGATGACAAGGTGACAGAGCA
c-Mpl Cmpl_common CAGGAACCTGAGGGGCTGGC
Cmpl_WT GTTTGGAAGGGCCAAGAGGA  
Cmpl_bGal AAGCGCCATTCGCCATTCAG  
LysM-cre LysM_common GGGCTGCCAGAATTTCTC
LysM_WT ACTCCATAGTAGCCAGCCATTCC
LysM_mutant GGTTATTCAACTTGCACCATGCC
Flt3-cre Flt3fw2 ACGGAGTCCAGGCAACTTCCC
Flt3ex1rev1 GCTGCGCCAACGCCCGCAT
Flt3crerev GAAGCATGTTTAGCTGGCCC
68
63
55
55
64
58
64
Table 8-1 – Routine PCR genotyping primers and melting temperatures 
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8.2 Quantitative PCR Primer Sequences  
Table 8-2 – Quantitative PCR primer names and sequences 
  
Gene Forward Primer Reverse Primer
Elastin AAAGCCTGGGAAAGTTCCTG TACACCTGGAAGACCAACAC
Collagen I ATGGATTCCCGTTCGAGTACG TCAGCTGGATAGCGACATCG
Collagen III CACCCTTCTTCATCCCACTCTTA ACCAAGGTGGCTGCATCC
Vimentin CGGAAAGTGGAATCCTTGCA CACATCGATCTGGACATGCTGT
aSMA ACTGGGACGACATGGAAAAG GTTCAGTGGTGCCTCTGTCA
MMP2 CTGATAACCTGGATGCCGTCGT TGCTTCCAAACTTCACGCTCTT
MMP9 GTCTCGGGAAGGCTCTGCTGTT CTCTGGGGATCCACCTTCTGAG
FXIII-A TGCTGGTGTCTTTAACACATTTTTAA TGGGCCGAGAATGAATTGGT
TG1 TTCGCTACCCGTACCGTCA CTTCATCCAGCAGTCGTT
TG2 ATTGGCAGTGTGGACATTC TCGTGGGCGGAGTTGTA
TG3 AAGAAGCTGACCATGAGTGCTTT TGCGCCCTTCGATTCATAG
TG4 CCCATCTATTTGACCATAACTTTGAA GCGAGAAACACCCTTGATT
TG5 AGGCAGGATTCTGGAGAATATG GGGCCACAGCCACAGCAGTAGAG
TG6 TCCGAGTCAATGTGAGCG GTCTTCTGTCAGGTCTCCTTTGTA
TG7 ATGTGCACGGTAATGAGATGCT TGTGTGCAGAATGGAAATTGG
CD163 ATGGGTGGACACAGAATGGTT CAGGAGCGTTAGTGACAGCAG
tPA CAACAGCGGCCTGGTACAA CCCCATTGAAGCATCTTGGTT
uPA GAAACCCTACAATGCCCACAGA GACAAACTGCCTTAGGCCAATC
Perilipin CTGTGTGCAATGCCTATGAGA CTGGAGGGTATTGAAGAGCCG
PAI-1 ACGGTGATGCGATATAATGTAAACG CATTCCTGAGAAACACAGCATTG
Fibrillin 1 CCTGTGCTATGATGGGTTCA AGGTCCCACTAAGGCAGATG
Fibrillin 2 CCACTCCTATTGCTGCCCAG TTGGGGCGGGAACAGAATC
MT-MMP CCCAAGGCAGCAACTTCA CAATGGCAGCTGAGAGTGAC
HO-1 AACAAGCAGAACCCAGTCTATG TGAGCAGGAAGGCGGTCTTA
MMP12 GCTAGAAGCAACTGGGCAAC ACCGCTTCATCCATCTTGAC
TIMP1 GTGGGAAATGCCGCAGAT GGGCATATCCACAGAGGCTTT
TIMP2 CCAGAAGAAGAGCCTGAACCA GTCCATCCAGAGGCACTCATC
TGFB CACCGGAGAGCCCTGGATA TGTACAGCTGCCGCACACA
B-Actin CGTGAAAAGATGACCCAGATCA TCGTACGACCAGAGGCATACAG
RPL32 AAAATTAAGCGAAACTGGCGG TGTTGCTCCCATAACCGATG
DLK GGTGTGGGAAGCAACAGTCT GCAGCAAGATCTGTCGGAAT
JNK1 ATGCAAATCTTTGCCAAGTG AGGCTTTAAGTCCCGATGAA
cJun AGCAGGGACCCATGGAAGTT AAAGATGACCTTTGCTTGTGCAT
Src AGCAACAAGAGCAAGCCCAAGGAC GTGACGGTGTCCGAGGAGTTGAAG
SEK1 TCGGACCTCCAGCTTCTG TAAACCCTGCTGTCGATTTG
ATF2 ACTGCCATGGCCTTTTACAG CCTCTCCTCAACCAGTCCAG
LOX GTGACATTCGCTACACAGGACATC CCAAACACCAGGTACGGCTTTATC
CD31 CTGGTGCTCTATGCAAGCCT AGTTGCTGCCCATTCATCAC
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8.3 Antibody Dilutions 
Table 8-3 – Western blot and immunocytochemistry antibody dilutions 
  
Antibody Host Type Source Product 
Code 
Dilution 
Phospho-JNK Rabbit Monoclonal CST 4668 1:1000 
(WB) 
DLK (MAP3k12) Rabbit Polyclonal Thermofisher PA5-32173 1:1000 
(WB) 
Streptavidin-HRP n/a n/a R&D 
Systems 
4800-30-
06 
1:1000 
(WB) 
β-actin Rabbit Monoclonal CST 8457 1:1000 
(WB) 
Anti-rabbit HRP Goat Polyclonal CST 7074 1:2000 
(WB) 
α-smooth muscle 
actin  
(Alexa Fluor 488) 
Mouse Monoclonal Abcam Ab184675 1:150 
(ICC) 
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8.4 Mass Spectrometry Peptide Identification 
Table 8-4 – LC-MS protein identification from a heart salt fraction 
ID Description -10lgP 
Coverage 
(%) 
# 
Peptide 
# 
Unique 
P
T
M 
Avg. 
Mass 
1 
Albumin 1 OS=Mus musculus 
GN=Alb PE=2 SV=1 
248.41 49 27 27 Y 68693 
2 
Myosin-binding protein C, 
cardiac-type OS=Mus musculus 
GN=Mybpc3 PE=1 SV=1 
239.29 26 25 25 Y 141308 
3 
Fructose-bisphosphate aldolase 
OS=Mus musculus GN=Aldoa 
PE=2 SV=1 
198.76 36 12 12 Y 39356 
4 
Aspartate aminotransferase, 
cytoplasmic OS=Mus musculus 
GN=Got1 PE=1 SV=3 
189.16 49 18 18 Y 46248 
5 
Eno3 protein OS=Mus musculus 
GN=Eno3 PE=2 SV=1 
187.2 37 15 13 Y 46998 
6 
Myoglobin OS=Mus musculus 
GN=Mb PE=2 SV=1 
181.78 55 15 15 Y 17070 
7 
Creatine kinase M-type OS=Mus 
musculus GN=Ckm PE=2 SV=1 
174.56 33 14 14 Y 43045 
8 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Mus 
musculus GN=Gapdh PE=1 
SV=2 
155.14 28 8 8 Y 35810 
9 
Triosephosphate isomerase 
OS=Mus musculus GN=Tpi1 
PE=1 SV=4 
154.54 34 10 10 Y 32192 
10 
L-lactate dehydrogenase B 
chain OS=Mus musculus 
GN=Ldhb PE=1 SV=2 
154.27 30 11 9 Y 36572 
11 
Malate dehydrogenase, 
cytoplasmic OS=Mus musculus 
GN=Mdh1 PE=1 SV=3 
145.02 26 8 8 Y 36511 
12 
Actin, aortic smooth muscle 
OS=Mus musculus GN=Acta2 
PE=1 SV=1 
144.51 21 7 7 N 42009 
13 
Glycogen phosphorylase, 
muscle form OS=Mus musculus 
GN=Pygm PE=1 SV=3 
134.35 15 11 6 Y 97286 
14 
Pyruvate kinase PKM OS=Mus 
musculus GN=Pkm PE=1 SV=4 
133.97 20 8 8 Y 57845 
15 
Phosphoglycerate kinase 1 
OS=Mus musculus GN=Pgk1 
PE=1 SV=4 
132.26 21 7 7 Y 44550 
16 
Alpha-enolase OS=Mus 
musculus GN=EG433182 PE=2 
SV=1 
130.85 14 5 3 Y 47141 
17 
Tropomyosin alpha-1 chain 
OS=Mus musculus GN=Tpm1 
PE=1 SV=1 
127.87 30 9 9 Y 32699 
18 
Phosphoglycerate mutase 2 
OS=Mus musculus GN=Pgam2 
PE=1 SV=3 
122.28 30 9 9 Y 28827 
19 
Phosphatidylethanolamine-
binding protein 1 OS=Mus 
musculus GN=Pebp1 PE=1 
SV=3 
121.67 33 4 4 N 20830 
20 
L-lactate dehydrogenase 
(Fragment) OS=Mus musculus 
GN=Ldha PE=2 SV=1 
120.89 24 8 6 Y 34503 
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21 
Elongation factor 1-alpha 2 
OS=Mus musculus GN=Eef1a2 
PE=1 SV=1 
116.23 13 6 6 N 50454 
22 
Adenylate kinase isoenzyme 1 
OS=Mus musculus GN=Ak1 
PE=1 SV=1 
116.03 30 4 4 Y 21540 
23 
Fatty acid binding protein 3, 
muscle and heart OS=Mus 
musculus GN=Fabp3 PE=2 
SV=1 
110.29 35 6 6 Y 14819 
24 
Putative uncharacterized protein 
(Fragment) OS=Mus musculus 
GN=Akr1b3 PE=2 SV=1 
106.13 18 6 6 Y 35052 
25 
Histone H1.4 OS=Mus musculus 
GN=Hist1h1e PE=1 SV=2 
103.1 17 5 5 N 21977 
26 
Myomesin-1 OS=Mus musculus 
GN=Myom1 PE=1 SV=1 
101.42 4 6 6 N 175480 
27 
Peroxiredoxin-1 (Fragment) 
OS=Mus musculus GN=Prdx1 
PE=1 SV=6 
101 28 5 5 N 18870 
28 
Glucose-6-phosphate isomerase 
OS=Mus musculus GN=Gpi1 
PE=2 SV=1 
98.92 14 4 4 N 38283 
29 
Heat shock protein 84b OS=Mus 
musculus GN=Hsp90ab1 PE=2 
SV=1 
89.45 9 5 5 N 83281 
30 
Nucleoside diphosphate kinase 
OS=Mus musculus GN=Nme2 
PE=2 SV=1 
86.3 32 5 5 Y 17363 
31 
Myosin light chain 3 OS=Mus 
musculus GN=Myl3 PE=1 SV=1 
86.23 19 2 2 Y 14227 
32 
Glutathione S-transferase Mu 1 
OS=Mus musculus GN=Gstm1 
PE=1 SV=2 
83.04 15 4 2 N 25970 
33 
Myomesin 2 OS=Mus musculus 
GN=Myom2 PE=1 SV=1 
80.4 4 5 5 Y 164737 
34 
ATP-dependent 6-
phosphofructokinase, muscle 
type OS=Mus musculus 
GN=Pfkm PE=1 SV=3 
77.39 5 3 3 N 85269 
35 
Troponin C, slow skeletal and 
cardiac muscles OS=Mus 
musculus GN=Tnnc1 PE=1 
SV=1 
77.36 17 2 2 N 18421 
36 
Putative uncharacterized protein 
(Fragment) OS=Mus musculus 
GN=Hspa8 PE=2 SV=1 
75.73 5 2 2 N 50464 
37 
Selenium-binding protein 2 
OS=Mus musculus 
GN=Selenbp2 PE=1 SV=2 
74.95 7 3 3 N 52610 
38 
Superoxide dismutase [Cu-Zn] 
OS=Mus musculus GN=Sod1 
PE=1 SV=2 
74.15 15 3 3 Y 15943 
39 
Protein Hbb-bs (Fragment) 
OS=Mus musculus GN=Hbb-bs 
PE=1 SV=1 
73.89 22 2 2 N 11084 
40 
Troponin I, cardiac 3 OS=Mus 
musculus GN=Tnni3 PE=2 
SV=1 
67.5 12 2 2 N 24259 
41 
Peroxiredoxin-6 OS=Mus 
musculus GN=Prdx6 PE=1 
SV=1 
63.29 13 3 3 Y 22494 
42 
Protein deglycase DJ-1 OS=Mus 
musculus GN=Park7 PE=1 
SV=1 
60.16 16 3 3 Y 20021 
43 
PDZ and LIM domain protein 5 
OS=Mus musculus GN=Pdlim5 
PE=1 SV=1 
56.24 12 2 2 N 23793 
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44 
Troponin T, cardiac muscle 
OS=Mus musculus GN=Tnnt2 
PE=1 SV=1 
53.44 7 2 2 N 35001 
45 
Putative uncharacterized protein 
(Fragment) OS=Mus musculus 
GN=Prdx5 PE=2 SV=1 
53.12 10 2 2 N 20713 
46 
Cofilin-2 OS=Mus musculus 
GN=Cfl2 PE=2 SV=1 
52.49 11 2 2 N 18710 
47 
Annexin OS=Mus musculus 
GN=Anxa6 PE=2 SV=1 
51.13 4 3 3 N 75273 
48 
Putative uncharacterized protein 
OS=Mus musculus GN=H1f0 
PE=2 SV=1 
47.97 9 2 2 N 19253 
49 
Serotransferrin OS=Mus 
musculus GN=Tf PE=1 SV=1 
45.98 2 2 2 N 76724 
50 
Peroxiredoxin-2 OS=Mus 
musculus GN=Prdx2 PE=1 
SV=3 
44.86 8 2 2 N 21779 
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8.5 Tissue Processing Settings 
 
70% ethanol  30 min 
70% ethanol 30 min 
70% ethanol 30 min 
90% ethanol 1 h 
100% ethanol 2 h 
100% ethanol 2 h 30 min 
100% ethanol 3 h 
Histoclear 30 min 
Histoclear 1 h 30 min 
Histoclear  1 h 30 min 
Paraffin 1 h 30 min 
Paraffin 2 h 
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8.8 Mouse Ear Notch Identification 
All mice were ear notched at point of weaning by University of Leeds CBS 
staff. The following notch identification system was used with all mice within 
the facility. 
● = site of ear notching 
  
Figure 8-1 – CBS mouse ear notch identification chart 
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